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Abstract 
Herpes Simplex Virus (HSV) types 1 and 2 are among the most common human viral 
pathogens and are capable of causing serious disease, including fatal disseminated neonatal 
herpes, encephalitis, genital herpes, and keratitis. Genital herpes increases the risk of acquiring 
HIV by 2-3 times. The only partially efficacious vaccine to date, a sub-unit vaccine produced by 
GSK which included HSV2 glycoprotein D with the adjuvant AS04 with deacylated 
monophospoholipid A (dMPLA), induced humoral and CD4+ T cell immunity but failed to induce 
protective CD8+ T cell immunity. CD4+ and CD8+ T cells play a major role in controlling HSV 
infection in humans. Development of a HSV peptide-based vaccine capable of inducing 
protective CD8+ T cell immunity has been impeded by the lack of identified epitopes and of 
understanding of suitable adjuvants. This study sought to identify immunodominant CD8+ T cell 
epitopes from HSV that could be combined with a previously identified CD4+ T cell epitope as a 
lipopeptide, then investigated as a proof-of-principle HSV vaccine candidate. As HSV entry into 
dendritic cells (DCs), and cross-presentation of lipopeptides and UV-inactivated HSV is 
incompletely understood, these were also investigated to further our understanding of HSV 
vaccines.  
To identify immunodominant CD8+ T cell epitopes from HSV, our study utilised epitope 
prediction programs. The selected peptides were screened using monocyte-derived DCs 
(MDDCs) and isolated CD8+ T cells from HSV seropositive donors. An immunodominant HSV 
CD8+ T cell epitope was identified in HSV2 ICP8 (referred to as peptide 9) that was capable of 
binding to HLA alleles from two different HLA supertypes, HLA A2 and A3. The full length peptide 
9, a 10 mer, was found to bind to HLA-A*03:01 through T2 binding assays, and with just one C-
terminal residue removed, the 9mer was able to bind to HLA-A*02:01. Peptide 9 was found to 
induce proliferation and a multi-functional CD8+ T cell response, with responding cells producing 
IFN-, TNF-α, and IL-2, measured by flow cytometry.  
Self-adjuvanted peptides are increasingly being considered as vaccine candidates, 
conjugation of peptides to the TLR2 agonist Pam2Cys as a lipopeptide has been found to elicit 
humoral and cell-mediated responses. To investigate the effect of Pam2Cys conjugation to HSV 
peptides, we investigated the CD4+ and CD8+ T cell response to three HSV lipopeptides using 
peripheral blood mononuclear cells (PBMCs) and MDDCs from healthy HSV seropositive donors. 
The lipopeptide Pam2Cys-p9 contains a CD8+ T cell epitope derived from HSV2 ICP8, Pam2Cys-
gD2-p30-5 from Kim et al (2012) (referred to as Pam2Cys-p30-5 in this thesis), contains a CD4+ T 
cell epitope from HSV1/2 gD, p9-Pam2Cys-p30-5 contains both the CD8+ T cell epitope and the 
CD4+ T cell epitope. IFN- ELISPOTs revealed that CD8+ T cells responded to Pam2Cys-p30-5, 
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which was initially identified as a CD4+ T cell epitope. This CD8+ T cell response to Pam2Cys-p30-
5 was found to be restricted to HLA-A*02:01 and HLA-B*44:02. The CD8+ T cell response to 
Pam2Cys-p30-5 was consistently greater than the response to Pam2Cys-p9 or p9-Pam2Cys-p30-
5. All the lipopeptides were found to mature MDDCs, upregulating the maturation markers CD80 
and CD83. The CD8+ T cell responses to Pam2Cys-p30-5 and Pam2Cys-p9 were found to be 
multi-functional, inducing a greater number of CD8+ T cells to secrete IFN-, TNF-α, and IL-2, and 
some killing through de-granulation measured by staining for CD107a/b. Pam2Cys-p30-5, which 
was now understood to contain both a CD4+ and a CD8+ T cell epitope, was found to 
synergistically enhance the total T cell response when CD4+ and CD8+ T cells were co-cultured 
compared to when CD4+ and CD8+ T cells were cultured separately. Pam2Cys-p30-5 was 
therefore identified as a potential vaccine candidate for HSV and is capable of eliciting of a 
strong human CD4+ and CD8+ T cell response. 
To rationally design HSV vaccines capable of inducing protective CD8+ T cell responses, 
greater understanding of cross-presentation of HSV lipopeptides and whole-inactivated HSV 
antigen is needed. HSV entry into DCs during infection is also incompletely understood. 
Therefore this study lastly examined cross-presentation of HSV lipopeptides and UV-inactivated 
HSV and HSV entry into MDDCs. The kinetics of lipopeptide cross-presentation as well as its 
cross-presentation pathways were examined. Pam2Cys-p30-5 cross-presentation was blocked by 
the presence of the inhibitors brefeldin A and monensin and required 5 hrs to be cross-
presented to CD8+ T cells. Pam2Cys-p9 was presented within 2 hrs and was much less sensitive 
to the presence of brefeldin A and monensin. The cross-presentation of Pam2Cys-p30-5 was 
unaffected by an inhibitor of endosomal acidification, bafilomycin A, but required proteasomal 
processing  Conversely, when presented to CD4+ T cells, Pam2Cys-p30-5 required endosomal 
acidification. Currently it is known that HSV utilizes at least three different entry pathways to 
infect different cell types, a pH-dependent endocytic pathway, a pH-independent endocytic 
pathway and a pH independent fusion pathway at the plasma membrane. Using inhibitors of 
endosomal acidification, bafilomycin A and monensin, and the protein tyrosine kinase inhibitor 
genistein, flow cytometry and PCR were used to measure infection, we showed that HSV1 and 
HSV2 enters MDDCs via a pH-dependent endocytic pathway. Presentation of UV-inactivated 
HSV1 to CD4+ T cells isolated from HSV seropositive donors, measured by IFN- ELISPOT, was 
inhibited by bafilomycin A but cross-presentation to CD8+ T cells was enhanced by bafilomycin A 
and blocked by the proteasomal inhibitor lactacystin. Therefore, endosomal acidification is 
necessary for HSV infection, the main pathway through which UV-inactivated HSV is cross-
presented does not require endosomal acidification.    
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This study identified an immunodominant CD8+ T cell epitope from HSV2 ICP8 that is 
able to bind to two HLA supertypes, HLA A2 and HLA A3. HSV lipopeptides were found to induce 
strong T cell responses with one lipopeptide, Pam2Cys-p30-5 shown to achieve induce of both 
CD4+ and CD8+ T cell responses. Antigen presentation to CD4+ T cells required acidified 
endosomes whereas cross-presentation of HSV lipopeptides and UV-inactivated HSV to CD8+ T 
cells was found to be dependent on proteasomal degradation. HSV was found to infect MDDCs 
via a pH-dependent endocytic pathway. Understanding of the intricacies of antigen cross-
presentation has increased in recent years but is still poorly understood. This study increases 
understanding of presentation of HSV antigens and infection, and will contribute to HSV vaccine 
design. 
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Chapter 1 -  Introduction 
1.1. Herpes Simplex Virus 
1.1.1. Biology 
A. Virus Structure 
Herpes simplex virus type 1 (HSV1) and herpes simplex virus type 2 (HSV2) were the first 
of the human herpesviruses to be discovered and fall under the subfamily of alphaherpesvirus, 
which they share with varicella zoster virus (VZV). The virion consists of a core containing a linear 
double-stranded DNA, an icosadeltahedral capsid surrounding the DNA, an amorphous 
tegument surrounding the core and an outer envelope derived from cell membranes and 
exhibiting glycoprotein spikes on the surface (Figure 1.1). The major proteins in the capsid 
include VP5, VP21, and VP22a. Located on the surface of the envelope are many glycoproteins 
gB, gC, gD, gE, gH, gI, gK and gL, many of which are involved in virus binding and entry to host 
cells. The tegument contains the remaining virion proteins including the trans-inducing factor 
VP16 and the virion host shutoff protein (VHS). 
 
 
 
Figure 1.1 HSV structure 
 
B. Replication Cycle 
HSV is known to enter host cells by three different pathways depending on the host cell 
(Figure 1.2). Vero and neuronal cells have been shown to be infected via pH-independent fusion 
at the plasma membrane (Nicola, Hou, Major, & Straus, 2005), C10 mouse melanoma cells are 
infected via a pH-independent endocytic pathway (Milne, Nicola, Whitbeck, Eisenberg, & Cohen, 
2005), epithelial cells such as keratinocytes, HeLa cells, and CHO-nectin 1 cells are infected via a 
pH-dependent endocytic pathway (Nicola et al., 2005; Nicola, McEvoy, & Straus, 2003). The 
envelope glycoproteins gB and gD, and the heterodimer gH-gL are required for both pH-
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independent and pH-dependent entry pathways.  Viral entry into the host cell is usually initiated 
by binding of the virion via glycoproteins gB and gC to host cell surface molecules including 
heparan sulfate proteoglycan and chondroitin sulfate proteoglycans. Glycoprotein D (gD) then 
interacts with a second surface molecule such as HveA or a modified heparan sulfate or nectin-1 
(HveC) or nectin-2 (HveB) (see Figure 1.3, step ). The mechanism of entry under mildly acidic 
conditions such as endsomes occurs through a conformational change in gB that occurs at low 
pH (pH~5.0 to 6.0) and an increase in the hydrophobic character of gB that occurs at a similar pH 
range (Dollery, Delboy, & Nicola, 2010).  As a result of the second receptor binding, fusion of the 
viral envelope with the host cell plasma membrane is initiated. The envelope containing viral 
glycoproteins remains on the host cell surface whilst the de-enveloped virus particle including 
some tegument proteins and the nucleocapsid is released into the cytoplasm. After fusion, the 
incoming nucleocapsids are transported to nuclear pores by the cellular microtubule-associated 
motor system to deliver viral DNA through the nuclear pore into the nucleus (Radtke et al., 2010) 
(step ).  The viral genome and certain tegument proteins like VP16 which activate transcription 
of the viral genome are translocated to the nucleus (S. J. Flint, 2004; Garner, 2003).  
 
Figure 1.2 HSV entry pathways 
Three different viral entry pathways have been shown to be utilized by HSV, Vero and neuronal 
cells are infected via a neutral fusion pathway at the plasma membrane, C10 mouse melanoma 
cells are infected via a pH independent endocytic entry pathway, and epithelial cells, such as HeLa 
and keratinocytes, are infected via a low-pH dependent endocytic pathway. 
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The replicative cycle of HSV involves three groups of virus specific polypeptides, 
designated as immediate early (IE), early (E) or late (L). These are synthesized during infection in 
a co-ordinated and cascaded fashion. IE genes are defined as genes whose expression occurs in 
the absence of de novo synthesis,  via a process that uses the host cell transcriptional apparatus, 
and five such genes have been identified encoding the proteins ICP0, ICP4, ICP22, ICP27, and 
ICP47 (Everett, 2014). The expression of these genes is controlled by the action of the virion 
trans-activation protein VP16 (step ), which forms a complex with cellular proteins and 
mediates IE gene activation. IE mRNAs are transported to the cytoplasm where they are 
translated and transported back to the nucleus to activate transcription of the E genes and 
regulate the IE genes (Weir, 2001).  
Functional ICP4 is necessary for transcription of the early genes (step ). Once 
transported to the nucleus and translated, early proteins are mostly responsible for DNA 
replication and production of substrates for DNA synthesis (step ). DNA replication leads to 
late gene expression (step ). After transport to the cytoplasm and translation, late proteins are 
primarily structural or involved in virus assembly and particle egress. Nucleocapsid assembly and 
DNA packaging is completed in the nucleus (step ). Thus nucleocapsids have to cross the 
nuclear envelope. How this occurs is a matter of debate and has been recently reviewed 
(Mettenleiter, Muller, Granzow, & Klupp, 2013). The nucleocapsid, together with some 
tegument proteins, buds from the inner nuclear membrane into the perinuclear lumen, 
acquiring an envelope containing immature viral membrane proteins (step ). Immature virions 
fuse with outer nuclear membrane releasing the nucleocapsid into the cytoplasm (step ). 
Tegument proteins added in the nucleus remain with the nucleocapsid whilst others are added 
in the cytoplasm. This particle is transported to a late Golgi compartment or endosome 
containing mature viral membrane proteins which it acquires as it buds into the compartment 
(step ). The enveloped virus particle then buds into a vesicle where it is released by exocytosis 
(S. J. Flint, 2004; Weir, 2001) (step (11)). 
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Figure 1.3 HSV life cycle 
  Adapted from (S. Flint, Enquist, Racaniello, & Skalka, 2004). 
  
C. Pathogenesis 
The transmission of human infection with either HSV1 or HSV2 is dependent on intimate 
personal contact of a susceptible individual with someone secreting HSV. Virus must come in to 
contact with mucosal surfaces or abraded skin for infection to be initiated. HSV2 usually affects 
the genital or adjacent areas, with transmission being sexual. In contrast, HSV1 usually causes 
oropharyngeal infection. However both viruses can cause oropharyngeal or genital infections. 
Approximately 20% of HSV2 seropositive people suffer overtly recognisable recurrences of 
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genital herpes, about 60% have lesions but do not recognize their herpetic nature and the 
remaining 20% have true asymptomatic viral shedding (Dwyer & Cunningham, 2002; Koelle & 
Corey, 2003a; Stanberry et al., 2000). Genital herpes can therefore be easily passed on 
unintentionally to sexual partners. 
Viral replication occurs at the site of infection (the skin or mucosal surface) within 
epidermal cells (primarily keratinocytes), the virus enters corresponding terminal axons of 
sensory neurons and unenveloped nucleocapsids are transported to the dorsal root ganglion, by 
retrograde axonal transport, where latency is established. Therefore, the fundamental principle 
of HSV disease is that HSV replicates at mucosal surfaces, is transported to dorsal root ganglia 
and becomes latent. After establishment of latency a stimulus such as stress can cause 
reactivation of the virus from its latent state, the virus is then transported anterogradely along 
the sensory nerves, through cutaneous nerve endings and then replicates in the epidermal cells 
at mucocutaneous sites where it is either shed without symptoms or becomes clearly apparent 
as vesicles or ulcers.  
1.1.2. Impact on human health 
A. Epidemiology 
HSV is a ubiquitous human pathogen, HSV1 seroprevalence is over 80-90% in many 
countries (Hofstetter, Rosenthal, & Stanberry, 2014; Smith & Robinson, 2002), and HSV2 is 
estimated to affect over 16% of the global population aged 15-49 years (Looker, Garnett, & 
Schmid, 2008). In the US, seroprevalance for HSV1 and HSV2 is approximately 58% and 16% 
respectively ("Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--
United States, 2005-2008," 2010; F. Xu et al., 2006). In Australia, HSV1 seroprevalance is 76% 
with significant differences by age, sex and ethnicity, HSV2 seroprevalence was 12% among 
adults (Cunningham et al., 2006). As HSV infection is so wide-spread across the global 
population, the disease burden is significant as the more rare complications caused by HSV are 
amplified across the global population. 
B. Disease Burden 
HSV infections, both types 1 and 2, present a significant global health burden and there 
is a critical need for a vaccine to alleviate suffering associated with HSV (Johnston, Koelle, & 
Wald, 2014). The most significant morbidities caused by HSV include vision loss, neonatal 
herpes, encephalitis, and genital herpes disease causing increased HIV acquisition. 
HSV causes significant eye disease, a delay in HSV1 seropositivity has been linked to an 
increase in ocular HSV (Liesegang, Melton, Daly, & Ilstrup, 1989) and a cell mediated Th1 
Chapter 1 - Introduction 
 
6 
 
response is associated with clearance of HSV ocular disease (Borkar et al., 2014). Eye disease 
caused by HSV2 has been linked to delayed neonatal recurrences (Liesegang, 2001 472). The 
precise prevalence of vision loss from HSV keratitis is unknown but is estimated to be 40, 000 
cases per year and is increasingly important relative to other causes of infectious blindness, the 
annual incidence of corneal epithelial ulceration or stromal disease from HSV is roughly 4.5 
million (Farooq & Shukla, 2012).   
HSV1 encephalitis is the most common cause of fatal sporadic encephalitis in the US 
(Hanley, Johnson, & Whitley, 1987), accounting for approximately 10-20% of the 20, 000 annual 
viral encephalitis cases (Levitz, 1998; Whitley, 1990). HSV is the most commonly identified 
pathogen in patients hospitalised with encephalitis in Australia (Huppatz et al., 2009). A 
nationwide retrospective study of HSV encephalitis in Sweden found an incidence of 2.2 cases 
per million per year with an overall mortality rate of 25.4%, of the survivors, 87% were 
readmitted to hospital with complications (Hjalmarsson, Blomqvist, & Skoldenberg, 2007). 
Genital herpes in developed countries is increasingly caused by HSV1 (Ryder, Jin, 
McNulty, Grulich, & Donovan, 2009), especially in adolescents. A decline in HSV1 seroprevalance 
in early life and adolescents (F. Xu et al., 2006) has resulted in the first exposure to HSV1 often 
occurring at initiation of sexual contact (Johnston et al., 2014). 
HSV2 infection affects an estimated 436 million people aged 15-49 years globally (Looker 
et al., 2008). People with a HSV2 infection have a three-fold increased risk of acquiring a HIV 
infection (Barnabas et al., 2011; Freeman et al., 2006; Horbul, Schmechel, Miller, Rice, & 
Southern, 2011) also, HIV and HSV2 co-infected persons have a higher HIV viral load and are 
more likely to transmit HIV (Celum et al., 2010; Gray et al., 2001). It has been estimated that in 
some areas, such as sub-Saharan Africa, HSV2 infection may account for 30-50% of new HIV 
infections (Freeman et al., 2007; Freeman et al., 2006), therefore a vaccine against HSV2 
infection could have a dramatic impact on HIV spread (Gottlieb et al., 2014). To achieve an 
effective HSV vaccine, a greater understanding of adaptive immunity, antigen presentation, and 
vaccine formulations are needed. 
1.2. Immunity to pathogens 
The immune system has a variety of mechanisms to defend against invading pathogens. 
Of great importance in modern medicine is the use of vaccines to harness the immune system’s 
ability to establish immunological memory so that adaptive immune responses may be mounted 
quickly against invading pathogens. Both the innate immune system and the adaptive immune 
system are involved in shaping the immune response to infections. Sensing of pathogen 
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associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs) on cells of the 
innate immune system including phagocytes (macrophages and neutrophils), dendritic cells 
(DCs), mast cells, basophils, esosinophils and natural killer (NK) cells, results in activation of 
these innate cells which respond with recruitment of immune cells to sites of infection through 
production of cytokines, killing of infected cells and uptake and clearance of microbes and cell 
debris. Through innate cells, two main arms of the adaptive immune response result in the 
development of memory through humoral and cell-mediated immunity. 
1.2.1. Humoral Immunity 
Stimulation of a potent, broad neutralising antibody response has long been an 
important correlate of protection against infectious pathogens. B cells can recognise free antigen 
directly (which can be protein or carbohydrate based antigen), or presented by antigen 
presenting cells (APCs), enhanced by CD4+ T cells help. Once activated, B cells proliferate and 
differentiate into antibody secreting plasma cells and memory B cells.  Antibodies are able to 
bind to and neutralise pathogens, preventing infection, activate opsonophagocytosis, 
complement fixation and ADCC. Understanding the precise mechanisms by which antibodies 
confer protection against pathogens and learning how to induce protective responses with 
appropriate adjuvants represent the key areas of current research (Plotkin, 2010). Antibodies 
play an important role during the acute phase of infection, however antibodies alone are often 
not capable of eliminating virus once infection has occurred, once infection is established, cell-
mediated mechanisms are of great importance in host defence.  
1.2.2. Cell-mediated Immunity (CMI) 
Cell-mediate immunity protects hosts from infectious pathogens through the activation 
of antigen-specific cytotoxic T cells that induce apoptosis of cells displaying foreign epitopes, 
such as a virally infected cell, the stimulation of cytokines leading to further recruitment of 
immune cells to the site of infection, and activation of additional immune cells such as 
macrophages and NK cells, enabling them to destroy intracellular pathogens. There are two main 
types of T cells, CD4+ T cells and CD8+ T cells. CD4+ T cells have been subdivided into many 
subsets, depending on the effector function they carry out and the cytokines they produce that 
promote different immune response such as T helper 1 (Th1), the predominant anti-viral 
phenotype, Th2, that promote humoral responses, Th17 that promote protective immunity 
against extracellular bacteria and fungi, T follicular helper (TFH) that promote germinal centre 
responses, particularly B cell class switching and regulatory T cells. CD8+ T cells predominantly 
carry out cytotoxic and cytokines production functions. 
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To stimulate activation, differentiation, and proliferation of naïve CD4+ and CD8+ T cells 
into effector and memory cells, naïve T cells need to receive three main signals from 
professional APCs. Signal one is received from the exquisitely specific interaction of the T cell 
receptor (TCR) with the antigen-derived peptide loaded onto the major histocompatibility 
complex (MHC) class I for presentation to CD8+ T cells and class II for presentation to CD4+ T 
cells. Minute amounts of surface antigens presented on MHC can trigger T-cell responses 
(Sykulev, Joo, Vturina, Tsomides, & Eisen, 1996; Valitutti, Muller, Dessing, & Lanzavecchia, 1996). 
Signal two is generally thought of as signalling through costimulatory molecules expressed on 
the surface of APCs, however, ‘signal two’ is likely to be a fine balance of positive and negative 
costimulatory signals emanating from many receptors (Reis e Sousa, 2006). Signal three is 
provided by the APC to the T-cell, generally cytokine signalling, that determine its differentiation 
into an effector cell (for example differentiation into TH1 cells or TH2 cells). All three signals play 
decisive roles in T cell immunity and will be discussed here, focussing particularly on responses 
to viral infections and generation of TH1 T cell immunity. 
It has become increasingly apparent that many factors affect the generation of these 
three T cell activation signals provided by APCs. DCs are consummate professional APCs, adept 
at antigen capture, processing, and peptide presentation as well as expressing a large array of 
innate PRRs, and are the main APCs responsible for activating T cells.  Antigen processing, 
presentation, costimulatory receptor expression, and secretion of cytokines, are all influenced 
by the type of antigen being taken up, processed and presented, and the environment around 
the DC. The presence and timing of inflammatory signals, such as PAMPs and danger-associated 
molecular patterns (DAMPs), all lead to differing T cell responses (Figure 1.4) (Fehres, Unger, 
Garcia-Vallejo, & van Kooyk, 2014; Nierkens, Tel, Janssen, & Adema, 2013).  
Chapter 1 - Introduction 
 
9 
 
 
Figure 1.4 T cell activation signals provided by DCs are affected by many factors 
  (Nierkens et al., 2013). 
 
1.2.3. Antigen presentation to T cells 
A. MHC structure and peptide binding 
The MHC molecules, also referred to as the human leukocyte antigen (HLA) on human 
cells, are a set of molecules displayed on the surface of cells that present antigen to T cells. The 
‘antigen’ is in the form of a linear peptide sequence commonly 8-10 amino acids (or 9-15 for 
class II) in length, derived generally from foreign (or self) protein degraded and cleaved within 
the cell. 
The MHC class I (MHC I) molecule, which presents peptide to CD8+ T cells, consists of a 
membrane-spanning α chain (heavy chain), derived from the MHC I genes (HLA-A, HLA-B, or 
HLA-C), and a β chain (light chain), referred to as β2-microglobulin (Figure 1.5).  The α1 and α2 
domains fold to form a deep groove where peptide binding can occur. The variation among 
different MHC alleles, dictating what peptides can bind, occurs in the α chain. The β2-
microglobulin interacts with the α chain and provides essential molecular stability to allow 
peptide binding. The deep peptide binding groove of MHC I has closed ends, consequently the 
MHC I molecule accommodates a shorter peptide, typically around 9 residues long, although 
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peptides 8-16 residues long have been found to bind with the longer peptides bulging out in the 
middle.   
The MHC class II (MHC II) molecule, which presents peptide to CD4+ T cells, is a 
heterodimer consisting of an α and a β chain, both with transmembrane regions. The peptide 
binding groove of a MHC II molecule contains a rather flat structure, the β-pleated sheet on the 
bottom of the groove and α-helices which form the ‘walls’ of the groove. In contrast to MHC I, 
the MHC II binding groove is open-ended, hence it can accommodate up to 20 amino acid 
residues. 
 
Figure 1.5 Structure of MHC class I and class II molecules. 
(Left) Peptide binding for MHC I occurs at the α1 and α2 binding domains, Beta2-microglobulim 
(β2m) stabilises MHC I and the immunoglobulin-like domain (α3) is connected to the 
transmembrane region (TM) and the cytoplasmic tail. The MHC II molecule is a heterodimer 
where the α1 and β1 domains form the peptide binding groove, the immunoglobulin-like 
domains (α2 and β2) connect to the TMs and the cytoplasmic tails (Klein & Sato, 2000). (Middle) 
Ribbon structure of the tertiary structure of MHC I (Klein & Sato, 2000). (Right) The α-helices of 
MHC I have ends that enclose, therefore it can only accommodate a smaller peptide (8-11 
residues long). In contrast, the ends of class II MHC have open ends, allowing for accommodation 
of a longer peptide (Abbas & Lichtman, 2005). 
 
Peptides binding to MHC molecules have a fixed orientation, most of the amino acid 
side-chains protrude out of the groove, those pointing into the groove are generally housed in 
special pockets in the groove floor (referred to as anchoring pockets) which are responsible for 
determining binding specificity. These anchoring pockets dictate which amino acids (referred to 
as anchoring residue) are able to bind to the MHC molecule (Figure 1.6). HLA alleles are highly 
polymorphic with nearly 12,000 known today, with 8,900 of them belonging to HLA I (Robinson 
et al., 2011). Different HLA alleles (or types) show strong preference for specific anchoring 
residues in their binding pockets. These binding preferences have allowed development of 
peptide binding prediction as well as clustering HLA alleles into HLA supertypes where members 
belonging to a supertype bind a highly shared set of peptides (O. Lund et al., 2004; Sette & 
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Sidney, 1999). This increased understanding of peptide binding and HLA supertypes has enabled 
the practicabilty of peptide based vaccines, immune-therapeutic targets, and diagnostic agents. 
 
 
Figure 1.6 Peptide binding to HLA class I molecules 
(Left) Peptides bind to HLA molecules through specific anchoring residues that preferentially fit 
into peptide binding pockets. Different HLA alleles preference different anchoring residues 
(highlighted in yellow) (Klein & Sato, 2000) (Right) HLA alleles have been clustered into HLA 
supertypes according to their peptide binding repertoires (O. Lund et al., 2004). 
 
 
 
B. MHC antigen presentation pathways 
A major difference between MHC class I and class II is the pathway through which 
peptides are sourced.  MHC antigen presentation has been thoroughly reviewed (Blum, 
Wearsch, & Cresswell, 2013; van Montfoort, van der Aa, & Woltman, 2014; Vyas, Van der Veen, 
& Ploegh, 2008). As a simplified classical paradigm, MHC I peptides are derived from proteins 
originating in the cytoplasm of the cell, such as cytosolic self-proteins or intracellular pathogens. 
MHC II peptides are derived from extracellular proteins, endocytosed by the cell into endosomes 
that eventually mature into late endosomes and lysosomes. Endosomal maturation is driven in 
part by processes such as increased luminal acidification and fusion with trans-Golgi network 
derived vesicles delivering enzymes that promote antigen denaturation and proteolysis (Figure 
1.7). As such, MHC I is present on the cell surface of all nucleated cells and MHC II is present only 
on professional APCs such as B cells, macrophages, and DCs or induced on some cells by 
cytokines such as TNF- and IFN-. In professional APCs, particularly DCs, there is a process 
through which exogenous antigen, engulfed by the DC, can be presented on MHC I, referred to 
as cross-presentation.  
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Figure 1.7 MHC class I and class II presentation pathways 
The MHC II pathway – peptides loaded onto the class II MHC molecule and presented to CD4+ T 
cells are derived from extracellular proteins that have been phagocytosed, endocytosed, 
pinocytosed, or autophagocytosed. The MHC class I pathway – peptides loaded onto the class I 
MHC molecule and presented to CD8 T cells are derived from cytosolic proteins, either self or 
non-self such as from viral replication within an infected cell. Cross-presentation pathway – 
antigen derived from exogenous sources is taken up by DCs and transported into the cytosol to 
follow the classical MHC I presentation pathway or follow the vacuolar pathway where peptides 
are degraded by lysosomal proteases and transferred loaded onto recycled MHC I molecules and 
transported to the cell surface. 
 
B.i. The classical MHC class I antigen presentation pathway 
As viruses are obligate intracellular pathogens and replicate and synthesize their 
proteins within infected cells, it is important for the immune system to recognize cytosolic 
antigens harboured within any cell type. In the classical MHC I presentation pathway, cytosolic 
proteins, derived from either self-proteins or from infectious pathogens, are degraded mainly by 
the proteasome into peptides between 3 and 20 amino acids in length. This process of 
proteasomal degradation is a highly complex process and not completely understood (Hansen & 
Bouvier, 2009). In a steady-state system this proteolysis occurs in an ATP-dependant manner by 
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constitutively expressed catalytic subunits that make up the proteasome, called the 20S core 
particle, which is capped at both ends by the 19S regulatory particle (Baumeister, Walz, Zuhl, & 
Seemuller, 1998; Hansen & Bouvier, 2009). A so-called ‘immunoproteasome’ also exists; 
immunomodulatory cytokines, particularly IFN-, induce the synthesis of new proteasomal 
subunits which replace constitutive subunits in the core 20S proteasome, altering the cleavage 
mechanism resulting in an optimised generation of dominant T cell epitopes (Dick et al., 1996). 
Immunoproteasomes are constitutive to some degree in APCs, particularly in DCs, further 
induction of the immunoproteasome can be activated through cytokines or TLR ligands such as 
LPS which triggers up-regulation of the proteasome activator PA28β (Ossendorp et al., 2005). 
The peptide products of proteasomal degradation are then transported into the endoplasmic 
reticulum (ER) by transporter associated with antigen processing (TAP) complex. The TAP 
complex consists of TAP1 and TAP2, the transmembrane helices of these two molecules form a 
pore across the ER membrane through which peptides can then be transported (Schmitt & 
Tampe, 2002). In the ER, peptides can be further trimmed by peptidases ER aminopeptidase 1 
(ERAP1) and ER aminopeptidase 2 (ERAP2) in humans, as well as other as-yet-unidentified 
peptidases (Saveanu et al., 2005). Nascent MHC I heavy chains and β2-microglobulin molecules 
associate with calreticulin, tapasin, and ERp57 to form the peptide loading complex, which 
facilitates the loading of peptides into the peptide binding groove. Kinetically stable MHC I 
molecules then transit to the cell surface to be presented to CD8+ T cells.  
B.ii. The cross-presentation pathway 
Cross-presentation is a highly complex process that is still incompletely understood. It 
has been the subject of much study and many extensive reviews in recent years (Blum et al., 
2013; Fehres et al., 2014; Joffre, Segura, Savina, & Amigorena, 2012; Kreer, Rauen, Zehner, & 
Burgdorf, 2011; Nair-Gupta & Blander, 2013; Neefjes & Sadaka, 2012; Nierkens et al., 2013; 
Schuette & Burgdorf, 2014; van Montfoort et al., 2014; Wagner, Grotzke, & Cresswell, 2012). 
The main ideas will be briefly discussed here. Cross-presentation is an efficient mechanism 
exploited by DCs to initiate immunity against exogenous antigen, derived from infectious 
pathogens that both do and do not infect DCs. The wealth of available experimental evidence 
has shown that multiple pathways can lead to cross-presentation of exogenous antigen on MHC 
I and appears dependent on the type of antigen and the signals it triggers, the nature of the 
antigen presenting cell, and the immunologic environment around the cell.   
Two main model pathways have been proposed for cross-presentation of exogenous 
antigens, referred to as the ‘cytosolic’ and the ‘vacuolar’ pathways. In the vacuolar pathway, 
endocytosed antigens remain in the endosomal/ lysosomal compartments where they are 
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degraded by lysosomal proteases and loaded onto MHC I recycled from the cell surface. A 
tyrosine motif in the cytoplasmic tail of the MHC I heavy chain facilitates recycling of low levels 
of MHC I molecules from the cell surface to endosomes, although direct delivery of immature 
MHC I from the ER to endosomes may also occur in DCs (Ackerman, Kyritsis, Tampe, & Cresswell, 
2003; Basha et al., 2012; I. Chiu, Davis, & Strominger, 1999; Reid & Watts, 1990). In the cytosolic 
pathway exogenous antigens are translocated from the endosome into the cytosol, degraded by 
the proteasome and presented via the classical MHC I pathway. The cytosolic pathway is 
therefore susceptible to proteasomal inhibitors.  
How antigens are translocated from endosomes to the cytosol remains an open 
question, several proteins have been implicated in this process and it is still poorly understood. 
Unfolding of protein appears to be essential, -interferon-inducible lysosomal thiol reductase 
(GILT) has been found to be required for efficient translocation (Singh & Cresswell, 2010; West & 
Cresswell, 2013). The ER-associated degradation (ERAD) machinery has been implicated as 
having a crucial role in this process (Ackerman, Giodini, & Cresswell, 2006; Imai, Hasegawa, 
Maruya, Koyasu, & Yahara, 2005). A suggested pore-building protein, Sec61, has been 
demonstrated to be involved in cross-presentation, but currently it’s mechanism and role is still 
controversial (Ackerman et al., 2006; Imai et al., 2005; Schuette & Burgdorf, 2014).  After 
translocation to the cytosol and proteasomal degradation, it was presumed antigen-derived 
peptides were transported to the ER by TAP to enter the classical MHC I presentation pathway. 
However it has been demonstrated that functional TAP is found on phagosomal membranes 
(Ackerman et al., 2006; Guermonprez et al., 2003; Houde et al., 2003) and that at least in the 
instance of a soluble mannose receptor (MR)-internalised antigen, loading of MHC I occurs 
within early endosomes (Burgdorf, Scholz, Kautz, Tampe, & Kurts, 2008). When MHC I loading is 
occurring within endosomes, the insulin-regulated aminopeptidase (IRAP) is potentially a 
substitute for ERAP1 as it has been shown to promote antigen cross-presentation (Saveanu et 
al., 2009). Endosomal/phagosomal loading has been further supported by the observation that 
proteasomes are often found in association with endosomes (Houde et al., 2003). The derivation 
of new MHC I molecules is also a matter of great debate: the ER-phagosome fusion pathway 
involves fusion of the ER-Golgi intermediate compartment (ERGIC). The trafficking of the ERGIC 
to phagosomes/ lysosomes has been shown to be mediated by Sec22b, peptide loading 
machinery, such as TAP (Cebrian et al., 2011), are transported. This process occurs under steady-
state conditions and is not influenced by PRRs (Nair-Gupta et al., 2014).  However, it has been 
recently shown that Rab11a positive vesicles that are enriched in MHC I molecules are rapidly 
recruited to phagosomes upon signalling by PRRs (Nair-Gupta et al., 2014), suggesting that 
specialised vesicles enriched in MHC I are heavily involved in cross-presentation. 
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One major influence on cross-presentation appears to be the length of time that the 
antigen is able to persist in early endosomal compartments and not progress to degradative 
acidified lysosomes (Savina et al., 2006).  It does appear that when antigens are targeted to 
specific receptors, this has a large influence on the endosomal compartments to which they are 
trafficked, which in turn influences how well the antigens are cross-presented. Burgdorf et al 
found that the model antigen OVA was directed towards degradative lysosomal compartments 
where it was quickly degraded and poorly cross-presented when it was endocytosed via 
scavenger receptors by murine DCs. However, when OVA was endocytosed via MR it was 
targeted to a pool of early endosomes that did not mature to lysosomes, and therefore escaped 
rapid degradation and allowed OVA to be cross-presented (Burgdorf, Kautz, Bohnert, Knolle, & 
Kurts, 2007). Similarly it was found that targeting MR or CD40 through antibody-conjugated 
antigens, delivered antigen into non-degradative endosomes, and was more efficient at inducing 
cross-presentation (Chatterjee et al., 2012).  DEC-205 antibody-targeted antigens, in contrast, 
delivered antigens into lysosomal compartments where it was rapidly degraded resulting in poor 
cross-presentation. Adding to the confusion, it has been identified that targeting different 
regions of the C-type lectin receptor DC-SIGN directed antigen to different endosomal 
compartments; using OVA conjugated to antibodies specific for the neck region or the 
carbohydrate recognition domain, antigen was being directed towards early endosomes and 
efficient cross-presentation or lysosomal compartments and poor cross-presentation 
respectively (Tacken et al., 2011). While it is now apparent that PRRs direct cross-presentation 
by trafficking to different endosomal compartments, much work still needs to be done to find 
what are the ideal receptors to target with different antigens. 
B.iii. The MHC class II antigen presentation pathway 
Peptides presented on MHC II molecules are mainly derived from exogenous antigen. 
MHC II molecules are assembled in the ER with a specific chaperone, called the invariant chain, it 
associates in the peptide-binding groove and stabilises the MHC II molecule. The invariant chain 
ensures that there is minimal peptide binding early in MHC II synthesis (Roche & Cresswell, 
1990; Teyton et al., 1990). After assembly, the MHC II-invariant chain complex leaves the ER and 
is routed to the endocytic pathway. After fusion with endosomes, the invariant chain is released 
by progressive proteolysis in acidified endosomes (Blum et al., 2013). The invariant chain is 
eventually broken down to a variably extended peptide of roughly 20 amino acids, called class II-
associated invariant chain peptide (CLIP), which is associated with the peptide binding groove. 
With the facilitation of HLA-DM, a MHC-coded protein that is highly homologous to MHC II, CLIP 
is released from the MHC II peptide binding groove after HLA-DM promotes a conformational 
change that induces CLIP dissociation. CLIP removal only occurs at an acidic pH (Denzin & 
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Cresswell, 1995; Sherman, Weber, & Jensen, 1995; V. S. Sloan et al., 1995). Assisted by HLA-DM, 
antigenic peptides can then be loaded onto the MHC II peptide binding groove. When exported 
from the ER, HLA-DM is in association with HLA-DO in certain subsets of DCs and B cells. The role 
of HLA-DO has not yet been fully elucidated but appears to up- or down-modulate presentation 
of certain peptides resulting in an altered peptide repertoire (Poluektov, Kim, & Sadegh-Nasseri, 
2013). The peptide-loaded MHC II molecules can then be trafficked to the cell surface for 
presentation to CD4 T cells.  
Endogenous antigen can also access the MHC II presentation pathway through 
autophagy. Indeed 10-30% of the peptides bound to MHC II are derived from cytoplasmic and 
nuclear proteins (Crotzer & Blum, 2010). In autophagy, nuclear, cytoplasmic material and 
intracellular pathogens are engulfed by isolation membranes to form autophagosomes. The 
autophagosomes then fuse with endosomes and lysosomes, facilitating antigen presentation by 
MHC II (Blum et al., 2013).  
C.  Dendritic cells 
C.i. Subsets 
The orchestration of an effective adaptive immune response in vertebrates is dependent 
on DCs, a class of bone-marrow derived cells found in the blood, non-lymphoid tissue suck as 
skin, and lymphoid tissues. DCs are highly effective at detecting and capturing antigens and 
subsequently influence the magnitude of the innate and adaptive immune response. Much of 
our understanding of DCs, subset ontogeny, and function, have been extrapolated from studies 
in murine systems, human DC immunobiology, however, is only just beginning to be understood. 
In humans, the most studied DCs are found circulating in blood and skin. Several recent reviews 
have discussed human DC immunobiology (Collin, McGovern, & Haniffa, 2013; Guilliams et al., 
2014; Merad, Sathe, Helft, Miller, & Mortha, 2013; Segura & Amigorena, 2014), the most 
relevant aspects will be discussed here. 
In humans, all DCs express high levels of MHC II (HLA-DR) and classically lack the typical 
lineage markers (CD3, CD19, CD20, CD14, and CD56) (Figure 1.8). There are two main 
populations of DCs found in the blood, plasmacytoid DCs (pDCs) and myeloid DCs (mDCs). pDCs 
represent a subset of DCs that are the most divergent from the other DC populations, they are 
found mainly in the blood and lymphoid tissues. They express lower levels of MHC II, co-
stimulatory molecules, and PRRs, in their steady state compared to other DCs but upon 
recognition of foreign antigen, particularly CpG motifs, produce massive amounts of type I IFN, 
particularly IFN-α. mDCs are often thought of as mouse CD11c+ ‘conventional’ or ‘classical DCs’, 
in humans both monocytes and mDCs express CD11c, but mDCs lack CD14 and CD16. There are 
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two mDC subsets expressing the nonoverlapping markers BDCA1 (CD1c) and BDCA3 (CD141). 
BDCA1+ DCs are by far the most predominant, the BDCA3+ DCs are a much smaller population.  
 
Figure 1.8 Phenotype of human DC subsets. 
This figure summarises the phenotype and pathogen receptor profile of human DC subsets and 
their mouse equivalents. ND means not determined. Adapted from (Merad et al., 2013). 
 
 In the skin, the epidermis is populated by a subset of dendritic cells termed Langerhans 
cells (LCs). LCs stand apart from other tissue DCs through their unique ontogeny and 
homeostatic properties (Ginhoux & Merad, 2010; Merad et al., 2013). Compared to the dermal 
DCs, LCs express lower levels of MHC II, intermediate levels of CD11c and very high levels of the 
C-type lectin receptor langerin (CD207) (Valladeau et al., 1999). Human (but not mouse) LCs also 
express high levels of CD1a (Fithian et al., 1981). Earlier studies identified two main subsets of 
dermal DCs, CD1a+CD14-DCs and CD1a-CD14+DCs (Lenz, Heine, Schuler, & Romani, 1993; Nestle, 
Zheng, Thompson, Turka, & Nickoloff, 1993), however the CD1a-CD14+DCs have very recently 
been identified as being from macrophage lineage, as such their murine counter parts are 
CD11b+CD64+ monocyte-derived-macrophages (MDM) (McGovern et al., 2014) . Recent studies 
have also identified BDCA3+ DCs that express the receptors XCR1, TLR3, CLEC9A, and Necl2 
(Haniffa et al., 2012; Merad et al., 2013; Zaba, Fuentes-Duculan, Steinman, Krueger, & Lowes, 
2007; Zaba, Krueger, & Lowes, 2009).  
In addition to blood and tissue resident DCs, there is also a population of DCs that are 
now referred to as inflammatory DCs that transiently form in response to infection or 
inflammatory stimuli and disappear once the inflammation resolves. The phenotype of 
inflammatory DCs are likely influenced by the nature of the stimuli and the kinetics of analysis 
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(Merad et al., 2013). In HSV infection in the skin in mice, inflammatory DCs are differentiated 
from infiltrating monocytes and these monocyted-derived DCs (MDDCs) form the predominant 
population in a HSV lesion (Eidsmo et al., 2009; A. S. Macleod & Havran, 2011). In humans, it has 
been shown that inflammatory DC are present in ascites from untreated ovary and breast cancer 
patients, and from synovial fluid from rheumatoid arthritis patients, and are enriched for a 
MDDC gene signature, suggesting they are also derived from monocytes (Segura et al., 2013). 
 Experimentally, in vitro models of dendritic cells are differentiated from isolated CD14+ 
monocytes by the cytokines interleukin (IL)-4 and granulocyte-macrophage colony-stimulating 
factor (GM-CSF) (Palucka, Taquet, Sanchez-Chapuis, & Gluckman, 1998; Sallusto & Lanzavecchia, 
1994). They are generated with an immature phenotype and are termed immature monocyte-
derived dendritic cells (iMDDCs) in this thesis. Using inflammatory cytokines they can also be 
stimulated into a mature phenotype. iMDDCs are not the same as their in vivo counterparts, but 
are functionally and phenotypically similar. Indeed, cluster analysis of dendritic cell subsets from 
skin showed that iMDDCs clustered closely with CD14+ dermal DC, suggesting they represent a 
real in vivo subset and are a relevant human model (Harman et al., 2013). Another study found 
MDDCs clustered closely with inflammatory DCs (Segura et al., 2013). However, as Harman et al 
did not include inflammatory DCs, and Segura et al did not include CD14+ dermal DCs in their 
studies, it is still not possible to suggest which in vivo subset iMDDCs are most representative of. 
In mice, a similar model is used, generally referred to as bone-marrow-derived DCs (BMDCs) (Y. 
Xu, Zhan, Lew, Naik, & Kershaw, 2007). 
 Between the different DC subsets, they present a different array of PRRs and differ in 
their ability to cross-present. This has been most appreciated in the mouse where it appeared 
there is a striking difference between DCs, CD8+ DCs, inflammatory DCs, and the model BMDC 
cross-present efficiently due to specific features in their endocytic pathway, where as other DCs 
rarely cross-present (Joffre et al., 2012). However, if the right stimulus and antigen are provided, 
other DC types are capable of cross-presenting and activating CD8+ T cells (Desch et al., 2014). 
Studies of cross-presentation of human DCs are much more limited than the mouse and have 
been recently reviewed (Segura & Amigorena, 2014).  There is large variability in the DC subsets 
found to be capable of cross-presenting, it is likely very dependent on both the type of antigen 
and the stimulus, and there is much more work to be done to elucidate the specifics of these 
complex processes. 
C.ii. PRRs/ Toll-like receptors 
PRRs are evolutionary conserved receptors that recognise and respond to PAMPs that 
are unique to microbes (Blander & Sander, 2012). Upon PRR activation, intracellular signal 
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transduction pathways are initiated that are critical for providing immunity against infection by 
many pathogens. Several families of mammalian PRRs have been identified, namely Toll-like 
receptors (TLRs), nucleotide-binding oligomerisation domain-like (NOD-like) receptors, RIG-I like 
receptors (RLRs), and C-type lectin receptors (CLRs). TLRs were the first family of PRRs to be 
studied in detail (Nair-Gupta & Blander, 2013). 
The existence of TLRs was first predicted in 1989 by Charles Janeway (Janeway, 1989), 
Toll-like receptor 4 (TLR4) was eventually identified in 1998 as the lipopolysaccharide (LPS) 
receptor, shortly after that discovery, several other microbial products were tested as possible 
ligands for other TLRs (the history of TLRs has been reviewed recently (O'Neill, Golenbock, & 
Bowie, 2013) as well as many other reviews on TLR signalling (Akira & Takeda, 2004; Kawai & 
Akira, 2011; Nair-Gupta & Blander, 2013; Reynolds & Dong, 2013).  Ten human TLRs have now 
been identified (TLRs 1-10) and twelve mouse TLRs (TLRs 1-9 and 11-13). TLRs are differentially 
located in cells, TLRs 1, 2, 5, 6, and 10 are located at the cell membrane, TLRs 3, 7, 8 and 9 are 
located in endosomes only, TLR4 is located at both the cell surface and in endosomes (Figure 
1.9). The TLRs are dimers and appear to be activated and form ‘m’ shaped structures when their 
respective ligands bind (Jin & Lee, 2008; L. Liu et al., 2008). The ligands of TLRs 1-9 have been 
identified and are shared between humans and mice. TLR5 senses flagellin, TLR4 senses LPS and 
some viral envelope glycoproteins, TLR2 forms heterodimers with TLR1 and TLR6 to bind 
triacylated or diacylated lipopeptides respectively, TLR3 senses double stranded RNA, TLRs 7 and 
8 have been found to sense viral single stranded RNA, and recently TLR8 has been found to also 
sense bacterial RNA releases within phagosomal vacuoles (Cervantes, Weinerman, Basole, & 
Salazar, 2012), TLR 9 has been found to sense CpG-rich hypomethylated DNA motifs. The ligand 
for TLR10 has not yet been identified, however it’s sequence is most similar to TLR1 and appears 
to belong to the same sub-family as TLR1 and TLR6 and therefore may heterodimerize with TLR2 
(Govindaraj, Manavalan, Lee, & Choi, 2010), and it has been recently found that TLR10 is 
activated by influenza A virus (IAV) (S. M. Lee et al., 2014). Mouse TLR11 has been found to 
detect a component of uropathogenic bacteria, and with TLR12, a Toxoplasma gondii profilin 
protein. Mouse TLR13 has been shown to recognise bacterial ribosomal RNA (O'Neill et al., 
2013). These findings have established the TLRs as a family of receptors that can sense danger 
signals from infection or tissue damage. 
Once TLRs are activated by their respective ligands, they begin an intricate signalling 
pathway. Most of the TLRs signal through the myeloid differentiation primary-response protein 
88 (MYD88). Endosomal signalling from TLR 7, 8, and 9 was shown to be dependent on MYD88 
signalling, which led to activation of interferon-regulatory factor 7 (IRF7) signalling and the 
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induction of type I interferon (IFN) gene expression (Honda et al., 2005; Kawai et al., 2004; Latz 
et al., 2004).  TLR5, located on the cell plasma membrane, also signals through MYD88, TLR2-
TLR1, TLR2-TLR6, and TLR4 require and additional molecule, MYD88-adaptor-like-protein (MAL) 
to enable MYD88 signalling. MYD88 then interacts with a protein kinase termed IL-1R-associated 
kinase 1 (IRAK1), other IRAKs, particularly IRAK4 have been shown to be important receptor-
proximal kinases (reviewed in (Flannery & Bowie, 2010)). IRAK1 interacts with TNF receptor-
associated factor 6 (TRAF6), which is known to activate the NF-B pathway, resulting in the 
induction of expression of pro-inflammatory cytokines. TLR3 and endosomal TLR4 signal through 
a MYD88-independent signalling pathway involving the receptor TIR domain-containing adaptor 
protein inducing IFNβ (TRIF), with endocytosed TLR4 also requiring the adaptor molecule TRIF-
related adaptor molecule (TRAM) (Lundberg et al., 2013).  This MYD88-independent signalling 
pathway leads to induction of a type I IFN response via IRF3 (Kaisho, Takeuchi, Kawai, Hoshino, & 
Akira, 2001; Kawai et al., 2004). 
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Figure 1.9 Human Toll-like receptor signaling 
Ten human TLRs have now been identified, the respective ligands for TLRs 1-9 have now been 
identified (shown in grey boxes above). TLRs form dimers, TLRs 3, 4, 5, 7, 8, and 9 form 
homodimers and TLRs 1, 6, and possibly 10 form heterodimers with TLR2. TLRs are differentially 
located within the cell, some located on the cell plasma membrane, and others located within 
endosomes. TLR4 is the most complex, as it is located both at the cell surface and within 
endosomes. Most of the TLRs signal through MYD88, some in-conjunction with the adaptor 
protein MAL. TLR3 signals through an alternative molecule TRIF. TLR4 has the most complex 
signaling pathway as when located on the cell plasma membrane it signals through MAL and 
MYD88, but when endosomal TLR4 signals through TRIF and an additional adaptor molecule 
TRAM. Downstream signaling pathways involve interactions with IRAKs, and the adaptor 
molecules TRAFs, that lead to activation of mitogen-activated protein kinases (MKK 3-7), 
activation of  JUN N-terminal kinase (JNK) and p38 which go on to activate transcription factors 
such as cyclicAMP-responsive element binding protein (CREB) and activator protein 1 (AP1). Two 
important families are of transcription factors are activated downstream of TLRs are NF-B and 
IRFs culminating in induction of pro-inflammatory cytokines and type 1 IFN. 
 
Production of type 1 IFNs are crucial for mounting antiviral responses, type 1 IFNs 
activate the transcription of various genes involved in host resistance to viral infections, in 
addition to activating components of the innate and adaptive immune system. Type 1 IFNs 
include IFN-α, IFN-β, IFN-δ, IFN-ε, IFN-ω, IFN-κ, IFN-τ, and IFN-ζ, although IFNα and IFNβ and 
their roles are the best characterised (Takaoka & Yanai, 2006). The pro-inflammatory cytokines 
triggered by the TLRs in addition to the type 1 IFNs also include IL-1, IL-6 and TNFα (Akira & 
Takeda, 2004). Transcription of IFN-β requires both a IRF3 and NF-B pathways, IFN-β then 
initiates a classical positive-production feedback loop by binding to the type 1 IFN-α/β receptor 
in an autocrine and paracrine manner (Akira & Takeda, 2004). The JAK/ STAT pathway, inducing 
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the production of effector molecules called interferon stimulated genes (ISGs), this includes 
IRF7, which acts to further amplify type 1 IFN expression by activating transcription of IFN-α 
(Chan, Barra, Lee, & Ashkar, 2011). Collectively, the type I IFNs create an ‘antiviral’ state within 
the host cells and surrounding cells to aid in control of  viral infection. 
Activation of TLRs results in both maturation of DCs and alters antigen presentation 
pathways, resulting in increases in both cross-priming, where more CD8+ T cells are activated 
due to greater provision of signals two and three, and increases in cross-presentation, where 
more antigenic peptide makes its way on to MHC I to provide signal one. These two processes 
are difficult to tease apart, though several studies have shown that TLR signalling enhances 
cross-priming (Kurts, Robinson, & Knolle, 2010). Cross-presentation was found to be dependent 
on TLR signalling as DCs from TLR9-/- and MYD88-/- mice were unable to cross-present OVA after 
exposure to TLR ligands, however as the studies relied exclusively on T cell activation, cross-
priming and cross-presentation are impossible to distinguish (Datta et al., 2003; Maurer et al., 
2002).  Specific contributions of TLRs to cross-presentation are beginning to be elucidated, the 
use of biodegradable microspheres for the delivery of phagocytic cargo to DC showed that the 
presence of both the TLR ligand and antigen in the same phagosome induced efficient CTL 
responses compared to when the ligand and antigen are located in separate phagosomes 
(Schlosser et al., 2008). Recently it has been shown that both TLR4 and TLR2 induce recruitment 
of Rab11a vesicles enriched for MHC I to phagosomes, this process is MYD88 and TRIF 
dependent, demonstrating that TLRs directly orchestrate presentation machinery, Sec22b 
trafficking, in contrast, constitutively occurs independently of TLRs (Nair-Gupta et al., 2014).  
1.2.4. DC- T cell cross-talk 
As mentioned earlier, DCs provide three signals that shape the resulting T cell response, 
the first being the exquisitely specific interaction between MHC-peptide and the TCR, the second 
and third referring to signals provided by the DC itself. In steady-state conditions, where 
pathogens are absent and there are no additional inflammatory stimuli, DCs continuously 
sample the environment around them with ‘self’ antigen uptake and presentation to T cells. In 
the absence of additional stimuli, signal one, in the absence of signals two and three, renders the 
naive T cells anergic, to be deleted, or drives them into a regulatory cell fate, thus  promoting 
tolerance to these ‘self’ antigens.  
In an inflammatory setting, such as during a virus infection, DCs are triggered through 
PRRs and inflammatory cytokines to undergo a process that has been termed maturation (Figure 
1.10). Immature DCs are not very motile with expression of tissue homing receptors, such as the 
skin homing receptors cutaneous lymphocyte antigen (CLA) (Ebner et al., 1998). Migration of DCs 
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to lymph nodes and presentation of ‘self’ antigen does occur constitutively in the steady state, 
however, endocytosis of MHC II on the surface of DCs is high so the expression of MHC-peptide 
complexes is transient (Wilson, El-Sukkari, & Villadangos, 2004).  Immature DCs express lower 
amounts of MHC and adhesion molecules and are inefficient at forming conjugates with T cells 
compared to their mature counterparts (Benvenuti et al., 2004). They express low levels of the 
classical DC maturation markers CD40, CD80, CD83, and CD86 that are important for providing 
signal two to T cells. They also secrete negligible amounts of cytokines. 
 
Figure 1.10 Maturation of dendritic cells 
Once a maturation signal is sensed, antigen uptake and processing functions are transiently 
increased, then the DC switches states to reduced antigen uptake, increased migration capacity, 
increased MHC II and adhesion molecules, and increased co-stimulatory molecules and co-
stimulatory cytokine secretion. 
 
Upon response to maturation signals such as PAMPs and  pro-inflammatory cytokines, 
antigen uptake and processing functions of immature DCs are transiently increased (Reis e 
Sousa, 2006), subsequently the DC switches functional states, reducing antigen uptake and 
increasing phenotypic and functional molecules involved in antigen presentation. Fully mature 
DCs express high levels of CD40, CD80, CD86, and CD83 that are involved in T cell priming. MHC 
II expression is increased dramatically, adhesion molecules such as ICAM-1 are enhanced. Pro-
inflammatory cytokines are produced that stimulate T cells. DCs matured by PAMPs have been 
found to produce cytokines that make responding T cells resistant to the suppressive actions of 
regulatory T cells (Pasare & Medzhitov, 2003). It is now understood that there are more than just 
immature DCs and mature DCs, DCs can drive T cell responses in semi-mature states and never 
reach a ‘fully’ mature state, showing the variability and plasticity of DC responses (Dudek, 
Martin, Garg, & Agostinis, 2013; Reis e Sousa, 2006). 
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Signals two and three that lead to CD8+ T cell activation, as discussed above, can be 
provided by DC after maturation induced by PAMPs such as TLR ligands. Co-stimulation can be 
provided by CD80 and CD86, both members of the B7 family that interact with CD28 located on 
CD4 and CD8+ T cells (Figure 1.11). CD80/86 also engages with cytotoxic T-lymphocyte antigen 4 
(CTLA-4), which rather than activating T cells, can lead to tolerogenic T cell responses. DC-T cell 
conjugate formation is enhanced by adhesion molecules such as ICAM-1, ICAM-2, and ICAM-3 
interacting with LFA-1 on the T cell surface. Cytokine secretion provides signal three that leads to 
T cell activation. Cytokine secretion from activated CD4+ T cells can further activate CD8+ T cells, 
leading to stronger CD8+ T cell immunity. 
Mature DCs can prime CD4+ T cells but can also receive help and then become ‘licensed’ 
to prime (helper-dependent) CD8+ T cell responses (Behrens et al., 2004). DC licensing is a 
process that is achieved through cognate interactions between antigen-specific CD4+ T cells and 
antigen bearing DCs. The CD40 ligand (CD40L) expressed on activated memory T cells plays a key 
role in licensing DCs to activate both human CD8+ T cells (Caux et al., 1994; Cella et al., 1996) 
and murine CD8+ T cells (Bennett et al., 1998; Ridge, Di Rosa, & Matzinger, 1998; Schoenberger, 
Toes, van der Voort, Offringa, & Melief, 1998). T cell help is not mediated exclusively through 
CD40, an additional licensing pathway mediated through lymphotoxin-αβ (LTα1β2)-LTβ receptor 
interaction (Summers deLuca & Gommerman, 2012), an absence of LTβR signalling during T cell-
DC interactions renders DCs functionally defective ex vivo (Summers-DeLuca et al., 2007), 
suppresses CD8+ T cell mediated graft rejection (Z. Guo et al., 2001), and impairs antiviral CD8+ T 
cell responses (Berger et al., 1999; Suresh et al., 2002).  The licensed DC activates the CD8+ T cell 
through CD70-CD27 interactions (Feau et al., 2012). Licensed DCs are also induced to increase 
cytokine secretion, including IL-12 and IL-15, which further stimulates CD8+ T cell responses. 
 
Chapter 1 - Introduction 
 
25 
 
 
Figure 1.11 Dendritic cell-T cell cross-talk 
Antigen is presented to MHC I and CII molecules through the TCR and requires co-receptors CD4 or 
CD8 and generation of signals from CD3. After signaling by PAMPs, DCs upregulate co-stimulatory 
molecules such as CD80 and CD86 which interact with CD28 on the surface of CD4+ T cells. 
Adhesion molecules enhance DC conjugate formation through adhesion molecules such as ICAM-1 
binding to LFA-1 on CD4+ T cells. In response to PRR signaling, DCs also secrete cytokines such as 
IL-12 and type I IFN that provide further stimulatory signals to T cells. Activated CD4+ T cells can 
further license DCs through CD40L-CD40 or LTα2β2-LTβR that leads to enhanced CD8+ T cell 
activation through additional cytokine signaling both the DC and the CD4+ T cell and CD70-CD27 
signaling. 
 
1.2.5. Limitations to studying human antigen presentation to T cells 
Many technical advancements have been made in recent years to improve our 
understanding of antigen presentation by human DCs to T cells, however several important 
limitations still exist (van Montfoort et al., 2014). One of the major challenges at the moment is 
the ability to measure antigen presentation at the level of the DC, currently most studies are 
reliant on in vitro T cell responses as the read-out when investigating antigen presentation and 
cross-presentation. Using such methods it is generally not possible to delineate between cross-
presentation and cross-priming, as specific T cell responses result from a combination of signals 
one, two, and three. Ideally, the best readout would be to measure MHC-peptide complexes on 
the cell surface, however tools are lacking to achieve this (Joffre et al., 2012; van Montfoort et 
al., 2014). 
Studying human virus-specific CD8+ T cells is also impeded by the low frequency of naive 
T cells, as well as the difficulties in obtaining sufficient cell numbers of antigen-specific memory T 
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cells. The most frequently studied virus IAV, HIV-1, CMV, and EBV used to investigate human 
CD8+ T cell responses elicit specific-memory cells that occur at relatively high frequencies (Giest 
et al., 2012; X. S. He et al., 2003; Kuzushima et al., 1999), other viruses have such low 
frequencies of specific T cells circulating that investigating antigen presentation remains a great 
challenge.  
1.3. Immunology of HSV 
HSV primary infection and reactivation elicits a variety of host immune responses in 
order to limit viral spread and eventually eliminate infectious virus from the lesion. 
A. Innate immune response 
Innate recognition of HSV initiates via TLRs and other PRRs. HSV is known to interact 
with TLR2, TLR3, and TLR9, of these three, TLR2 is the most influential driver of the innate 
immune response. During HSV infection, viral glycoproteins, particularly gH/ gL and gB interact 
with TLR2, each acting as a ligand to TLR2, but gH/ gL alone and not gB alone is sufficient to 
activate the NF-B pathway (Leoni, Gianni, Salvioli, & Campadelli-Fiume, 2012). Inflammatory 
events resulting in greater pathogenesis in stromal keratitis (Sarangi, Kim, Kurt-Jones, & Rouse, 
2007) and high mortality in neonatal mice (Kurt-Jones et al., 2004) are mediated by TLR2. TLR2, 
synergistically with TLR9, has also been shown to be required to reduce viral load in tri-geminal 
ganglia (Lima et al., 2010; Sorensen et al., 2008). It has been found, however, that not all HSV 
strains induce TLR2 activation, Sato et al tested a range of laboratory and clinical strains and 
found large variability in their ability to stimulate TLR2 and found it was restricted to a subfamily 
of HSV isolates (Sato, Linehan, & Iwasaki, 2006). Sato et al also found TLR2 worked synergistically 
with TLR9 in bone-marrow derived DCs (BMDCs) to produce IL-6 and IL-12. The importance of 
TLR2 in HSV immunity has been highlighted by the finding that two TLR2 haplotypes that result 
in decreased TLR2 activity are associated with greater genital herpes disease severity (Bochud, 
Magaret, Koelle, Aderem, & Wald, 2007). Other TLR single nucleotide polymorphisms (SNPs) 
were investigated, no other TLRs showed disease associations.  
HSV genomic DNA contains abundant un-methylated CpG motifs that induce early type I 
IFN responses mediated by TLR9 in pDCs (J. Lund, Sato, Akira, Medzhitov, & Iwasaki, 2003; 
Rasmussen et al., 2007). Both HSV1 and HSV2 infections can stimulate IFN-α production in pDCs, 
which requires TLR9, MYD88, and an intact endocytic pathway but not viral replication (Krug et 
al., 2004; J. Lund et al., 2003). pDCs are the main effectors of the previously well described 
production of IFN-α by human peripheral blood mononuclear cells (PBMCs) in response to HSV 
antigen (Siegal et al., 1999). TLR9-/- mice are capable of controlling HSV1 replication in vivo, 
indicating other recognition pathways compensate for the loss of TLR9 (Krug et al., 2004). It 
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appears TLR9 partially contributes to the innate antiviral response to HSV, it particularly seems 
to work synergistically with TLR2 (Ma & He, 2014).  
TLR3 has also been implicated as being important in the innate immune response to HSV 
(Ma & He, 2014). TLR3 senses dsRNA, it is not completely understood how HSV activates TLR3, 
however, it has been shown that HSV viral gene expression generates viral dsRNAs (Jacquemont 
& Roizman, 1975), and these dsRNAs are detectable in infected Vero cells (Weber, Wagner, 
Rasmussen, Hartmann, & Paludan, 2006). TLR3-mediated type I IFN responses to HSV appear to 
be cell-type dependent, PBMCs from TLR3-deficient patients effectively produce IFN types I and 
III, however TLR3-deficient fibroblasts are unable to produce IFN (Z. Guo et al., 2001), TLR3-
deficient monocytes, pDCs, and macrophages all produced IFN. HSV has been found to replicate 
more efficiently in TLR3-deficient neurons as type I IFN production is impaired (Lafaille et al., 
2012). TLR3 appears particularly protective in the CNS, TLR3-deficiency, TRIF-deficiency, and 
TBK1-deficiency all predispose humans to HSV encephalitis in early childhood (Y. Guo et al., 
2011; Herman et al., 2012; Sancho-Shimizu et al., 2011). These individuals with deficiencies in 
the TLR3-signalling pathway succumb to HSV encephalitis, but are free of clinical HSV 
dissemination, suggesting TLR3 is dispensable beyond the CNS. A murine model has suggested 
that TLR3 precludes HSV2 entry into the CNS through astrocyte-mediated IFN response (Reinert 
et al., 2012).  
Other PRRs are also involved in the innate immune response to HSV. Cell lines lacking 
the RLRs retinoic acid-inducible gene I (RIG-I), melanoma differentiation-associated gene 5 
(MDA5), and its adaptor molecule mitochondrial antiviral signal protein (MAVS), display 
increased HSV replication and drastically reduced type I IFN responses to HSV infection (Cheng, 
Zhong, Chung, & Chisari, 2007; Ma & He, 2014; Rasmussen et al., 2009; Rasmussen et al., 2007). 
DC responses to HSV in contrast, do not require RLRs (Cotter et al., 2011). Further work still 
needs to be done on RLR to determine their involvement with HSV infection. Many other DNA 
sensors have also been identified to be involved in HSV infections (Ma & He, 2014; Unterholzner, 
2013), with most inducing type I IFN responses.   
Type I IFNs induce the expression of several antiviral genes that are directly involved in 
inhibiting viral replication in host cells, they also activate multiple effector cell types during the 
innate response to HSV. Among the most essential innate cells are natural killer (NK) cells and 
DCs. Type I IFN signalling generally leads to maturation of DCs and subsequently activating NK 
cells (Lucas, Schachterle, Oberle, Aichele, & Diefenbach, 2007), particularly through production 
and trans-presentation of IL-15, promoting NK cell survival and proliferation (Swann et al., 2007). 
NK cells are involved in cytokine production and recognition and killing of virally infected cells. 
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Activated NK cells induce apoptosis of virally infected cells through the release of perforin and 
granzyme B, NK cells are also an important source of IFN- (Martinez, Huang, & Yang, 2008). 
Allotypes of NK cell receptors killer-cell immunoglobulin-like receptor (KIR) and NKG2C and their 
HLA-encoded ligands modify the risk of suffering clinical HSV1 (Moraru et al., 2012), highlighting 
the importance of these innate cells in HSV immunity . 
IFN- exerts effects on a wide range of cellular processes including upregulation of an 
antiviral state, antigen processing and presentation, increases in proteasomal processing,  
immunomodulation, and leukocyte trafficking and apoptosis (Bigley, 2014). IFN- causes an 
increase in both MHC I and CII expression on the surface of cells, this trafficking is dependent on 
the cytoskeletal network (Barois, Forquet, & Davoust, 1998). Monocyte migration is suppressed 
by the inhibitory effects of IFN- on actin re-modelling of the cytoskeleton and polarisation in 
response to the chemokine CCL2 (Hu, Hu, Boumsell, & Ivashkiv, 2008). IFN- also aids in the 
antiviral response against HSV by activating the inducible nitric oxide synthase (iNOS) gene that 
catalyses the oxidation of L-arginine to L-citrulline and nitric oxide (NO) in local epithelial cells, 
macrophages, and DCs (Bogdan, 2001). The downstream products of the iNOS gene induction 
interfere with viral replication by reacting with nucleic acids and proteins, ultimately aiding viral 
clearance (Bogdan, 2001; Chan et al., 2011).  
Monocyte-derived inflammatory DCs are major contributors to immunity and are by far 
the most abundant DC type in HSV infected skin (Eidsmo et al., 2009; B. L. Macleod et al., 2014). 
The DCs are thought to exert multiple effector functions, including local production of 
inflammatory cytokines (Leon & Ardavin, 2008), trafficking of antigen to lymph nodes (Leon, 
Lopez-Bravo, & Ardavin, 2007), and replenishment of peripheral DC populations following the 
resolution of infection (Eidsmo et al., 2009; Ginhoux et al., 2006; B. L. Macleod et al., 2014). 
B. Adaptive immune response 
The average duration of lesions, from first vesicle to complete healing during primary 
HSV infection is 16 days for males and 20 days for females, where as an episode of classic 
recurrent genital herpes lasts about  10 days (Stanberry & Bernstein, 2000). This large difference 
in length of clinical symptoms displays the benefit of the secondary immune response as the 
adaptive immune response has already been primed to combat the HSV infection. 
B.i. Humoral Immunity 
The role humoral immunity plays in the response against HSV has been controversial, 
but does have a role in the host defense against HSV infection (Chan et al., 2011). Passive 
transfer of immune serum (Morrison, Zhu, & Thebeau, 2001) or anti-HSV monoclonal antibodies 
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(McDermott, Brais, & Evelegh, 1990) failed to protect against vaginal infection in murine models.   
Some human HSV2 vaccine trials, despite inducing strong neutralizing immunity, failed correlate 
antibody responses with protection (Bernstein et al., 2005; Corey et al., 1999; Langenberg et al., 
1995). However in a follow-up study, cross-protection against HSV1 infection was found to 
correlate with antibody responses (Belshe et al., 2012).  A mouse study demonstrated that 
adoptive transfer of IgG isolated from HSV2 vaccinated mice was able reduce viral load and 
pathological signs of disease (Parr & Parr, 1997), also administration of a monoclonal antibody 
targeting HSV2 gB protected against the vaginal transmission in mice (Eis-Hubinger, Schmidt, & 
Schneweis, 1993). Therefore antibodies appear to attenuate infection, conferring some 
immunity to HSV, mostly by limiting viral spread by neutralizing free virus, but as HSV is an 
obligate intracellular pathogen, antibodies aren’t generally sufficient to clear virus. Their role in 
antibody-dependent cellular cytotoxicity (ADCC) and further recruitment and activation of other 
cells to the site of infection is the humoral responses major role in control of HSV. Cell-mediated 
immunity is thought to play a much larger role in protection against HSV.  
B.ii. Cell-mediated Immunity to HSV 
CMI to HSV, like many viral infections, is essential to control and clearance of HSV 
infection in lesions. When lesions occur there is a brisk infiltration of NK cells and CD4 T helper 
cells followed by cytolytic CD8+ T cells (Cunningham, Turner, Miller, Para, & Merigan, 1985; 
Koelle et al., 2003; Koelle et al., 1998). The early infiltration of CD4+ T cells (Cunningham, Nelson, 
Fathman, & Merigan, 1985) are thought to support later expansion of antigen-specific CD8+ T 
cells (Koelle et al., 1998). Protection from HSV infection strictly requires effector T cell activities, 
with both CD4+ and CD8+ T cells contributing to virus control in skin, mucosa and sensory 
ganglia (Dobbs, Strasser, Chu, Chalk, & Milligan, 2005; Manickan & Rouse, 1995; Nash et al., 
1987; Simmons & Tscharke, 1992; van Lint et al., 2004). Efficient immunity against HSV has also 
been found to require IFN- (Bouley, Kanangat, Wire, & Rouse, 1995) and it has been proposed 
that production of this cytokine, rather than only cytolytic mechanisms, is the main contributor 
to virus protection and control in neuronal tissues (Khanna, Bonneau, Kinchington, & Hendricks, 
2003; T. Liu, Khanna, Carriere, & Hendricks, 2001), as well as being important during lytic 
infection in skin and genital mucosa (Dobbs et al., 2005; B. L. Macleod et al., 2014). 
The importance of CD8+ T cells in the response to HSV infection was not initially realised 
as HSV infected cells were shown to be resistant to lysis by CD8+ T cells due to the reduced 
expression of MHC I on the surface of HSV infected human fibroblasts and keratinocytes (Koelle 
et al., 1993). This was found to be due to HSVs immediate early protein ICP47 (Tomazin et al., 
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1998). However, IFN-, which is secreted by infiltrating CD4 lymphocytes, restores MHC I 
expression on infected keratinocytes (Mikloska, Kesson, Penfold, & Cunningham, 1996).  
Several studies from Koelle and colleagues have shown in a variety of ways that CD8+ T 
cells are required for control and clearance of HSV infections. Posavad et al (Posavad, Koelle, & 
Corey, 1996) demonstrated that all 10 of their recurrent genital herpes patients tested had HSV2 
specific CD8+ cytotoxic T cell precursors at frequencies 20 to 100 times higher than those seen in 
HSV-seronegative donors and were similar to those frequencies seen with infections of other 
herpesviruses. The high frequencies of CD8+ T cells suggest a role for these cells in resolving HSV 
infections. Koelle et al (Koelle et al., 1998) found that viral clearance from HSV lesions was 
temporally associated with local CD8+ T cell activity. NK activity and HSV-proliferative responses, 
while preferentially localized to HSV lesions, did not correlate in magnitude with viral clearance. 
The relative contributions of CD4+ and CD8+ T cells to overall cytotoxic T cell activity and control 
varies between patients (Koelle et al., 1998). The CD8+ T cell precursor frequency determines 
the severity of genital herpes recurrences in HIV/HSV co-infection (Posavad, Koelle, 
Shaughnessy, & Corey, 1997). There was a significant difference between CD8+ T cell precursor 
frequencies of patients with mild recurrent genital herpes (1 in 6,000) and those who suffered 
more severe genital herpes recurrences (1 in 77,000). Despite lower frequencies there was no 
difference in the proliferative capacity of these precursors.  
In response to whole virus, the combined responding CD4+ and CD8+ T cells from 
chronically infected individuals occupies just 0.1% - 3% of the PBMC compartment (Jing et al., 
2012; Moss et al., 2012),  with no correlation between the magnitude or functionality of the 
CD4+ T cell responses and shedding or clinical severity.(Jing et al., 2012; Johnston et al., 2014). 
Whether a critical level or phenotype of circulating CD8+ T cell responses will correlate with 
protective immunity is unknown.  
It was suggested that: “subclinical shedding in the absence of lesions or symptoms may 
be the outcome of particularly early or effective local cellular immune responses, but no 
experimental data support this hypothesis.” (Koelle & Corey, 2003b). A study in which regular 
biopsies were taken and the density and localisation of HSV-specific CD8+ T cells was measured 
has provided strong evidence that CD8+ T cells are important in not only clearing lesions but also 
appear to be a critical component of cutaneous viral containment. Zhu et al (J. Zhu et al., 2007) 
observed short reactivations in skin tissue averaging 103 to 104 copies of HSV-2 DNA per 
millimetre in swab specimens without evidence of epithelial cell destruction and there was an 
association with an increased localized infiltration with HSV2 specific  CD8+ T cells. This has 
highlighted the importance and role of the CD8+ T cell response in preventing disease. In Zhu et 
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als study, the CD8+ T cell responses were extensively observed both spatially and functionally in 
the HSV2 lesion. It was found that the CD8+ T cell infiltration was both highly concentrated and 
highly specific within the genital herpes lesion with HSV-2 specific T cells present at 100 times 
higher concentrations in lesional skin than in circulating blood. When comparing the amount of 
CD8+ T cell infiltration into both lesional skin and normal skin just 2 cm outside the lesion 
affected area, it was observed there was a dramatic reduction in T cell density in the normal skin 
indicating that CD8+ T cell infiltration to the HSV infection is a focused local event. After lesion 
resolution the enrichment of HSV2 specific CD8+ T cells persisted in genital skin in the upper 
dermis and the dermal-epidermal junction – coincident with sensory nerve endings. This physical 
closeness between persistent CD8+ T cells and sensory nerve endings provides evidence for a 
potential mechanism that would allow the local immune system to rapidly respond to and limit 
replication in keratinocytes following reactivation from nerves (J. Zhu et al., 2007). The current 
model is that early in the evolution of a herpetic lesion, CD4 T cells are important in controlling 
viral replication through IFN- secretion and possibly cytotoxicity whereas later CD8+ T cells 
eradicate cells targeting viral infection. Zhu et al’s (2007) study highlights the necessity and 
importance of CD8+ T cells. Such studies need to be repeated with CD4+ T cells to determine if 
they also persist between lesions. 
 Surprisingly, a recent study in mice found the only HSV-infected epidermal DCs 
were capable of activating CD8+ effector T cells, uninfected DCs that had access to viral antigen 
and efficiently activated CD4+ T cells failed to elicit IFN- production by CD8+ T cells (B. L. 
Macleod et al., 2014). Dendritic epithelial T cells (DETCs) are invariant δ-T cells that form a 
dense network in the epidermis of mice and have been implicated in both innate and adaptive 
immune responses (A. S. Macleod & Havran, 2011). DETCs and keratinocytes appeared to be the 
main drivers of IFN- production by CD8+ T cells, although various types of inflammatory cells 
that infiltrate the epithelial layer during infection may contribute to this response. Their 
contribution to CD8+ T cell responses may be particularly relevant at lesion borders where high 
numbers of infected DETCs could elicit strong IFN- responses required to curb the lateral spread 
of infection (A. S. Macleod & Havran, 2011; Puttur et al., 2010), DETCs however are not found in 
human skin at similar magnitudes to mice, so this is likely to be a major difference between 
human and mouse systems. 
DCs in inflamed skin play a key role in stimulating CD4+ T cell effector activity. The IFN- 
response by CD4+ T cells occurred in both draining lymph nodes and the epithelial and dermal 
layers of infected skin, including regions a considerable distance away from the infection foci in 
the epithelium (B. L. Macleod et al., 2014). CD4+ effector T cells carry out diverse functions in 
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infection control, ranging from class-switching in lymph nodes to the regulation of inflammatory 
cell infiltration and activity as well as direct antimicrobial effects within infected tissues.  
It has been recently discovered in both murine and human studies that T cells do not 
only infiltrate into lesions at times of infection but local T cells act as epithelial sentinels to 
prevent re-activation (Johnston et al., 2014). Prolonged persistence of HSV2 specific CD8+ T cells 
was previously documented at the dermal-epidermal junction in humans (J. Zhu et al., 2007). 
These cells have an effector cell phenotype, express tissue homing-molecules and express genes 
that suggest an cognate antigen is released frequently into the mucosa and that these tissue-
resident memory CD8+ T cells (termed TRM) act as functional effectors in controlling viral spread 
(Peng et al., 2012). Murine studies have shown these TRM cells are spatially limited to sites of 
previous infection and prevent infection in a model of murine re-activation (Mackay et al., 2012). 
Systemic HSV vaccination to elicit memory CD8+ T cells followed by application of a 
chemoattractant in the vaginal mucosal tract was found to draw TRM to the site of challenge that 
resulted in long-lived protection (Shin & Iwasaki, 2012). Mathematical models have found small 
decreases in the density of CD8+ T cells in the mucosa could tip the balance between sub-clinical 
and clinical reactivation (Schiffer et al., 2010). In these models, HSV reactivation is a slow ‘drip’ 
of virions released into axons. A decrease in TRM resulting in an increase of just 15 minutes in the 
lifespan of an HSV infected epithelial cell potentially leads to a thousand-fold increase in the 
number of infected cells, monitoring of genital lesions in humans confirmed this mathematical 
model showing that the rate of containment of infected cells by the peripheral mucosal immune 
system is the main driver of the duration and severity of HSV reactivation in the 
immunocompetent host (Schiffer et al., 2010). 
C. Immune evasion by HSV 
HSV, like many of the herpes viruses, employs a variety of immune evasion mechanisms 
to subvert the immune system that reflect the long history of co-evolution between HSV and the 
human host (recently reviewed in (Keith R Jerome, 2011)). Innate and adaptive immune 
mechanisms both play a critical role in controlling HSV infections. 
HSV controls many aspects of the innate immune response, the earliest acting are the 
viral proteins that antagonise the interferon response. ICP34.5, US11, ICP0, ICP27, US3, and vhs 
use a variety of mechanisms to antagonise the interferon response (reviewed by (Paladino & 
Mossman, 2009)). Complement is targeted for disruption by HSV, HSV gC binds to the 
complement protein C3b, inhibiting complement-mediated neutralisation and cell lysis (Harris et 
al., 1990; McNearney, Odell, Holers, Spear, & Atkinson, 1987). The modulation of complement 
has a large effect on HSV pathogenesis, a guinea pig model of infection showed reduced 
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pathogenicity when infected with HSV expressing a mutant gC unable to bind C3b compared to 
wild type (Lubinski et al., 1998). In addition, mice deficient in C3 show increased susceptibility to 
HSV infection (Verschoor, Brockman, Knipe, & Carroll, 2001).  
DCs, critical cells at the innate/ adaptive immune interface, are targets for modulation 
by HSV. After being infected by HSV, a significant proportion of infected DCs rapidly die via 
apoptosis (Jones et al., 2003; Mikloska, Bosnjak, & Cunningham, 2001). However, this apoptosis 
enables uptake of HSV antigen by bystander DCs leading to cross-presentation and activation of 
CD8+ T cells, working in favour of a protective host response (Bosnjak et al., 2005). When 
infection does not result in apoptosis, infection interferes with maturation of DCs, including 
lowering expression of co-stimulatory molecules such as CD80 and CD86, preventing efficient 
antigen presentation (Jones et al., 2003; Mikloska et al., 2001). HSV has also been shown to 
inhibit CD1d recycling, reducing CD1d surface expression and preventing the activation of 
natural killer T cells (Yuan, Dasgupta, & Cresswell, 2006). 
HSV employs many mechanisms to dampen the adaptive immune response. Humoural 
immunity is undermined by the gE/ gI heterodimer which forms a high affinity Fc receptor, this 
binds HSV-specific antibody, blocking activation of complement and ADDC (Frank & Friedman, 
1989).  
Many immune evasion strategies are directed at the cell-mediated immune response, 
underscoring the importance of T cells in the control of HSV infection. One of the major 
mechanisms is the potent inhibition of TAP by ICP47 (Fruh et al., 1995; Hill et al., 1995), resulting 
in inhibition of peptide loading and down regulation of MHC I. This potent down-regulation of 
TAP is one major disparity between mouse and human studies as murine TAP is unaffected by 
ICP47 (Tomazin et al., 1998). MHC I presentation can be restored by IFN-, present in lesions 
(Tigges, Leng, Johnson, & Burke, 1996). MHC II presentation is also disabled with HSV gB 
diverting MHC II molecules to the exosome pathway (Temme, Eis-Hubinger, McLellan, & Koch, 
2010). HSV is capable of inhibiting apoptosis (reviewed in (Nguyen & Blaho, 2007)), the 
expression of anti-apoptotic proteins renders infected cells resistant to the induction of 
apoptosis by T cells (K. R. Jerome, Tait, Koelle, & Corey, 1998). Similar to the effect on DCs, HSV 
infection of T cells is pro-apoptotic, resulting in the death of T cells (Han et al., 2007). T cells that 
are not killed by HSV have most of their anti-viral effector mechanisms disabled (D. D. Sloan et 
al., 2006), and are skewed towards production of the immunosuppressive cytokine IL-10 (D. D. 
Sloan & Jerome, 2007).  
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1.4. HSV Vaccines 
Once HSV is acquired it remains latent, causing recurrences of symptomatic or 
asymptomatic shedding, so a prophylactic vaccine preventing latency would reduce HSV spread. 
A vaccine for both HSV1 and HSV2 would have a dramatic effect on global health. Ideally an HSV 
vaccine would provide sterilising immunity such that latency in the ganglion would be 
prevented. Given the short distance between infection of epidermal cells, and access to sensory 
nerve endings, this is a difficult goal.  However, the size of the HSV inoculum in the epidermis 
resulting in mucosal infection, and the burden of latent virus within the ganglion influence the 
frequency of subsequent reactivations, at least in animal models (Hoshino, Pesnicak, Cohen, & 
Straus, 2007; Sawtell, 1998). Also, the reactivation of HSV2 from ganglia ex vivo is determined 
both by the latent viral load and the number of infiltrating CD8+ T cells (Hoshino et al., 2007). 
Therefore, a HSV vaccine that limited HSV infection of, or reactivation from the ganglion as well 
as rapid clearing of epidermal virus by inducing HSV-specific T cell immunity should lead to a 
decrease in HSV reactivation and subsequent transmission.  
1.4.1. Vaccines approaches 
There have been many approaches to vaccine design with some of the most successful 
and immunogenic being whole live-attenuated or killed/ inactivated pathogens (Strugnell, Zepp, 
Cunningham, & Tantawichien, 2011). These complete pathogens contain all the pathogen-
specific protein and carbohydrate antigens for effective vaccination and some innate defensive 
triggers. The long-lasting immunity achieved by live-attenuated vaccine is thought to be 
achieved through the higher intensity of innate immune responses and replication resulting in 
higher antigen content and prolonged antigen persistence. However, there are significant 
drawbacks to this style of vaccine; loss of attenuation, in cases of immunodeficiency such as HIV 
infection, vaccinated individuals may not be able to adequately restrict growth of the attenuated 
pathogen. High frequency local or systemic reactogenicity has been associated with the previous 
whole-cell pertussis vaccine and the first-inactivated whole-virus influenza vaccine, alternative 
subunit and split-pathogen vaccines are now used for these pathogens. Unwanted immune 
effects have also been caused by whole virus preparations, a respiratory syncytial virus (RSV) 
vaccine caused enhanced pulmonary pathology (H. W. Kim et al., 1969), thought to be due to 
low antibody avidity for protective epitopes caused by poor PRR stimulation (Delgado et al., 
2009). Due to pathogen complexity, latency, and immunoevasion, attenuated strains may not be 
desirable if they cannot prevent establishment of latency and immunevasion mechanisms allow 
persistence of the virus. To address the limitations of whole-pathogen approaches, alternative 
safer approaches are being investigated. 
Chapter 1 - Introduction 
 
35 
 
Split-pathogen and subunit vaccines have now been successfully used to vaccinate 
against pathogens such as influenza, pertussis and hepatitis B virus (Figure 1.12). Polysaccharide 
vaccines have been successful at inducing antibody-mediated immunity against bacteria, but do 
not induce cell-mediated immunity. Even shorter peptide vaccines are also now being 
considered. The two major drawbacks of subunit and peptide-based vaccines are the need to 
identify appropriate and potent target proteins and epitopes, and the requirement of an 
appropriate adjuvant to require sufficient stimulus to activate the adaptive immune response 
(Strugnell et al., 2011).  
 
Figure 1.12 Vaccine approaches  
 (Strugnell et al., 2011) 
Most successful vaccines currently in use have been shown to depend on neutralising 
antibodies to prophylatically prevent infection. Few vaccines have been shown to be adept at 
inducing cell-mediated immunity. For those that do, cell-mediated immunity was shown to be an 
important correlate of protection (Salerno-Goncalves & Sztein, 2006; Siegrist). In order to induce 
cell-mediated immunity through rational vaccine design, harnessing the optimal antigenic, 
PAMPs and environmental signals for DCs to optimally activate T cells is needed. Better 
understanding of these complex signalling processes is the first step needed to achieve this. 
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1.4.2. HSV vaccine trials 
Almost all vaccines for HSV to date that have been tested have failed once they have 
reached clinical trials several platforms have been tested. These have been recently reviewed 
(Johnston et al., 2014). The most promising candidates have been the recombinant glycoprotein 
subunit vaccines. Four HSV glycoproteins gD, gB, gH, and gL elicit neutralizing antibodies. The 
first two glycoproteins are particularly attractive as they are sequence-conserved between 
strains and relatively conserved between HSV1 and HSV2.  A recombinant vaccine formulated 
with an oil/ water emulsion adjuvant and the subunits gB2 and gD2 was safe and induced strong 
neutralizing antibody responses in humans. However it did not prevent HSV2 infection in sero-
discordant couples and was not shown to produce T cell responses (Corey et al., 1999; 
Langenberg et al., 1995). The only efficacious vaccine so far has been the GSK subunit vaccine 
that included HSV2 gD with the TLR4 adjuvant AS04 containing dMPLA . This vaccine elicited 
neutralizing antibody and CD4+ T cell responses but failed to induce CD8+ T cell responses. The 
vaccine reduced HSV2 disease by 73-74% and infection by 48% in HSV1/2 seronegative women, 
but did not prevent genital herpes disease in men or HSV1 seropositive women (Stanberry et al., 
2002). A follow up study, in a random cohort, unfortunately failed to prevent HSV2 infection or 
disease, but decreased HSV1 genital disease by 58% and HSV1 infection by 35% (Belshe et al., 
2012) In this study, HSV1 was the pre-dominant cause of genital herpes. A lower gD2 antibody 
titre was associated with increased HSV1 infection suggesting a correlate of protection. Although 
CD4+T cell responses were induced they were not correlated with protection and no CD8+ T cell 
responses were induced. This showed HSV vaccines had the potential to be cross-protective, and 
the lack of CD8+ T cell responses suggest a need to improve upon existing vaccine candidates.  
1.4.3. Lipopeptide vaccines and Pam2Cys as a self-adjuvant 
Despite great efforts made up to now, no vaccine adjuvant that stimulates a human 
CD8+ T cell response is available (X. P. Zhu et al., 2014). Some focus has now moved towards 
new vaccine forms aimed inducing cross-presentation and strong CD8+ T cell responses. As it has 
been found that peptide-based vaccines are better at cross-presenting antigen and priming 
better CD8+ T cell responses than whole sub-units (H. Zhang et al., 2009), peptide-based 
vaccines are being considered. However peptides lack co-stimulatory signals, so on their own are 
poorly immunogenic. Conjugation to adjuvants is required to provide signals two and three to T 
cells. A HerpV vaccine consisting of multiple CD4+ and CD8+ T cell epitopes conjugated to a heat-
shock protein (HSP) as a an adjuvant has reached phase I/II human clinical trials and has so far 
been proven safe and immunogenic, it still remains to be seen whether this vaccine is effective 
(Mo et al., 2011; Wald et al., 2011).  
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Lipopeptides, which consist of peptide antigens conjugated to TLR2 agonists, have now 
garnered much attention, and are increasingly being investigated (reviewed recently (Zaman & 
Toth, 2013)). Of particular interest are lipopeptides based on the TLR agonists Pam2Cys and 
Pam3Cys (Figure 1.13). These vaccines are attractive candidates and safe as no infectious virus is 
used. They have been found to be safe in human trials and appear to increase to T cells 
responses to HIV epitopes (Gahery et al., 2006; Richert et al., 2013; Salmon-Ceron et al., 2010). 
In recent years it has been demonstrated that peptides lipidated with Pam2Cys were effective in 
priming immunity in the contexts of viral (Alphs et al., 2008; Day et al., 2007; Deliyannis et al., 
2006; Jackson et al., 2004)  and bacterial (Batzloff, Hartas, Zeng, Jackson, & Good, 2006; Jackson 
et al., 2004) infections, tumour growth (Jackson et al., 2004; Zeng, Ghosh, Lau, Brown, & 
Jackson, 2002; Zeng, Pagnon, & Jackson, 2007), and even modulation of hormone action (Zeng, 
Gauci, Ghosh, Walker, & Jackson, 2005; Zeng et al., 2002; Zeng et al., 2007). Pam2Cys has been 
shown to induce Th1 immunity by evoking IL-12 secretion in DCs (Ghosh et al., 2006; Patel et al., 
2005; Thoma-Uszynski et al., 2000). Preclinical studies have demonstrated that Pam2Cys, unlike 
most other TLR agonists, lack detectable pro-inflammatory activity, pyrogenic (Hood et al., 
2010), or toxic effects (Wu et al., 2010), unlike TLR8 agonists for example, which were 
proinflammatory and therefore may exert systemic toxicity (Hood et al., 2010). All these features 
make Pam2Cys an attractive adjuvant to use as a vaccine candidate against HSV. They have also 
been investigated in the context of HSV infection, HSV2 gB is known to contain several mouse 
immunodominant epitopes, a HSV2 gB mouse epitope conjugated to Pam3Cys was found to 
efficiently activate CD8+ T cells and protect against HSV2 challenge in mice (X. Zhang et al., 2009; 
Zhang et al., 2012). 
 
 
Figure 1.13 Schematic of Pam2Cys and Pam3Cys lipidated peptide  
 (Zaman & Toth, 2013) 
 
 Investigations into lipopeptide vaccines are only just beginning. Their major drawback is 
the necessity of identifying suitable epitopes to conjugate and the limited knowledge of their 
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ability to be cross-presented in human systems. Pam2Cys-adjuvanted peptides are promising 
vaccine approaches targeting induction of cell-mediated immunity for the future, but much 
more work still needs to be done. 
1.5. Aims 
There is no effective HSV vaccine currently available. However development of HSV 
peptide-based vaccines capable of inducing protective CD8+ T cell immunity has been hampered 
by the lack of identified epitopes and suitable adjuvants. It is also incompletely understood how 
whole HSV enters DCs and cross-presentation of the viral antigen is poorly understood. As such, 
this study sought to: 
1) Identify immunodominant human CD8+ T cell epitopes from HSV 
2) Combine HSV CD8+ T cell epitopes with a previously identified CD4 T cell epitope, 
conjugated to the TLR2 agonist Pam2Cys, as a proof-of-principle HSV lipopeptide 
vaccine candidate and investigate subsequent T cell responses 
3) Investigate cross-presentation of HSV lipopeptides to CD8+ T cells and whether 
synergy with direct presentation to CD4 T cells is possible. 
4)  Determine the entry pathway HSV utilises to enter DCs and investigate cross-
presentation of viral proteins after uptake of UV-inactivated HSV 
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Chapter 2 -  Materials and methods 
2.1. Media and solutions 
2.1.1. Culture media 
A. RF10 
RPMI-1640 (Roswell Park’s Memorial Institute Medium) with L-glutamine (2.1 mM) 
recommended (Lonza, Basel, Switzerland) was supplemented with 10% (v/v) Fetal bovine serum 
(FBS) (Serana, Bunbury, WA, Australia)  
B. RH10 
RPMI 1640 (Lonza) was supplemented with 10% (v/v) human AB serum (HS) (Life Technologies, 
Carlsbad, CA, USA). 
C. DMEM5 
DMEM (Dulbecco’s Modified Eagle Medium with L-glutamine 4mM, 4.5g/L glucose, without 
sodium pyruvate (Lonza) was supplemented with 5% (v/v) FBS. 
D. Freezing media 
To freeze cells, 107 cells/ mL were resuspended in FBS containing 10% (v/v) dimethylsulfoxide 
(DMSO) (Sigma-Aldrich, St Louis, MO, USA). 
2.1.2. Buffers 
A. Magnetic cell sorting (MACS) wash buffer 
MACSwash buffer was made with sterile PBS (Lonza) containing 1% (v/v) HS and 2mM 
ethylenedinitrilotetraacetic acid (EDTA) (Sigma-Aldrich). 
B. Stemcell easysep wash buffer 
Stemcell buffer was made with sterile PBS containing 2% (v/v) FCS. 
C. FACSwash buffer 
FACSwash buffer was made with PBS containing 1% (v/v) HS, 2mM EDTA and 0.1% (w/v) NaN3 
(Sigma-Aldrich) 
D. Permwash 
Permwash was made from a 10 x buffer (BD), as per the manufacturer’s instructions. 
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2.2. Antibodies 
A. Primary 
Table 2.1 Primary antibodies 
 
B. Secondary 
Table 2.2 Secondary antibodies 
 
 
C. Conjugated 
Table 2.3 Conjugated antibodies 
Target Clone Isotype Format Binding assay Supplier 
HLA A2 HB82 (BB7.2) Mouse, 
IgG1 
Hybridoma 
Supernatant 
T2.A*02:01 Gift from Rajiv 
Khanna 
HLA A3  HB122 (GAP A3) Mouse, 
IgG1 
Hybridoma 
Supernatant 
T2.A*03:01 Gift from Rajiv 
Khanna 
HLA Bw4 HB165 Mouse, 
IgG1 
Hybridoma 
Supernatant 
C1R .ICP47 
B*44:05 
Gift fromScott 
Burrows 
Target Host Format Supplier 
Mouse IgG Goat Alexa Fluor 647 Life Technologies 
Target Clone Isotype Format Supplier 
CD1a HI149 Mouse, IgG1 FITC BD Pharmingen 
CD3 UCHT1 Mouse, IgG1 FITC 
PerCP 
BD Pharmingen 
CD4 SK3 Mouse, IgG1 PE Cy7 Biolegend 
CD8 RPA-T8 
 
Mouse, IgG1 V450 
APC 
BD Horizon 
BD Pharmingen 
CD14 M5E2 Mouse  IgG2a,  APC BD Pharmingen 
CD80 B7-1 Mouse, IgG1 FITC BD Pharmingen 
CD83 HB15e Mouse, IgG1 PE 
APC 
BD Pharmingen 
BD Pharmingen 
CD86 2331(FUN-1) Mouse, IgG1 APC BD Pharmingen 
CD107a eBioH4A3 Mouse, IgG1 Alexa Fluor 647 
Efluor 660 
eBioscience 
CD107b eBioH4B4 Mouse, IgG1 Alexa Fluor 647 
Efluor 660 
eBioscience 
DC-SIGN DCN46 Mouse,  IgG2b  PE BD Pharmingen 
IFN- B27 Mouse, IgG1 PE Cy 7 BD Pharmingen 
TNF- 6401.1111 Mouse, IgG1 PE BD Fastimmune 
IL-2 JES6-5H4 Rat, IgG2b FITC BD Pharmingen 
HLA Class I W6/32 Mouse,  IgG2a  APC Cy7 Biolegend 
HLA DR L243 Mouse,  IgG2a  PE Cy7 Biolegend 
MR (CD206) 19.2 Mouse, IgG1 APC BD Pharmingen 
HSV2 gD  Mouse, IgG1 FITC Virostat (Monotope), Portland, ME 
HSV1 gC  Mouse, IgG2 FITC Virostat (Monotope) 
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2.3. Cell culture 
All cells were propogated in a bio-safety cabinet class II and maintained in a humidified 
incubator with 5% CO2 at 37°C (Thermo Scientific, Waltham, MA, USA). All plasticware used was 
from BD unless otherwise specified. 
2.3.1. Cell lines 
A. T2 Cells & C1R.ICP47 cells 
The non-adherant mutant LCL x T lymphoblastoid hybrid cell line, 174xCEM.T2 (referred 
to as T2 cells), are TAP-deficient and express empty HLA molecules (Salter & Cresswell, 1986). T2 
cells were used for HLA-peptide binding assays. All T2 cells were kindly given to us by Rajiv 
Khanna & Scott Burrows (QIMR Berghofer Medical Research Institute). Parental T2 cells 
expressing HLA-A*02:01 were grown in RF10. T2 cells transfected with a plasmid to express HLA-
A*03:01 were grown in media with 800 µg/ mL G418 (Promega, Madison, WI, USA) to maintain 
the plasmid in the T2 cells. Cells were split at a ratio of 1:5 every 3-4 days in 75 cm2 tissue culture 
vented flasks (BD Biosciences).  
The non-adherant  class I reduced B lymphoblastoid cell line Hmy2.C1R (C1R), that 
expresses very low levels of HLA Cw4 and HLA-B*35:03 (Zemmour, Little, Schendel, & Parham, 
1992), transfected with HLA B*4405 and the HSV TAP inhibitor ICP47 (Zernich et al., 2004), 
referred to as C1R.ICP47 B*4405 cells were used for HLA*B4405 binding assays.  C1R.ICP47 
B*4405 cells were kindly given to us by Scott Burrows (QIMR). C1R.ICP47 B*4405 cells were 
grown in RF10 with 0.2 mg/ mL hygromycin B and 4 µg/ mL puromycin to maintain the plasmids 
in the C1R cells and were passaged every 3-4 days. 
B. Hybridomas 
All hybridomas (shown in Table 2.1) were grown in RF10 and passaged every 3-4 days with the 
exception of HB165, which was grown in RPMI with 20% (v/v) FBS. To collect hybridoma 
supernatant to use for staining as an antibody, hybridoma were washed with PBS and 
resuspended in AIM-V serum free media (Life Technologies) at 106 cells/mL and incubated at 
37°C for two days. Cells were then centrifuged at 300 g for 5 mins and supernatant was 
collected, passed through a 0.45 µm syringe filter (Merck Millipore, Darmstadt, Germany), and 
stored at 4°C until use. 
C. HeLa and Vero cells 
The adherent cell lines HeLa and Vero were grown in DMEM5 and split at a ratio of 1:10 
every 3-4 days using 0.01% trypsin-EDTA (Life Technologies). 
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2.3.2. Primary Cells 
A. Isolation of peripheral blood mononuclear cells (PBMCs) from blood 
Blood donors who had self-reported occurrences of coldsores were recruited through 
posters at Westmead Hospital . Three blood donors were genital herpes patients attending 
Parramatta or Taylor Square Sexual Health Clinics.  Blood (100-120 mLs) was collected in tubes 
containing lithium heparin (BD). Informed consent was obtained from all blood donors and the 
study was approved by the Ethics Committee for Sydney Western Area Health Service Research. 
Alternatively, a bag of whole blood was obtained from healthy donors from the Sydney Red 
Cross Blood Bank (Sydney, Australia). Peripheral blood mononuclear cells (PBMCs) were isolated 
by standard density gradient centrifugation protocol using Ficol-Hypaque (GE Healthcare, 
Buckinghamshire, UK). Blood from collection tubes or a bag were transferred to 50 mL centrifuge 
tubes and diluted with 1:1 v/v with sterile PBS then underlayed with 15 mL of Ficcol-Hypaque 
using a sterile cannula. Tubes were centrifuged at 450g for 20 min with no brake. PBMCs were 
collected from the Ficoll-plasma interface using a transfer pipette, pooled and washed 3 times 
with PBS. 
B. Generation of monocyte derived dendritic cells (MDDCs) 
To generate immature monocyte derived dendritic cells (iMDDCs), CD14+ monocytes 
were first isolated from PBMCs by positive selection using CD14 microbeads (Miltenyi Biotec, 
Gladbach, Germany). PBMC were incubated with microbeads (10 L per 107 PBMC in 40 L ice-
cold PBS) on ice for 30 mins, washed with 10 mL ice-cold PBS and resuspended in 500 L ice-cold 
PBS. An LS column (Miltenyi Biotech), loaded on a magnet was primed with 3 mL ice-cold PBS, 
PBMC suspension was then applied to the column followed by three 3 mL washes with ice-cold 
PBS. Column was then removed from the magnet and 5 mL of ice-cold PBS was pushed through 
to remove cells attached to the column. Cells were counted then resuspended at 0.5 x 106 cells/ 
mL in media containing  0.3 µg / mL IL-4 (Biosource, Life Technologies) and 0.3µg / mL gm-csf 
(Biosource, Life Technologies). Each new stock of cytokines was titrated for optimal iMDDC 
phenotype. For antigen presentation to T cells, iMDDCs were generated in RH10 to minimize 
background T cell responses. For peptide screening experiments RPMI 1640 was supplemented 
with 10% autologous serum. For HSV infection experiments, iMDDCs were generated in RF10. 
For experiments investigating maturation, a maturation mix containing 10 ng/ mL IL-1b, 1000 IU/ 
mL IL-6, 10 ng/ mL TNF-α (all R & D systems, Minneapolis, MN, USA) and 1 µg/ mL prostaglandin 
E2 (PGE2) (Sigma-Aldrich) (A. W. Lee et al., 2002; Mehlhop et al., 2002) was used as a positive 
control.  
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C. Isolation T cells 
CD8+ T cells were isolated from fresh or thawed PBMCs by positive selection using CD8 
microbeads (Miltenyi Biotech). Method is the same as described above for CD14+ cells, CD8 
microbeads were used at 20 L per 107 PBMC in 80 L ice-cold PBS.  
CD4+ T cells were isolated by negative selection from PBMCs using the EasySep human 
CD4 T cell enrichment kit (Stemcell technologies, Vancouver, BC, Canada). PBMC or CD8 negative 
PBMC were resuspended in StemCell buffer at 5 x 107 cells/ mL in a Falcon 5 mL polystyrene 
round-bottom tube (BD Biosciences). The human CD4+ T cell enrichment cocktail was added to 
the cell suspension at 50 L/mL and incubated at room temperature for 10 minutes. Magnetic 
particles at 100 L/ mL  were added and the cell suspension was incubated at room temperature 
for minutes. The cell suspension was brought up to a total volume of 2.5 mL and mixed then 
placed into the magnet for 5 minutes. CD4+ T cells were poured out of the tube. counted and 
purity was checked.  
After CD4+ and CD8+ T cell isolation,  purity of cells was measured by labelling with CD3-
FITC, CD4-PE Cy7 and CD8-APC (all BD Biosciences), incubated at 4°C for 20 minutes, washed 
with FACSwash and analysed by a BD CantoII. 
2.4. Virus culture 
A. Preparation of crude HSV stocks 
Stocks of HSV1 (strain F) and HSV2 (strain 186) were generated by passage in Vero cells. 
Vero cells were grown to 80-90% confluence in 150 cm2 tissue culture vented flasks then split at 
a ratio of 1:2 and incubated for 24 hrs.  The cells were washed with PBS then 2 mL of DMEM 
containing HSV (MOI 1) was added, and incubated for 1 hr at 37°C.  Virus solution was removed 
and 15 mL DMEM supplemented with 2% (v/v) FCS was added. After 48 hrs, culture media 
containing cells was placed in a 50 mL falcon tube and centrifuged for 5 mins at 300 g. 
Supernatant containing virus was aliquoted and stored at -80°C. The pellet was resuspended in 5 
mLs of DMEM, sonicated using a cup horn Branson sonicator (Ultrasonics, CT) 4 times for 1 
minute each, after sonication, cell debris was pelleted by centrifugation at 1000 g for 30 min. 
The supernatant containing virus was then aliquoted and stored at -80 °C.  
B. Purification of HSV1 
HSV1 (strain F) were purified by passage in Vero cells and Ficoll-gradient purification. 
Vero cells were grown as above. After 48 hrs, culture media containing cells was placed in a 50 
mL falcon tubes and centrifuged for 5 mins at 300 g. The pellet was resuspended in 10 mL of the 
supernatant per tube and sonicated using a cup horn Branson sonicator 4 times for 1 minute 
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each. After sonication, cell debris was pelleted by centrifugation at 1000 g for 30 min. The 
supernatant was then put into 40 mL ultracentrifuge tubes (Beckman Coulter, CA, US) and virus 
was pelleted at 23000g for 2 hours (fixed rotor, 70Ti, Beckman Coulter). The pellet was 
resuspended in 3 mLs PBS and placed on a Ficoll gradient of 15%, 12.5%, 10%, 7.5% and 5% (v/v) 
Ficoll in PBS (1 mL of each) in a 10 mL ultracentrifuge tube (Beckman Coulter). The virus was 
then spun on the gradient at 26000g for 2 hrs in a spin-out rotor (SW41, Beckman Coulter) with 
slow acceleration and deceleration. One mL fractions were taken and diluted in PBS and was put 
into 40 mL ultracentrifuge tubes (Beckman Coulter, CA, US) and virus was pelleted at 80000 g for 
2 hours (fixed rotor, 70Ti, Beckman Coulter).  Pellet was resuspended in PBS, aliquoted and 
stored at -80°C. To determine which fraction contained purified virus, plaque assay was 
performed. 
C. Plaque Assay 
To determine the titre of the HSV stocks a plaque assay was performed. Two 12-well 
plates were seeded with 106 Vero cells in 2 mL of DMEM supplemented with 5% (v/v) FCS per 
well. After 18 hrs media was removed and wells were washed with PBS. The supernatant and 
cell-associated aliquots of virus stock were (10-fold) serially diluted, and 100 µL of each dilution 
was added to each well in triplicate. The plate was incubated for 1 hr at 37ºC in a humidified 
incubator with 5% CO2 and rocked every 15 mins. The inoculum were removed and 1 mL of fresh 
DMEM media containing 2.5% (v/v) FCS and 2% (w/v) carboxymethyl cellulose (CMC; Sigma-
Aldrich) was added to each well. After 2 days, medium was removed and cells were washed with 
PBS, fixed and stained with 0.1% crystal violet in 70% ethanol for 15 mins. Wells were washed 
under running water and plaques were counted after drying the plate. The number of plaques 
were counted and the titre as plaque forming units (pfu) per mL was determined. 
D. UV-inactivation of HSV stocks 
UV-inactivation of HSV was performed by placing virus in a 6-well plate within 10 cm of a 
30-W UV light source for 30 min, with brief mixing every 10 min. UV-inactivated HSV was 
aliquoted and stored at -80°C. UV-inactivated HSV was tested by plaque assay to ensure 
inactivation was effective. 
2.5. Peptide prediction 
To predict immunodominant epitopes, HLA types A*01:01, A*02:01, A*03:01, B*07:02, 
B*08:01 and B*44:03 were focused on as they are more common, more extensively studied and 
available in all three of the databases that were used. In the first step of the analysis, 38 open 
reading frames (ORFs) of HSV-2 (Hosken et al., 2006) were screened individually for the best 
binding epitopes with the common online predictive algorithms SYFPEITHI (Rammensee, 
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Bachmann, Emmerich, Bachor, & Stevanovic, 1999), RankPep (Reche, Glutting, & Reinherz, 
2002), and BIMAS (Parker, Bednarek, & Coligan, 1994).  The top 30 scoring peptides of each HLA 
type in each prediction program were selected, then narrowed by selecting only those epitopes 
that occurred in the top 30 scoring epitopes in two prediction programs and occurred in the top 
2% of predicted epitopes in the third prediction program (as it has been reported that 
approximately 80% of all MHC-restricted epitopes are found among the 2% of top scoring 
peptides from their protein sources (Reche et al., 2002)). Epitopes were further selected by 
choosing only those that are predicted to be naturally cleaved by Rankpep and NetChop3.0 
(Nielsen, Lundegaard, Lund, & Kesmir, 2005). Finally epitopes that were homologous between 
HSV2 and HSV1 were chosen so that the epitope should be present in both viruses.  After 
moving through all the selection criteria, 16 peptides were chosen as well as one negative 
peptide that gave a negative binding score to all of the predicted HLA types.  
2.6. Peptides and lipopeptides 
Selected peptides were synthesized at 95% purity by Mimotopes (Melbourne, Australia). 
Some peptides as indicated in Table 2.4 were kindly given by Rajiv Khanna, Scott Burrows (QIMR) 
and David Jackson (University of Melbourne). 
Pam2Cys-p9, Pam2Cys-30-5, and p9-Pam2Cys-p30-5 were synthesized by Weiguang 
Zeng and David Jackson (University of Melbourne). They were synthesized by covalently coupling 
of Pam2Cys lipid moiety through two serine residues to each parental peptide. All peptides were 
cleaved from the solid support and side chain protecting groups simultaneously removed before 
being purified and characterized as described (Zeng, Eriksson, Chua, Grollo, & Jackson, 2010).  All 
peptide or lipopeptide samples were solubilised at a concentration of 10 mM in DMSO and 
stored at -80°C. 
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Table 2.4 Peptides used in this study 
Designation Sequence Protein HLA type Source 
1 LLDNAAAVY UL19-HSV-2 HLA-A1 Mimotopes 
2 VLDECLAEY UL21-HSV-2 HLA-A1 Mimotopes 
3 APDGTPLQY UL36 (ICP1-2)-HSV-2 HLA-A1 Mimotopes 
4 AMAPATIAAV UL19 (VP5)-HSV-2 HLA-A2 Mimotopes 
5 YLACEVLPAV ICP4-HSV-2 HLA-A2 Mimotopes 
6 YLITNYLPSV UL26-HSV-2 HLA-A2 Mimotopes 
7 TLRPNTLLLK UL39(ICP6) -HSV-2 HLA-A3 Mimotopes 
8 YLIYDASPLK UL19-HSV-2 HLA-A3 Mimotopes 
9 ALHTVVNNIK UL29 (ICP8) -HSV-2 HLA-A3 Mimotopes/ David Jackson* 
10 FPRDPGQLL UL22 (gH) -HSV-2 HLA-B7 Mimotopes 
11 APPGRQTERL UL38 -HSV-2 HLA-B7 Mimotopes 
12 APADLTAAAL UL36-HSV-2 HLA-B7 Mimotopes 
13 GPRVRVVDI UL47(VP13/14) -HSV-2 HLA-B8 Mimotopes 
14 AARERRAQI UL36-HSV-2 HLA-B8 Mimotopes 
15 LEIPGARSF UL13-HSV-2 HLA-B44 Mimotopes 
16 AETNTHGLAY UL13 -HSV-2 HLA-B44 Mimotopes 
17 EGTAGDHSPS HSV-2 No Binding Mimotopes 
30-5 PEDPEDSALLED gD-HSV-2  Mimotopes/ David Jackson* 
VTE VTEHDTLLY pp65 -  CMV HLA-A1 Rajiv Khanna** 
NLV NLVPMAVATV pp65 – CMV HLA-A2 Mimotopes/ Rajiv Khanna** 
AVK AVKDVTITKK VITF-3S Vaccinia Virus HLA-A3 Mimotopes 
TPR TPRVTGGGAM pp65 – CMV HLA-B7 Mimotopes/ Rajiv Khanna** 
ELR ELRRKMMYM pp65 – CMV HLA-B8 Rajiv Khanna** 
9-K ALHTVVNNI UL29 (ICP8) -HSV-2 HLA-A2 Mimotopes 
30-5-11-1 PEDPEDSALLE gD-HSV-2  Mimotopes 
30-5-11-2 EDPEDSALLED gD-HSV-2  Mimotopes 
30-5-10-1 PEDPEDSALL gD-HSV-2  Mimotopes 
30-5-10-2 EDPEDSALLE gD-HSV-2  Mimotopes 
30-5-10-3 DPEDSALLED gD-HSV-2  Mimotopes 
30-5-9-1 PEDPEDSAL gD-HSV-2  Mimotopes 
30-5-9-2 EDPEDSALL gD-HSV-2  Mimotopes 
30-5-9-3 DPEDSALLE gD-HSV-2  Mimotopes 
30-5-9-4 PEDSALLED gD-HSV-2  Mimotopes 
30-5-8-1 PEDPEDSA gD-HSV-2  Mimotopes 
30-5-8-2 EDPEDSAL gD-HSV-2  Mimotopes 
30-5-8-3 DPEDSALL gD-HSV-2  Mimotopes 
30-5-8-4 PEDSALLE gD-HSV-2  Mimotopes 
30-5-8-5 EDSALLED gD-HSV-2  Mimotopes 
SS30-5-14-1 SSPEDPEDSALLED gD-HSV-2  Mimotopes 
SS30-5-13-1 SSPEDPEDSALLE gD-HSV-2  Mimotopes 
SS30-5-13-2 SPEDPEDSALLED gD-HSV-2  Mimotopes 
SS30-5-12-1 SSPEDPEDSALL gD-HSV-2  Mimotopes 
SS30-5-12-2 SPEDPEDSALLE gD-HSV-2  Mimotopes 
SS30-5-11-1 SSPEDPEDSAL gD-HSV-2  Mimotopes 
SS30-5-11-2 SPEDPEDSALL gD-HSV-2  Mimotopes 
SS30-5-10-1 SSPEDPEDSA gD-HSV-2  Mimotopes 
SS30-5-10-2 SPEDPEDSAL gD-HSV-2  Mimotopes 
SS30-5-9-1 SSPEDPEDS gD-HSV-2  Mimotopes 
SS30-5-9-2 SPEDPEDSA gD-HSV-2  Mimotopes 
*Peptides synthesized by Weiguang Zeng and David Jackson were used as controls for Pam2Cys-
peptide conjugate experiments. 
**Peptides from Rajiv Khanna were used in T2 binding assays. 
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2.7. HLA-typing 
Genomic DNA was isolated from 5 x 106 PBMCs per sample using a QIAamp DNA mini kit 
(QIAGEN, Venlo, Netherlands) as per the manufacturer’s instructions. HLA-typing was performed 
to medium resolution by Proimmune (Oxford, UK), using PCR-specific oligonucleotides (PCR-
SSOP) to resolve major allele groups to 4 digits with some degeneracy. 
2.8. HSV serology 
HSV serology of blood donors was performed by Janette Taylor (Western Sydney Local 
Health District) by ELISA. The ELISA was unable to distinguish between HSV1 and HSV2, as 
peptides were homologous between  HSV1 and HSV2 this was not necessary. 
2.9. IFN- enzyme linked immunospot assay (ELISPOT)  
A 96 well ELISPOT plate (immunobilon-PPVDF membrane, Millipore) was coated with a 
purified IFN- monoclonal capture antibody (1D1K; Mabtech, Nacka Strand, Sweden) by 
incubating at a concentration of 10 g/ mL, 50 L/ well for 2 hrs at room temperature. The plate 
was then washed three times with sterile PBS and blocked with RH10 (150 L/ well) for 1 hr at 
room temperature. The plate was washed three times with PBS and PBMC or isolated CD8+ or 
CD4+ T cells were added to wells. If isolated T cells were used, MDDC were added to the well at 
a ratio of 1 MDDC: 10 T cells. Appropriate peptides/ Pam2Cys-peptide conjugates were added to 
the wells in duplicate or triplicate. The ELISPOT plate was incubated for about 40 hrs at 37°C. The 
plate was then washed three times with PBS and 3 times with PBS/ 0.05% Tween-20 (Sigma). 
Biotinylated IFN- monoclonal antibody (7-B6-1; Mabtech) diluted to a concentration of 1 g/mL 
in PBS/0.05% Tween 20/ 1% BSA and added at 100 L/ well. After a 2 hr incubation at room 
temperature and six washes with PBS/ 0.05% Tween-20, 100 L of streptavidin-alkaline 
phosphatase (Bio-rad, CA, US) diluted 1:1000 in PBS was added to each well for 45 min. The 
plate was then washed three times with PBS/ 0.05% Tween-20 and four times with PBS followed 
by incubation with 100 L 5-bromo-4-chloro-3-indolyl-phosphate/ NBT plus substrate (Bio-rad) 
per well at room temperature in the dark for approximately 5 mins or until spots appeared. The 
reaction was stopped by under running water. The plate was allowed to dry and spots were 
counted using an ELISPOT reader (AID, Staßberg, Germany). 
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2.10. Flow cytometry 
All flow cytometry was performed on BD flow cytometers using BD FACSDiva software 
6.0 (BD). All analysis was performed using FlowJo V7.6.5 or FlowJo X 10.0.7r2 (Tree Star Inc. 
Ashland, OR, USA). 
A. HLA-peptide binding assays 
To assess whether peptides were able to bind to HLA molecules T2.A*02:01, T2.A*03:01, 
or C1R ICP47 B*44:05 cells were used. The cells were washed in RPMI twice, counted, and 2 × 
105 cells were resuspended in 100 µL of AIM-V media per FACS tube. Peptide was added in 100 
µL of AIM-V media at final concentrations of 0.1, 1, 10, and 100 M. FACS tubes were placed in 
the incubator with lids removed to allow gas exchange for 15 min, before placing the lids on 
tightly. Cells were then incubated in a 26°C waterbath overnight, lids were then loosened and 
cells were incubated at 37°C for 2 hrs. HLA A*2:01, A*03:01, or B*44:05 surface expression was 
then measured by labelling on ice for 30 min with a monoclonal antibody for the specific HLA 
type (Table 2.1, if hybridoma supernatant 100 L was used). The cells were washed with 
FACSwash, labelled with a goat-anti-mouse-alexa fluor 647 antibody on ice for 20 mins, washed 
with FACswash and analysed by flow cytometry on a FACSCantoII. Data was expressed as Mean 
Fluorescence Intensity (MFI) and compared to a positive and negative control peptide. 
B. Proliferation assay 
Freshly isolated PBMCs (30 x 106) were placed in 10 mL of RPMI and incubated for 20 
minutes at 37°C in 5 M CellTrace Violet (Life Technologies) prepared according to the 
manufacturer’s instructions. Cells were washed with 40 mL RPMI and resuspended 1 x 106/ mL in 
RH10. PBMC (3 mL) were placed in each FACS tube and 10 M of peptides 9 and 17 or DMSO 
were added followed by incubation at 37°C. On Day 6, autologous iMDDCs in RPMI 1640 were 
peptide pulsed for 2 hr with 10 M peptide or DMSO. Peptide-pulsed iMDDCs were added to 
PBMCs (at a ratio of 1: 20) with addition of 1 ng/ mL IL-2 (Roche, Basel, Switzerland) or 1 ng/mL 
IL-15 (Roche) or no cytokine treatment. On Day 10, cells were washed with FACS wash and 
labelled with CD3-FITC (BD) and CD8-APC (BD) and incubated at 4°C for 20 mins then washed 
with FACSwash. Propidium iodide (PI), 10 g/ mL (Life Technologies), was added to cell 
suspension immediately before being analysed on the BD FACSCantoII. Proliferation in response 
to peptide was detected by CellTrace Violet dilution after gating on lymphocytes on FSC/SSC, 
then the PI negative cells followed by gating on the CD3/CD8 positive population. 
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C. CD107a/b and intracellular cytokine staining (ICS) assay 
Freshly isolated PBMC were resuspended at 1 x 106 cells/ mL in RH10 and 1 mL was 
placed in each FACS tube. Peptide (10 M), DMSO or anti-CD3 (Biolegend) (1 g/ mL) was added. 
To each tube, anti-CD28 (Biolegend) (1 g/ mL), anti-CD49d (Biolegend) (1 g/ mL), brefeldin A 
(Sigma) (10 g/ mL), Golgistop containing monensin (BD) (0.7 g/ mL), and of anti-CD107a-Alexa 
Fluor 647 (5 L/ mL), and anti-CD107b-Alexa Fluor 647 (5 L/ mL) or anti-CD107a-efluor 660 and 
anti-CD107b- efluor 660 (all eBioscience) were added. PBMCs were incubated for 6 hr at 37°C 
then washed with PBS twice before being stained with Live/ Dead fixable Aqua dead cell stain 
(Life Technologies) as per the manufacturer’s instructions. After 30 mins incubation on ice, cell 
were washed in FACS wash and permeabilised with 100 L Cytofix/ Cytoperm (BD) at room 
temperature then washed with 1 mL permwash (BD) and labeled with CD8 V450 (BD), CD3 PerCP 
or CD3 V450 (BD), IFN- PE Cy7, TNF- PE (BD) and IL-2 FITC (BD) antibodies at optimal 
concentrations at room temperature for 30 mins in the dark. Cells were washed with permwash 
then analysed by flow cytometry on the BD LSRII or the BD Fortessa. 
D. Quantitation of HSV infection 
To examine the infection of Vero and HeLa cells, HSV infected cells were washed with 
PBS and incubated with cell-dissociation buffer (Life Technologies) for 30 min. Cells were then 
transferred to FACS tubes. HSV infected MDDCs, Vero, and HeLa cells were then washed with 
PBS, and stained with Live/ Dead Aqua as per the manufacturer’s instructions. After 30 mins 
incubation on ice, cell were washed in FACSwash and stained with a HSV2-gD-FITC or a HSV1-gC-
FITC antibody. After 30 mins incubation on ice, cells were washed with FACSwash and incubated 
with 100 L Cytofix/ Cytoperm (BD) for 15 mins then analysed by a BD FACSCantoII. 
2.11. Quantitative PCR (QPCR) 
QPCR was carried out to measure gene expression of HSV1 in MDDCs. Total RNA was 
extracted using the RNAqueous kit (Ambion). RNA was DNase I treated (Life Technologies) and 
reverse transcribed using oligo(dT) and SuperScript III RNase H reverse transcriptase (Life 
Technologies). The cDNA was diluted 1:100 then subjected to QPCR where 5 µL of cDNA, 0.3 µM 
of each primer to ICP4 and gB and Platinum Sybr Green qPCR Supermix UDG and water was 
added. No template and no reverse trancriptase controls were included as negative controls. 
Primer pairs are shown in Table 2.5 and were all purchased from Sigma-Aldrich. Fluorescent PCR 
amplicons were detected using a real-time PCR machine Mx3005P (Stratagene, Agilent 
Technologies, Santa Clara, CA) using a 96-well microtiter plate under the following cycle 
conditions: 50°C for 2 min, 95°C for 2 min, 45 cycles of 95°C for 15 sec, 55°C for 30 sec and 72°C 
for 30 sec. The relative quantitation method (∆∆CT) (Livak & Schmittgen, 2001) was used to 
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evaluate the expression of selected genes with glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) amplicons used as an internal control to normalize all data, GAPDH is a reliable 
housekeeping gene for HSV infected cells (Watson et al., 2007). Data was analysed using 
MxProTM QPCR software (version 4). 
 
    Table 2.5 QPCR primers used. 
 
Primers Sequence 
HSV1 ICP4 – forward primer 5′ CGACACGGATCCACGACCC 3′ 
HSV1 ICP4 – reverse primer 5′ GATCCCCCTCCCGCGCTTCGTCCG 3′ 
HSV1 gB    – forward primer 5’ GTCAGCACCTTCATCGACCT 3’ 
HSV1 gB    – reverse primer 3’ CAGGGGGACAAACTCGTG 3’ 
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Chapter 3 -  Identifying immunodominant CD8+ T cell 
epitopes of HSV 
3.1. Introduction 
All vaccines for HSV to date have proven ineffective once they have reached clinical trials 
with the most efficacious thus far being the GSK subunit vaccine. This vaccine elicited 
neutralizing antibody and CD4+ T cell responses but failed to induce protective CD8+ T cell 
responses (Belshe et al., 2012). Peptide-based vaccines are better at cross-presenting antigen 
and priming better CD8+ T cell responses (H. Zhang et al., 2009). There are several challenges to 
developing an effective HSV peptide based vaccine candidate, including identification of target 
antigens and human epitopes. At the commencement of this study, very little was known about 
the HSV target antigens for CD8+ T cells and very few human epitopes had been identified.  
The first HSV antigen targets were identified by Tigges et al by deriving five HSV specific 
cytotoxic T lymphocyte (CTL) clones from genital herpes patients (Tigges et al., 1992). One CTL 
clone was directed towards gD2 and the others were directed towards other internal virion 
proteins. Tigges et al later derived four more CTL clones that were directed towards internal 
virion proteins (Tigges et al., 1996). The precise epitope targets or the corresponding HLA 
restriction of these CTL clones were not reported.  
Target antigens were also investigated by Mikloska et al, vaccinia virus recombinants 
expressing the IE proteins ICP0, ICP4 and ICP27 were utilised to investigate whether any re-
stimulated HSV2 specific CD8+ T cells recognized any of these IE proteins (Mikloska et al., 2000). 
Re-stimulation conditions used in the study were designed to simulate in vivo conditions with 
HSV2 infected keratinocytes, treated with IFN-to restore MHC I expression, used to restimulate 
CD8+ T cells so the whole gamut of HSV2 proteins that could be presented in vivo was available.  
Autologous epidermal cell cultures infected with the vaccinia virus recombinants were used to 
test for specific lysis by HSV2 CTL from a total of 19 subjects (a much greater number of subjects 
than any previous study). ICP27 and ICP4 were found to be recognised by 19/19 and 17/19 
subjects respectively, and were therefore likely candidates for immunodominant proteins.  
An approach which directly isolated CTL clones from genital lesions was used by Koelle et 
al. This study was the first to identify HLA restriction of the target protein and defined some HLA 
restricted epitopes, identifying: A*02:01 targets in UL47 (one epitope was further identified for 
one clone as UL47551-559), some B*07:02 targets in UL49, VP2249-57, and ICP0743--751 and a B*45:01 
target in ICP0 (Koelle et al., 2001; Koelle et al., 2002). This was followed up, using a method of 
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gating on CD8+ T cells expressing the skin homing receptor CLA to identify HSV specific CD8+ T 
cells. The previously identified HSV epitopes were confirmed as well as several new epitopes 
being identified in eight donors (Koelle et al., 2003). Two epitopes specific for HLA B*14:02 and 
one each for B*07:02, A*01:01, B*27:052, and B*57:01 were identified from the proteins UL7, 
UL25, UL26, VP11/12, gD2, and gE2 respectively. Most of the epitopes identified were HSV type-
specific and not cross-reactive with HSV1. This showed that in the few individuals tested, the 
CD8+ T cell responses to HSV2 were broad and diverse with few cross-reactive epitopes. 
The very broad and diverse CD8+ T cell responses to HSV2 were more fully appreciated 
after a study surveying the ex vivo CD8+ T cell response to pooled overlapping peptides covering 
48 ORFs of HSV2 (Hosken et al., 2006). This study was the first to move away from artificially re-
stimulated CTL clones and look at the CD8+ T cell response directly ex vivo without any bias 
created from re-stimulation. Precise CD8+ T cell epitopes were not identified in this study, rather 
the CD8+ T cell response to pooled peptides were surveyed, showing cumulative precursor 
frequencies in blood ranged from 500 – 6,000 HSV2 spot-forming units/ 106 CD8+ T cells (or 0.5-
6 % of CD8+ T cells). This study also showed that amongst just 21 individuals, all 48 ORFs tested 
induced CD8+ T cell responses, illustrating HSV2 induces very broad and diverse CD8+ T cell 
responses.  
The limited number of epitopes identified at the commencement of this study, 
particularly HSV1/ HSV2 cross-reactive epitopes, highlighted the need to identify more epitopes, 
particularly for those amongst the most common HLA types for use as potential vaccine 
candidates. Covering just a few epitopes in a peptide vaccine across the most common HLA 
supertypes is potentially effective as a vaccine approach. Epitopes from just the six most 
frequent HLA supertypes (A2, A3, B7, A24, B44, and A1) afford an average population coverage 
of 99.3% (98.1-100% for the five major ethnic groups encompassing Caucasian, North-American 
Black, Japanese, Chinese, and Hispanic) (Sette & Sidney, 1999). Indeed just the three HLA 
supertypes A2, A3, and B7 have an average population coverage of 86.2% (83-88.4%) among 
those five major ethnic groups. This makes the potential for a peptide-based HSV vaccine 
tantalizingly possible if the ideal HSV epitopes were identified. 
Screening of large numbers of overlapping peptides for multiple ORFs of HSV to identify 
immunodominant epitopes is extremely costly, both financially to purchase the peptides, and 
difficult to achieve by screening with a limited amount of blood and limited access to blood from 
donors that are HSV seropositive and with specific HLA types0. The aim of this project was to 
identify an immunodominant peptide for CD8+ T cells that could later be conjugated to Pam2Cys 
to increase its immunogenicity and study whether combining it with a CD4+ T cell epitope would 
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lead to an enhanced CD4+ and CD8+ T cell response. It was therefore not necessary to identify 
many CD8+ T cell epitopes from HSV, just at least one or two for proof of principle. To achieve 
this within a reasonable budget and reasonable donor material, in silico prediction of epitopes 
from HSV ORFs was undertaken. 
Peptides binding to particular HLA alleles fit patterns due to requirements for particular 
amino acids to bind to key amino acids in the HLA class I groove. This has allowed the 
development of epitope prediction programs based on experimental data from known peptides 
binding to their respective HLA molecules. It has been shown that combining multiple epitope 
prediction programs enhances the accuracy of HLA binding prediction (Trost, Bickis, & Kusalik, 
2007). The approach taken in our study was to use multiple epitope prediction programs, 
including proteosomal cleavage prediction, and restrict peptides to those homologous between 
HSV1 and HSV2, as there is a great need for protection against both HSV types. The peptides 
would then be screened for CD8+ T cell responses from HSV seropositive donors, to identify 
immunodominant epitopes restricted to the most common HLA types to be used for follow up 
study as a peptide-based vaccine candidate. 
 
3.2. Results 
3.2.1. In Silico Epitope prediction of CD8+ T cell epitopes from HSV 
The three epitope prediction programs SYFPEITHI, Rankpep, and BIMAS were used to 
select the highest ranked predicted binders across 48 ORFs of HSV2. Six of the most common 
HLA types were chosen to select epitopes for: HLA A*01:01, A*02:01, A*03:01, B*07:02, 
B*08:01, and B*44:02. Peptides were selected according to their predicted binding affinity to 
their respective HLA types. A cut-off of the top 30 predicted binders from each program for each 
HLA type was chosen. Peptides were then selected according to the following requirements: 
they had to score within the top 30 from at least two of the epitope prediction programs in 
addition to being in the top 2% of predicted binders for the third prediction program; selected 
peptides were then only selected if they were predicted to be naturally proteasomally cleaved at 
the C-terminus by the prediction programs RankPep and NetChop 3.0; only peptides that were 
largely homologous between HSV1 & HSV2 were selected (they had 0-2 conservative amino acid 
substitutions e.g. a lysine to an arginine). In the end, sixteen peptides in total were selected; 
three each for HLA types A*01:01, A*02:01, A*03:01, and B*07:02; two each for HLA types 
B*08:01, and B*44:02. A peptide 17 which gave negative binding scores for all HLA types, was 
selected to use as a negative control (Table 3.1).  
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Table 3.1 Peptides selected through epitope predition 
Peptide HLA type Protein Sequence 
SYFPEITHI 
score 
Rankpep 
score 
BIMAS 
score 
Rankpep 
Cleavage 
predicted? 
Netchop 
Cleavage 
predicted? 
1 HLA A*0101 UL19 
LLDNAAAVY 
LLDNAAAVY 
28 126 50 Yes Yes 
2 HLA A*0101 UL21 
VLDECLAEY 
VLDECLAEY 
28 111 50 Yes Yes 
3 HLA A*0101 
UL36 - 
ICP1-2 
APDGTPLQY 
VPDGTPLQY 
29 133 31.25 Yes Yes 
4 HLA A*0201 UL19 - VP5 
AMAPATIAAV 
AMAPATIAAV 
31 90 115.534 Yes Yes 
5 HLA A*0201 ICP4 
YLACEVLPAV 
YLACELLPAV 
30 75 735.86 Yes Yes 
6 HLA A*0201 UL26 
YLITNYLPSV 
YLITNYLPSV 
31 82 735.86 Yes Yes 
7 HLA A*0301 UL39 - ICP6 
TLRPNTLLLK 
TLRPNTLLLK 
29 52 90 Yes Yes 
8 HLA A*0301 UL19 
YLIYDASPLK 
YLVYDASPLK 
23 71 30 Yes Yes 
9 HLA A*0301 UL29 - ICP8 
ALHTVVNNIK 
ALHTVVNNVR 
23 70 30 Yes Yes 
10 HLA B*0702 UL22 - gH 
FPRDPGQLL 
FPRDPGQLL 
26 117 1200 Yes Yes 
11 HLA B*0702 UL38 
APPGRQTERL 
APPGRQTERL 
25 126 240 Yes Yes 
12 HLA B*0702 UL36 
APADLTAAAL 
APADLTAAAL 
25 152 240 Yes Yes 
13 HLA B*0801 
UL47 
VP13/14 
GPRVRVVDI 
GPRVRVVDI 
30 78 80 Yes Yes 
14 HLA B*0801 UL36 
AARERRAQI 
AARERRAQL 
26 96 120 Yes Yes 
15 HLA B*4402 UL13 
LEIPGARSF 
LEIPGARSF 
28 109 600 Yes Yes 
16 HLA B*4402 UL13 
AETNTHGLAY 
AETNTHGLAY 
27 135 240 Yes Yes 
17 negative 
 
EGTAGDHSPS 
     
SYFPEITHI scores using Position Specific Scoring Matrices (PSSMs), higher scores indicate a greater prediction of 
binding 
Rankpep scores using Position Specific Scoring Matrices (PSSMs), higher scores indicate a greater prediction of 
binding 
BIMAS employs amino acid/position coefficient tables to estimate the half time of disassociation, higher scores 
indicate a greater prediction of binding 
The HSV2 sequence is listed in bold, the homologous HSV1 sequence is listed in italics for each peptide. The 
peptides peptides synthesized were the HSV2 sequence. 
 
3.2.2. CD8+ T cell responses to predicted HSV peptides. 
After peptides were selected and synthesized, HSV 1 and/or 2 seropositive donors were 
screened for CD8+ T cell responses to peptides using IFN- ELISPOT. To minimize bias created by 
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re-stimulating CD8+ T cells with peptides, and to measure actual frequencies of circulating HSV-
specific CD8+ T cells in HSV seropositive donors, screening of donors was undertaken directly ex 
vivo without any additional short term culture of the T cells.  It was found that day 5 or 6 
autologous iMDDC and isolated CD8+ T cells (T cells were frozen as PBMC, then thawed, and 
isolated on day 5 or 6 when the iMDDC were ready) at a ratio of 1 MDDC : 10 T cells gave the 
cleanest IFN- ELISPOT results with lower background IFN- responses than using PBMC or PBMC 
depleted of CD4+ T cells. There was no difference in activation of the CD8+ T cells using positive 
or negative selection and positive selection gave a better purity, therefore CD8+ T cells were 
positively selected by microbeads.  
A response was considered positive when the spots in the peptide stimulated wells were 
above mean +2 SD of mock (un-stimulated) wells (indicated by the dotted line in Figure 3.1). 
Samples were run in triplicate in most experiments. If there were insufficient cell numbers for 
triplicate, experiments were run in duplicate. 
 
Figure 3.1 Peptide screening – measuring CD8+ T cell responses to HSV peptides by IFN- ELISPOT.  
Representative response from Donor 7. Day 5 or 6 autologous iMDDCs  (10
4
)
 
were co-cultured with  
isolated CD8+ T cells (10
5
) and  peptides (10  µM)  in triplicate or duplicate for 40 hrs in an IFN- 
ELISPOT. After development, spots were counted using an AID ELISPOT reader. A positive response 
was taken as 2 times the standard deviation above mock as indicated by the dotted line. A total of 
50 donors were screened. 
 
 
Using IFN- ELISPOT to detect CD8+ T cell responses to HSV peptides presented by 
autologous MDDC, a total of 50 donors were successfully screened (purity for CD8+ T cells was 
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87.8-98.8% median = 95.1%). All donors were HSV seropositive as tested by ELISA, the ELISA 
used was not able to distinguish between HSV types 1 and 2. The clinical status of 50 donors is 
summarized in Table 3.2,   35 donors recalled having occurrences of symptomatic coldsores, 3 
donors presented with symptomatic genital herpes, 3 donors were asymptomatic who never 
recalled having a coldsore, and for 9 donors their clinical status was unknown. 
Table 3.2 Donors screened for HSV peptide responses 
HSV clinical Status of Blood Donors Number of Blood Donors Screened 
Cold Sores 35 
Genital Herpes 3 
Asymptomatic 3 
Unknown 9 
Total 50 
 
From the total of 50 donors screened for HSV peptides, 18 donors showed positive 
responses to one or more peptides (summarized in Table 3.3, ELISPOT results are shown in 
Appendix A). Nearly all donors showing positive responses (17/18) recalled having symptomatic 
coldsores, donor 16 was of unknown clinical status. CD8+ T cell frequencies for single HSV 
peptide responses were 0.008-0.104% (average =0.029%, median= 0.016%), calculated by 
subtracting the average of unstimulated wells from the average of peptide stimulated wells. 
Most significantly a total of 9/50 (18%) donors responded to one peptide in particular, peptide 9. 
Peptides 6, 7, and 15 were each responded to by 2 individual donors. Peptides 1, 2, 5, 13, and 16 
were responded to by just 1 donor each. 
Only donors that showed positive responses to peptides were HLA A and B typed to 
medium resolution, which either fully resolves the HLA type or resolves it to 4 digits with some 
degeneracy e.g. A*03:04/100/101/105/106/131. As HLA alleles are named in order of discovery 
the first allele is the most common and therefore the most likely (e.g. A*03:04 is much more 
common than the rare allele A*03:100). In Table 3.3, an asterisk indicates it was resolved with 
degeneracy and the most common allele is listed. Full listing of HLA typing including degeneracy 
for each donor is listed in Appendix B. 
Predicted HLA restriction for peptides 2, 5, 6, 13, and 15 was consistent with empirical 
data whereas donors responding to peptides 1, 7, and 16 did not match predicted HLA types. 
Peptide 9 was predicted to bind to HLA-A*03:01, however only 1/9 of the donors responding to 
peptide 9 were HLA A3+ (donor 2) and 6/9 of the donors were HLA A2+. The remaining 2 donors 
were neither HLA A3+ nor A2+ (donors 10 & 12). 
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Table 3.3 Positive donor responses to predicted HSV peptides 
Donor HLA A type  HLA B type  Response to 
Peptides  
% CD8 T cells 
responding  
1 02:01:1 
26:01:1  
44:03:1 
15:01:1  
5, 6 , 15  0.017, 0.011, 0.016  
2 01:01:1 
03:01:1  
07:02/61 
08:01:1  
2, 9  0.012, 0.011  
3 03:01/01N 07:02/61 15  0.04  
4 02:03:01 
02:07  
39:01* 
46:01  
9  0.011  
5 02:01* 
03:01 * 
08:01/02 
44:02* 
6  0.048  
6 01:01* 
11:01 * 
13:02:01 
15:17:01  
7  0.018  
7 02:01* 
24:02* 
44:02* 
40:01/47 
9  0.082  
8 02:01* 
68:02/18N  
51:01/02/03* 
53:01/02  
9  0.026  
9 01:01* 
02:01*  
08:01 
57:01/06  
7  0.011  
10 24:02* 
31:01/09  
44:02* 
57:01/06/08 
9  0.016  
11 03:02  
26:01* 
44:03/13/26 
38:01/09 
10  0.104  
12 11:01* 
29:01* 
08:01* 
44:03/13/26 
1, 9  0.012, 0.012  
13 01:01* 
02:01*  
08:01* 
44:02*  
13  0.008  
14 02:01* 
24:03/23/33 
51:06 
15:13  
9  0.09  
15 03:01* 
26:01*  
07:02* 
08:01*  
16  0.013  
16 02:01* 
11:01* 
15:01* 
35:01* 
9 0.05 
17 11:01* 
-  
13:01* 
15:02  
11  0.012  
18 02:01 
29:02 
44:02 
44:03 
9 0.015 
* Indicates allele was resolved to 4 digits with degeneracy e.g. HLA A*03:04/100/101/105/106/131 
is listed above as A 03:04* as HLA alleles are named in order of discovery the first allele is the most 
common and therefore the most likely. Full listing of HLA typing including degeneracy for each 
donor is listed in Appendix B. 
 
3.2.3. Peptide 9 is predicted to bind to multiple HLA types  
Despite in silico epitope prediction showing peptide 9 (ALHVVNNIK) bound to HLA-
A*03:01, only 1/9 donors responding to peptide 9 were HLA-A*03:01+, therefore additional HLA 
types that might bind peptide 9 were investigated. HLA-A*11:01 and A*31:01 (donors 12 & 10 
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respectively) are both members of the HLA A3 supertype (O. Lund et al., 2004; Sette & Sidney, 
1999), and therefore were good candidates for binding peptide 9. The remaining 6 donors that 
responded to peptide 9 were all HLA A2+, including 5 donors that were HLA-A*02:01+ and one 
that was heterozygous for two HLA-A2 alleles: A*02:03, and A*02:07 (donor 4). 
To investigate peptide 9 binding to other HLA types, the epitope prediction programs 
SYFPEITHI, RankPep, BIMAS, and NetMHC 3.0 were used to predict epitopes within HSV2 ICP8 to 
see if peptide 9 or epitopes within peptide 9 were predicted to bind. Published reference 
peptides were used for comparison of scores against peptide 9 binding to HLA A*03:01, A*11:01, 
A*31:01, and all the A2 subtypes that were available (Table 3.4). 
In silico epitope prediction suggests peptide 9 (ALHTVVNNIK) binds to HLA-A*11:01 with 
SYFPEITHI, Rankpep, and BIMAS giving similar binding scores to the known HLA-A*11:01 peptide 
GPISGHVLK (Li et al., 2007). Peptide 9 was also predicted to be a weak binding peptide by 
NetMHC. Peptide 9 was not predicted to bind to HLA-A*31:01 by any of the epitope prediction 
programs. The already known HLA-A*31:01 binding peptide KLAFHHMAR (Borghan, Oka, & 
Takiguchi, 2005) was predicted to bind by all the prediction programs (SYFPEITHI did not have 
HLA A*31:01 available). 
For HLA-A*02:01, all four epitope prediction programs predicted a 9 mer within peptide 
9 with just one lysine removed from the C-terminus, referred to in this text as peptide 9-K 
(ALHVVNNI). As one of the donors responding to peptide 9 was not HLA-A*02:01+ and was 
instead HLA-A*02:03+/ A*02:07+ (donor 4), other HLA A2 subtypes were investigated. The HLA 
A2 subtype A*02:03 was available on RankPep and NetMHC, A*02:05 was available on BIMAS 
only and the remaining listed A2 subtypes were available on NetMHC only. Peptide 9-K 
(ALHTVVNNI) was indeed also predicted to bind to multiple HLA A2 subtypes including A*02:01, 
A*02:02, A*02:03, A*02:11, A*02:12, A*02:16, and A*02:50 (Table 3.4). There were some HLA 
A2 subtypes that were predicted not to bind peptide 9-K including A*02:05, A*02:06 and 
A*02:19. 
The results of the epitope prediction programs suggest peptide 9 may be capable of 
binding multiple HLA types including some members of the HLA A3 supertype including HLA 
A*03:01, and HLA-A*11:01, also by removing just one amino acid from the C-terminus, peptide 
9-K may bind multiple HLA A2 subtypes. 
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Table 3.4 Peptide prediction of peptide 9 binding to HLA types 
HLA type Peptide SYFPEITHI Rankpep  BIMAS  NetMHC 
  Rank Score Rank Score Rank Score Rank Score 
A*03:01 AVKDVTITKK  26  10.6  3  WB-121 
 ALHTVVNNIK 14 23 8 70 5 30 6 WB - 99 
A*11:01 GPISGHVLK  21  9.6  0.9 - - 
 ALHTVVNNIK 16 20 17 65 14 0.4 8 WB – 165 
A*31:01 KLAFHHMAR  NA  13.129  12.000  SB – 7 
 ALHTVVNNIK  NA - - - - - - 
A*02:01 NLVPMVATV  30  102  159.970  29 
 ALHTVVNNI 20 25 4 93 24 23.995 29 WB – 172 
A*02:02 ALHTVVNNI  NA    NA 27 SB – 31 
A*02:03 ALHTVVNNI  NA 10 103  NA 17 SB – 12 
A*02:05 ALHTVVNNI  NA  NA - -  NA 
A*02:06 ALHTVVNNI  NA  NA  NA - - 
A*02:11 ALHTVVNNI  NA  NA  NA 13 SB – 5 
A*02:12 ALHTVVNNI  NA  NA  NA 19 SB-31 
A*02:16 ALHTVVNNI  NA  NA  NA 32 WB - 78 
A*02:19 ALHTVVNNI  NA  NA  NA - - 
A*02:50 ALHTVVNNI  NA  NA  NA 40 SB - 13 
SYFPEITHI scores using Position Specific Scoring Matrices (PSSMs), higher scores indicate a greater prediction of 
binding 
Rankpep scores using PSSMs, higher scores indicate a greater prediction of binding 
BIMAS employs amino acid/position coefficient tables to estimate the half time of disassociation, higher scores 
indicate a greater prediction of binding 
NetMHC gives a readout of SB (Strong Binder) or WB (Weak Binder) – score indicates the predicted affinity 
presented in nM, therefore lower scores indicate a greater prediction of binding. 
- indicates peptides were not predicted to bind by the epitope prediction program. 
NA indicates that the specific HLA type was not available to use for that epitope prediction program. 
3.2.4. Peptide 9 binds to HLA A*03:01, peptide 9-K binds to HLA A*02:01 as shown by T2 
binding assay 
As in silico epitope prediction suggested peptide 9 binds to HLA-A*03:01, as well as HLA-
A*02:01 with one lysine removed from the C-terminus, binding of the two peptides, peptide 9 
(ALHTVVNNIK) and peptide 9-K (ALTHVVNNI) to HLA molecules was tested by T2 binding assay.  
T2 cells are deficient in TAP and present empty HLA molecules on their cell surface, 
however empty HLA molecules are unstable and are quickly endocytosed; exogenous peptides 
that can bind to HLA molecules, stabilize the molecules, preventing them from being 
endocytosed. By staining for the cell surface expression of HLA molecules, the ability of peptides 
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to bind and stabilize the HLA molecules can be measured, therefore an increase in surface HLA 
expression indicates an increase in the binding affinity of the peptide for the given HLA allele 
over increasing peptide concentrations. 
 
Figure 3.2 Peptide 9 binds to HLA-A*03:01, peptide 9-K binds to HLA-A*02:01 as shown by 
T2 binding assay 
T2 cells (2 x 10
5
) expressing (A) HLA-A*02:01 or (B) HLA-A*03:01 were incubated in AIM-V serum 
free media with indicated concentrations of peptides at 26°C for 14 hrs, then moved to 37°C for 2 
hrs before staining for surface HLA A*02:01 or HLA A*0:301 expression. Expression, indicated by 
mean fluorescence intensity, was analysed by flow cytometry. Peptides 9, 9-K and positive controls 
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were done in duplicate, error bars indicate standard deviation. Negative controls were done with 
one replicate for each concentration. 
 
 
The HLA-A*02:01 T2 binding assay confirmed peptide 9-K does bind to HLA A*02:01, 
increasing surface HLA-A*02:01 was detected with increasing concentrations of peptide (Figure 
3.2A). The full length peptide 9 itself did not bind, with surface expression of HLA-A*02:01 for 
peptide 9 similar to the negative control. 
As suggested by epitope prediction, the T2 binding assay showed peptide 9 binds to 
HLA-A*03:01, increasing surface expression of A*03:01 detected with increasing concentrations 
of peptide (Figure 3.2B). Peptide 9-K did not bind, surface expression of HLA-A*03:01 for peptide 
9-K was similar to the negative control. 
The T2 binding assays confirmed peptide 9 and peptide 9-K were able to bind to HLA-
A*03:01 and HLA-A*02:01 respectively. 
3.2.5. Peptide 9 induces specific proliferation of CD8+ T cells 
To confirm peptide 9 was an immunodominant epitope, the ability of peptide 9 to 
induce specific proliferation was examined. Proliferation was measured by the frequency of 
CellTrace Violetlow CD8+ T cells following stimulation with peptide 9, peptide 17, or mock (where 
DMSO only was added). PHA was used as a positive control for proliferation. Freshly isolated 
PBMC were incubated with peptide (10 µM). After 5 days of culture, PBMCs were re-stimulated 
with autologous peptide-pulsed iMDDCs and low concentrations of IL-2 or IL-15 (1 ng/ mL) 
(inducing specific CD8+ T cell proliferation was problematic, therefore low levels of cytokine 
were used to assist specific proliferation).  The frequency of CellTrace Violetlow CD8+ T cells were 
measured on day 10 by flow cytometry by staining for CD3, CD8, and propidium iodide to 
exclude dead cells.  
Peptide 9 induced specific proliferation of CD8+ T cells from donor 4 with the assistance 
of re- stimulation with peptide-pulsed iMDDCs and low concentrations of IL-2 or IL-15 ( 
 
Figure 3.3). The presence of cytokines slightly increased the frequency proliferating CD8+ 
T cells in mock stimulated PBMC from 0.12% in the absence of cytokine to 0.4% and 0.27% in the 
presence of IL-2 or IL-15 respectively. Peptide 9 increased CD8+ T cell proliferation to 0.71% and 
1% in IL-2 and IL-15 supplemented PBMC respectively. The response to peptide 17 (the negative 
control) remained similar to mock. 
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In total, four donors have shown specific proliferation in response to peptide 9 
stimulation (Figure 3.4). Similar to the responses seen in donor 4, donors 18 and 7 had no 
response to peptide 9 without the assistance of cytokines and addition of cytokine did slightly 
increase proliferation in mock stimulated PBMC (Figure 3.4A). Donor 8 showed a similar amount 
of background proliferation in no cytokine, IL-2, and IL-15 supplemented samples and there was 
an increase in proliferation in response to peptide 9 in the no cytokine, IL-2, and IL-15 
supplemented samples. 
As background responses were very different in each donor (backgrounds ranged from 
0.12 - 3.81%), responses were converted to fold-change compared to mock for each cytokine 
treatment in order to compare between donors (Figure 3.4B). There was no significant 
difference between mock and peptide 9 without addition of any cytokine, there was a significant 
difference with addition of low levels of IL-2 or IL-15 (p=0.034 and p=0.022 respectively). 
As CD8+ T cells from four donors did induce specific proliferation in response to peptide 
9, and not in response to peptide 17, it confirmed peptide 9 is an immunodominant epitope. 
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Figure 3.3 Peptide induces specific proliferation of CD8+ T cells 
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Freshly isolated PBMCs were stained with CellTrace Violet and cultured in RH10 media (1 x10
6
 
PBMC/ mL). Peptide (10 µM) was added and cells were cultured for 10 days. On day 5 of culture, 
autologous iMDDCs were peptide pulsed for 2 hours and added to culture with IL-2 or IL-15 (1 ng 
/mL). On day 10, cells were stained with antibodies to CD3 and CD8. Cells were stained with PI 
immediately before being anaylsed by flow cytometry on the BDCantoII. The gating strategy is 
shown in the top panel. Flow cytometry dot plots show the percentage of proliferating cells CD8+ 
T cells in response to peptide, results from donor 4 are shown as a representative result. Four 
donors in total were tested. 
 
 
Figure 3.4 Peptide 9 induces specific proliferation of CD8+ T cells in four donors 
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Freshly isolated PBMCs were stained with CellTrace Violet and cultured in RH10 media (1 x10
6
 
PBMC/ mL). Peptide (10 µM) was added and cells were cultured for 10 days. On day 5 of culture, 
autologous iMDDCs were peptide pulsed for 2 hours and added to culture with IL-2 or IL-15 (1 ng 
/mL). On day 10, cells were stained with antibodies to CD3 and CD8. Cells were stained with PI 
immediately before being anaylsed by flow cytometry on BD Canto II. (A) The percentage of CD8+ 
T cells proliferating in response to peptide from 4 donors. (B) To compare proliferation between 
donors, percentage of proliferation was converted to fold-change compared to mock. p-values 
listed show significance between mock and peptide 9 using a paired student t-test. 
 
 
3.2.6. Peptide 9 induces a multi-functional CD8+ T cell response 
Multi-functional CD8+ T cells that secrete multiple Th1 cytokines, such as IFN-, TNF-α, 
and IL-2, as well as killing by de-granulation which can be measured by staining for CD107a/b, 
have been correlated with protective immunity (Almeida et al., 2007; Betts et al., 2006). As it 
was now confirmed that peptide 9 was an immunodominant epitope, we were also interested to 
see if peptide 9 induced a multi-functional CD8+ T cell response. 
To determine if responding CD8+ T cells were multi-functional, freshly isolated PBMCs 
were mock stimulated or stimulated with peptide 9 in RH10 media in the presence of brefeldin A 
and monensin.  After 6 hrs, cells were stained and analysed by flow cytometry. There was a 
distinct population of CD8+ T cells from donor 4 that produce IFN-, TNF-and IL-2 in response 
to peptide 9 that was not present in either mock or peptide 17 stimulated PBMC, showing that 
the response to peptide 9 was indeed multi-functional (Figure 3.5A). A small de-granulation 
response was detected with CD107a/b (Figure 3.5B). 
Multi-functional CD8+ T cell responses to peptide 9 were observed in 3 donors (Figure 
3.6). The percentage of CD8+ T cells producing cytokines was calculated by subtracting the mock 
stimulated CD8+ T cells from peptide 9 stimulated cells. CD8+ T cells produced significant 
amounts of IFN- (0.11-0.13%) and TNF- (0.11-0.18%) in response to peptide 9. Less IL-2 (0.04-
0.19%) was produced than IFN- and TNF-. Only a small amount of CD107a/b was detected 
(0.005-0.077%). 
 As a comparison to peptide 9 the CMV immunodominant peptide NLV was used (donors 
7 & 18 are CMV positive, donor 4 is CMV negative and therefore does not respond to NLV). The 
CD8+ T cell response to NLV showed large amounts of IFN- and TNF-α produced, less IL-2 
produced and in contrast to peptide 9 responding cells, many NLV responding cells were 
CD107a/b+. 
To look at the poly-functionality of CD8+ T cells responding to peptide 9, the relative 
proportions of responding cells expressing one, two, three, or four functional markers were 
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analysed after background responses in mock were subtracted. (Figure 3.6A). The proportions of 
poly-functional CD8+ T cells were very different across the three different donors examined. 
Donor 4 exhibited a predominantly poly-functional response with 88% of responding cells 
expressing two or more functional markers, 34% produced all three cytokines, less than 1% of 
responding cells expressed all four functional markers, only 12% were monofunctional.  Donors 
18  and 7 exhibited a much greater proportion of mono-functional responding cells (30% and 
41% respectively).  Donor 7 had just 4% of cells poly-functional for all three cytokines in the cells 
responding to peptide 9, in response to NLV, 5% of cells expressed all four functional markers 
and 17% three functional markers. Donor 18 had a small proportion (12%) of responding CD8+ T 
cells secreting all three cytokines, the response to NLV in donor 18 was more polyfunctional with 
7% expressing all four functional markers, and 18% expressing three functional markers. 
Interestingly, in response to NLV, the presence of three functional markers predominantly 
consisted of IFN-, IL-2 and CD107a/b+ cells, whereas in response to peptide 9, all three 
cytokines accounted for the three functional markers, with little contribution from CD107a/b. 
These results show that the CD8+ T cells responding to peptide 9 were indeed multi-
functional, however, there was large variability between donors. 
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Figure 3.5 Peptide 9 induces a multi-functional CD8+ T cell response in Donor 4, detected 
with intracellular cytokine staining and CD107 a/b assay.  
Freshly isolated PBMCs were mock stimulated or incubated with peptides 9 or 17 in the presence 
of brefeldin A, monensin, anti-CD28/anti-CD49d and CD107a/b antibodies for 6 hrs at 37°C. Cells 
were stained with a fixeable Live/ Dead stain and antibodies to CD3, CD8, CD4, IFN-, TNF-α and IL-
2 and analysed on the BDLSRII or Fortessa. (A) Flow cytometry dot plots of CD8+ T cells producing 
multiple cytokines. (B) The percentage of CD8+ T cells positive for IFN-, TNF-α, IL-2 or CD107a/b. 
Results of Donor 4 are representative of 3 donors. 
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Figure 3.6 Peptide 9 induces a multi-functional CD8+ T cell responses in 3 donors, detected 
with intracellular cytokine and CD107a/b staining.   
Freshly isolated PBMCs were mock stimulated or incubated with peptide 9 or the CMV HLA A2 
restricted immunodominant peptide NLV in the presence of brefeldin A, monensin, anti-
CD28/anti-CD49d and CD107a/b antibodies for 6 hrs at 37°C. Cells were stained with a fixeable 
Live/ Dead stain and antibodies to CD3, CD8, CD4, IFN-, TNF-α and IL-2 and analysed on the BD 
LSRII or Fortessa. Background staining from mock stimulated CD8+ T cells was subtracted from 
peptide 9 stimulated CD8+ T cells. Student T-test was used to determine significance of peptide 9 
stimulation compared to mock for each of the cytokines (displayed as p-values for each cytokine). 
(A) The percentage of CD8+ T cells producing cytokines IFN-, TNF-α or IL-2 or stained for CD107 
a/b. (B) The relative proportions of responding cells stained positive for one, two, three, or four 
functional markers are represented as the inner circle of the pie charts, the proportions of each 
functional marker are represented in the outer circle.  
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3.3. Discussion 
Immunodominance refers to the phenomenom that despite the generation of hundreds 
of distinct antigenic peptides for recognition following and infection, a large portion of the anti-
viral T cell population targets only some MHC class I-peptide complexes. In this study we 
identified a human MHC I restricted HSV immunodominant peptide capable of binding two HLA 
supertypes, A2, and A3. To our knowledge this peptide from HSV2 ICP8 (ALHTVVNNIK) is novel 
and the first HSV peptide reported that is capable of binding and inducing CD8+ T cell responses 
in donors from two different HLA supertypes. 
HLA supertypes for A2 and A3 are now well defined and studies agree on their peptide 
binding pattern (O. Lund et al., 2004; Sette & Sidney, 1999).  The HLA A2 supertype is 
characterized by peptides that are generally 9-10 amino acids in length and bear small or 
aliphatic hydrophobic residues at position 2 (AILMVT or Q) and L, I, V, M, A or T at the C-
terminus. The A2 supertype includes A*02:01, A*02:02, A*02:03, A*02:04, A*02:05, A*02:06, 
A*02:07, A*68:02, and A*69:01. Peptides binding to the HLA A3 supertype are generally 9-10 
amino acids in length and are characterized by a broad motif (overlapping substantially with the 
A2 motif) of A, I, L, M, V, T or S at position 2 and the basic amino acids R or K at the C-terminus. 
The A3 supertype includes A*03:01, A*11:01, A*31:01, A*33:01, and A*68:01. As reported from 
both these studies, the most critical component for binding to these two HLA supertypes is the 
amino acids found at position 2 and the C-terminus residue. Indeed Lund et al. found that a 
leucine was the most frequent amino acid found at position 2 for HLA alleles A*02:01, A*02:02, 
A*02:03, A*02:04, A*02:05, A*02:06, A*02:07, A*03:01, A*33:01, A*68:01 ,and A*68:02. 
A*11:01 had isoleucine as its most frequent peptide at position 2. This preference for leucine is 
perhaps the reason why peptide 9 (ALHTVVNNIK) bound so well to both types. Peptide 
prediction suggested peptide 9-K bound to most HLA A2 alleles and peptide 9 was predicted to 
most HLA A3 supertype alleles but not HLA A*31:01, this may be due to Lund et al.’s finding that 
A*03:01 and A*11:01 cluster very closely and A*31:01 is only remotely related to the other HLA 
alleles in the HLA A3 supertype. Other studies have also found peptides containing motifs 
associated with two or more supertypes. A large scale analysis of the capacity of a set of 252 
known EBV and HIV epitopes to bind a panel of 30 HLA I A and B molecules found 62% had 
motifs associated with two or more supertypes  (Sidney, Peters, Frahm, Brander, & Sette, 2008). 
Peptide 9 is therefore not unique in its capacity to bind two HLA supertypes, but is still important 
as a HSV vaccine candidate. 
As shown in Table 3.1, peptides were selected if they had 0-2 conservative amino acid 
substitutions. Peptide 9 from HSV2 ICP8612-621 had two C-terminal between HSV2 (ALHTVVNNIK) 
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and and HSV1 (ALHTVVNNVR). These were conservative substitutions and should still allow the 
same binding. Epitope prediction programs suggested the peptides bound in a similarly. As most 
responding donors clinically presented with coldsores, and the HSV2 peptide was used for 
peptide screening, this suggests the epitope is cross-reactive. Nevertheless, the ability of 
ALHTVVNNVR to bind should be experimentally investigated in the future.   
The in silico epitope predictions need to be followed up and confirmed by in vitro 
binding assays. Only T2 cells expressing HLA-A*02:01 or A*03:01 were available, kindly gifted to 
us by Rajiv Khanna and Scott Burrows, for testing in our lab. The in vitro T2 binding assays 
confirmed the epitope prediction for peptide 9 and peptide 9-K. It would be of interest to 
investigate in the future whether peptide 9 and 9-K can bind to many of the HLA A2 and A3 
supertype alleles. 
At the commencement of this project, few human MHC I restricted HSV epitopes had 
been identified. More recently, a number of epitopes have been identified, particularly HLA-
A*02:01 epitopes. BenMohamed et al has identified three immunodominant epitopes from 
HSV1 gD (gD53-61, gD70-78 and gD224-232) and four immunodominant epitopes from HSV1 gB (gB183-
191, gB342-350, gB441-449 and gB561-569) (Chentoufi, Zhang, et al., 2008; Dervillez et al., 2013). The 
methods used to select the epitopes were similar to the methods used in our study, epitope 
prediction programs were used to predict peptides that bind to HLA A*02:01, followed by 
measuring peptide binding with the T2 HLA-A*02:01 binding assay. CD8+ T cell responses to 
peptides were measured by IFN- ELISPOT or by ICS following a 5 day stimulation with peptides 
or heat-inactivated HSV1. Interestingly two of the gB epitopes, gB183-191 and gB342-350, appeared to 
bind HLA-A*02:01 (as measured by T2 binding assay) with only low affinity, these two peptides 
still induced a strong expansion of CD8+ T cells, implying that as long as the peptides bound to 
some extent, immunodominance was not only dependant on how strongly they bound.  
Laing et al followed on from the work done by Hosken et al by selecting the 14 ORFs that 
most frequently elicited CD8+ T cell responses for HSV2 seropositive subjects (Laing et al., 2010). 
Laing et al surveyed the 14 ORFs for CD8+ T cell responses, identifying 24 epitopes within 15mer 
peptides and suggested the most likely HLA restriction and epitopes using epitope prediction 
programs. CD8+ T cell responses to UL29 (ICP8) were investigated by Laing et al, overlapping 
15mer peptide pools did elicit CD8+ T cell responses in 7/55 (13%) of HSV2 seropositive donors 
tested. The response to the peptide, peptide 9, identified within ICP8 in our study was 
recognised in 9/50 (18%) of donors in our study, a little higher than those found in the Laing et al 
study responding to ICP8 peptide pools. In Lang et al study only one peptide within UL29 (ICP8) 
was further defined in one donor, the 15mer, CPLLIFDRTRKFVLA, was recognised by this donor, 
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peptide prediction was not able to further define the epitope as the donors HLA type (A24, B2, 
B14 and B50) were largely not available in the epitope prediction databases. To our knowledge 
this is the only epitope that has been defined within ICP8, peptide 9 identified in our study 
identifies an additional, novel, epitope within HSV2 ICP8 and has been well characterised by our 
study. 
Very recently Jing et al carried out an extensive screening of 7 individuals using a unique 
system of stimulating donor PBMC with autologous MDDC cross-presenting UV-inactivated HSV1 
for 20 hours before sorting for live CD3+CD8+ cells expressing CD137 (a tumour necrosis factor 
receptor family protein that identifies recently activated CD4+ and CD8+ T cells) (Jing et al., 
2012). These CD8+CD137hi cells were then expanded with non-specific mitogens and their 
responses were interrogated with panels of artificial APCs expressing one of the participants HLA 
A, B, or C types and specific fragments of HSV1 genes or fragments covering a total of 74 HSV-1 
ORFs. Using this unique approach it was found an average of 17 antigens were recognised per 
person with a broad kinetic, structural, and functional spectra. Some in silico epitope prediction 
was performed on the immunogenic ORFs and synthetic peptides were used to test for CD8+ T 
cell responses. Overall 45 distinct HSV1 CD8 epitopes in 22 ORFs were defined. The original 7 
individuals along with an additional 13 (10 in total) HSV1 infected individuals PBMC were tested 
directly ex vivo, without re-stimulation, to see if CD8+ T cell responses to 40 of the 45 identified 
epitopes could be detected by IFN- ELISPOT. Responses from direct PBMC testing showed 
12/20 (60%) individuals had 1-5 peptide-specific responses. Of the CD8+ T cell epitopes tested, 
12/40 (30%) were positive in one or more HLA-matched individuals. The number of net IFN- SFU 
ranged from 11-136 SFU/ 106 PBMCs which was similar to the number of IFN- SFU in our study 
with 8-104 IFN- SFU /105 CD8+ T cells (CD8+ T cells make up 15% of PBMC as a rough 
approximation).  
Among the 7 individuals tested by Jing et al, 4 individuals were HLA A*02:01 or a close 
variant, none of these individuals had responses to gD1. The gD epitopes discovered by 
Chentoufi et al were tested but none of the four donors responded to any of the previously 
identified epitopes (Jing et al., 2012). This inconsistency across different studies highlights the 
difficulty faced with identifying immunodominant HSV epitopes with broad responses, and 
immunodominant epitopes, varying largely between donors, coupled with very low numbers of 
circulating HSV-specific CD8+ T cells. 
Polyfunctional CD8+ T cell responses are thought to be important for as it has been 
correlated with protective immunity (Almeida et al., 2007; Betts et al., 2006). Polyfunctionality 
of HSV-specific epitopes has only been explored in two studies. Laing et al found several HLA 
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B7+ donors responding to UL4945-59. The study investigated the polyfunctionality of CD8+ T cells 
responding to HSV epitopes they had investigated, similar to our study they looked at the 
proportions of CD8+ T cells producing IFN-, TNF-α, IL-2 and those positive for CD107a indicating 
the CD8+ T cells are killing through de-granulation. Focusing on the responses to the epitope 
UL4945-59, they found that this epitope produced the greatest proportion (46%) of cells positive 
for three or more functional markers. Of the CD8+ T cells producing three or more functional 
markers more than 80% produced IFN-, TNF-α and IL-2 but showed no degranulation. In their 
study Laing et al found the most variable functional markers were CD107a and IL-2. For all 
subjects very few HSV2 specific T cells were observed that produced both IL-2 and exposed 
CD107a. IL-2 was found to be the least abundant cytokine and IFN- the most abundant 
cytokine. In our study, in response to peptide 9, de-granulation, measured by CD107a/b staining, 
was the least abundant functional marker with only donor 7 significantly de-granulating (Figure 
3.6A), whilst the percentage of CD8+ T cells positive for CD107a/b in response to NLV was similar 
to the number secreting TNF-α. In response to peptide 9 TNF-α was the most abundant cytokine 
in our study followed closely by IFN-. Just as was found by Laing et al, IL-2 was the least 
abundant cytokine, this was also seen in the CD8+ T cells responding to NLV. Interestingly donor 
4 had the lowest percentage of CD8+ T cells responding to peptide 9 (Figure 3.6A) but had the 
highest polyfunctional response, so even though not many cells responded, those that did were 
highly functional, only 12% were monofunctional. The CD8+ T cell response to peptide 9 in 
donors 18 and 7 was more monofunctional (41% and 30% respectively). In response to peptide 
9, less than 4% of CD8+ T cells were found to produce all three cytokines in donor 18, and only 
12% produced all three in donor 7. Greater polyfunctionality was observed in the response to 
the CMV peptide NLV. These results indicated responses to peptide 9 were similar in magnitude 
and cytokine profile to other identified HSV epitopes. 
Very recently a HLA A2 restricted epitope from VZVs ribonucleotide reductase subunit 2 
(RNR2) was found to be broadly cross-reactive with conserved epitopes from RNR2 homologues 
from other herpesviruses, specifically HSV1, HSV2, and EBV (C. Chiu et al., 2014). This proposes 
the intriguing possibility of a ‘pan-herpesvirus’ vaccine. Similar to our findings, phenotype of 
responses to this epitope were variable between individuals in both functional profile and 
phenotype, with some displaying evidence of exhaustion. HSV responses do appear to be highly 
variable between different individuals. In Chiu et als (2014) study, protective responses to the 
pan-herpes virus epitope was not induced by the VZV vaccine Zostavax. Different vaccine 
formulations from Zostavax would therefore be needed to target these particular epitopes. 
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In this study a novel HSV peptide was identified capable of binding to two HLA 
supertypes. It exhibited a similar pre-cursor frequency and induced a similar cytokine profile to 
HSV epitopes identified in other studies. As peptide 9 could bind to HLA A2 and A3 it was an 
excellent candidate to be included in a peptide based vaccine. 
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Chapter 4 -   Investigating the effects of Pam2Cys-
conjugation on the presentation of HSV epitopes to T cells. 
4.1. Introduction 
HSV infections, both types 1 and 2, present a significant global health burden and there 
is a critical need for a vaccine to alleviate suffering associated with HSV (Johnston et al., 2014). 
The most significant morbidities caused by HSV include vision loss, neonatal herpes, and genital 
herpes disease causing increased HIV acquisition. As HSV, once acquired, remains latent causing 
recurrences of symptomatic or asymptomatic shedding, a prophylactic vaccine preventing 
latency would reduce HSV spread. A vaccine for both HSV1 and HSV2 would have a dramatic 
effect on global health. 
All vaccines candidates for genital herpes that have been tested to date have failed to 
induce high level efficacy in clinical trials. The most efficacious so far has been the GSK subunit 
vaccine that included HSV2 gD with the adjuvants AS04 and dMPLA. It induced 73% efficacy 
against genital herpes caused by HSV2  in seronegative women in a in a cohort of serodiscordant 
couples (Stanberry et al., 2002), but more recently only 58% efficacy against genital herpes 
caused by HSV1 in young women but no efficacy against genital herpes caused by HSV2  (Belshe 
et al., 2012). This vaccine elicited antibody and CD4+ T cell responses but failed to induce CD8+ T 
cell responses (Belshe et al., 2012). Despite great efforts made up to now, no ideal HSV-2 vaccine 
adjuvant that stimulates a CD8+ T cell response is yet available (X. P. Zhu et al., 2014).  
Approaches using synthetic peptides for HSV epitopes are now being considered. 
Vaccines utilizing only peptides 9-11 amino acids in length have achieved protective T-cell 
immunity against viruses (Kast et al., 1991; Schultz et al., 2004) and HPV-16 induced tumours 
(Feltkamp et al., 1993). However, major flaws in the concept of vaccination with precise MHC I 
binding peptides have emerged with peptide-specific tolerance being induced resulting in 
adenovirus transformed tumours with enhanced outgrowth instead of protection (Toes, Blom, 
Offringa, Kast, & Melief, 1996; Toes, Offringa, Blom, Melief, & Kast, 1996). Aside from tolerance, 
other peptide based vaccines have induced sub-optimal and short-lived CD8+ T cell responses 
due to a lack of specific CD4+ T cell help and inadequate signalling by antigen presenting cells 
(Melief et al., 2000; van den Broeke, Daschbach, Thomas, Andringa, & Berzofsky, 2003; van 
Poelgeest et al., 2005). 
The dilemma of tolerance being induced has been attempted to be addressed through 
the use of synthetic long peptides (SLPs) containing both CD4+ and CD8+ T cell epitopes. 
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Vaccinations with the HPV-16 derived 35-amino acid long E7 peptide resulted in a much more 
robust E7-specific CD8+ T cell response and correlated with more effective tumour clearance 
than vaccinations with the short peptide containing the minimal CD8+ T cell epitope (Zwaveling 
et al., 2002). It was also found that linking class I and II epitopes is more effective than mixing 
class I and II epitopes (Zom, Khan, Filippov, & Ossendorp, 2012; Zwaveling et al., 2002).  
SLPS were more effective at inducing CD8+ T cell responses and avoiding tolerance as 
the peptides cannot be loaded exogenously on to all cell types, instead they must be taken up, 
processed, and presented by APCs preventing toleregenic signals and increasing CD8+ T cell 
responses through CD4+ T cell help. However, SLPs do not mature APCs such as DCs and without 
appropriate maturation may sub-optimally prime CD8+ T cell responses. To address this, recent 
approaches to improve synthetic peptide vaccines have been to conjugate peptides to molecules 
that will target DCs specifically. Some have approached this by conjugating peptides to 
antibodies against DC-expressed cell surface receptors including CLEC9A (Caminschi et al., 2008), 
DEC-205 (Bonifaz et al., 2002; Tsuji et al., 2011), and the mannose receptor (L. Z. He et al., 2007; 
Moyle & Toth, 2013; Tsuji et al., 2011). The most ideal approach has been through the use of 
adjuvants that bind PRRs (such as TLR ligands), as this results in activation and maturation of 
DCs, avoiding tolerance and optimally priming T cell responses (Caminschi & Shortman, 2012).  
Utilizing conjugated lipopeptides as an adjuvant has been demonstrated to elicit cell-
mediated and antibody-mediated immunity (Pejoski, Zeng, Rockman, Brown, & Jackson, 2010; 
Redecke et al., 2004; Zeng et al., 2012) with Th1 (Gowthaman, Rai, Khan, Jackson, & Agrewala, 
2012; Imanishi et al., 2007; M. Kim et al., 2012; Tan et al., 2012), Th2 (Redecke et al., 2004; 
Wenink et al., 2009), and Th17 (Reynolds et al., 2010; Wenink et al., 2009) responses reported 
(Moyle & Toth, 2013). TLR2, which is expressed on the cell surface of DCs and detects 
lipoteichoic acid, zymosan, peptidoglycan and bacterial lipoproteins (Olive, 2012), is a good 
candidate to be targeted for lipopeptide vaccines. TLR2 ligands represent a promising class of 
adjuvants for human use, with clinical trials suggesting such adjuvants are well tolerated with 
few or no side effects (Richmond et al., 2012; Schmidt et al., 2007; Seth et al., 2000). In recent 
years it has been demonstrated that peptides lipidated with the TLR2/ TLR6 agonist Pam2Cys 
were effective in priming immunity in the contexts of viral (Alphs et al., 2008; Day et al., 2007; 
Deliyannis et al., 2006; Jackson et al., 2004)  and bacterial (Batzloff et al., 2006; Jackson et al., 
2004) infections, tumour growth (Jackson et al., 2004; Zeng et al., 2002; Zeng et al., 2007), and 
even modulation of hormone action (Zeng et al., 2005; Zeng et al., 2002; Zeng et al., 2007). 
Pam2Cys has been shown to induce Th1 immunity by evoking IL-12 secretion in DCs (Ghosh et 
al., 2006; Patel et al., 2005; Thoma-Uszynski et al., 2000). Preclinical studies have demonstrated 
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that Pam2Cys, unlike most other TLR agonists, lack detectable pro-inflammatory activity, 
pyrogenic (Hood et al., 2010), or toxic effects (Wu et al., 2010), unlike TLR8 agonists for example, 
which were proinflammatory and therefore may exert systemic toxicity (Hood et al., 2010). All 
these features make Pam2Cys an attractive adjuvant to use as a vaccine candidate against HSV. 
A HSV2 vaccine utilizing a TLR2 ligand conjugated to HSV epitopes has already been 
investigated by Zhang et al – three palmitic acids were conjugated to a mouse CD8+ T cell 
epitope found in gB (SSIEFARL) and the universal HLA DR epitope PADRE (the Pan DR Epitope 
140 peptide that through synthetic modification has a low nanomolar affinity for most human 
HLA-DR molecules). This construction was found to be effective at inducing local and systemic 
CD8+ T cell responses leading to protection against genital HSV challenge in mice (X. Zhang et al., 
2009). This was a good proof-of-principle study showing that stimulating a CD4+ T cell response 
together with a TLR2 agonist lead to greater protection by CD8+ T cells in mice. Ideally though, 
an HSV vaccine would induce a protective CD4+ T cell response as well as a protective CD8+ T 
cell response, rather than relying on CD4+ T cell help that is not specific to HSV. 
No studies investigating the efficacy of HSV lipopeptides including a CD4+ and a CD8+ T 
cell epitope have been performed in a human system. The investigation of lipopeptide 
presentation and cross-presentation using human cells is vital as currently cross-presentation 
mechanisms and presentation pathways of synthetic PRR-ligand based conjugated vaccines are 
poorly understood. Constructs influence immunogenicity of the conjugates and studies with 
lipopeptides have been largely trial-and-error, with the outcome depending on the exact nature 
of the conjugated vaccine under investigation. No generally applicable, unambiguous guideline 
for the design of such vaccines can yet be discerned. Better understanding of cross-presentation 
mechanisms and presentation pathways is essential for future rational design of synthetic PRR-
ligand based conjugated vaccines (Zom et al., 2012). 
In this chapter we wanted to evaluate the effect of Pam2Cys-conjugation to HSV 
epitopes. In particular we wanted to investigate whether Pam2Cys-conjugation increased the 
CD8+ T cell response to HSV epitopes, we also wanted to investigate whether combining a CD4+ 
and a CD8+ T cell epitope in the same lipopeptide would synergistically increase the total T cell 
response.  
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4.2. Results 
To investigate the effect of Pam2Cys conjugation on HSV peptides, several synthetic 
lipopeptides were constructed (a schematic can be seen in Figure 4.1). Peptide 9 was identified 
as a CD8+ T cell immunodominant epitope in Chapter 3. Peptide 30-5 from HSV gD was identified 
by Kim et al (M. Kim et al., 2008) and is known to be a CD4+ T cell epitope. The lipopeptides for 
this study consist of peptide 9 conjugated to Pam2Cys (Pam2Cys-p9), peptide 30-5 conjugated to 
Pam2Cys (Pam2Cys-p30-5), a double conjugate with peptide 9 and peptide 30-5 (p9-Pam2Cys-
p30-5) or as a control conjugated to peptide 17 (p17-Pam2Cys-p30-5) and as a control Pam2Cys 
conjugated to four lysines (Pam2Cys). Pam2Cys-p30-5 has already been evaluated previously by 
Kim et al (M. Kim et al., 2012) and has shown an increase in CD4+ T cell responses, but it has not 
been evaluated in the donors used in this study or in the context of a CD8+ T cell response.  
4.2.1. The lipopeptide Pam2Cys-p30-5, p9-Pam2Cys-p30-5 and p17-Pam2Cys-p30-5 
induced strong IFN-  responses in PBMCs depleted of CD4+ or CD8+ T cells from HSV 
seropositive donors.  
Initially the lipopeptides Pam2Cys-p30-5, p9-Pam2Cys-p30-5, p17-Pam2CCys-p30-5, and 
Pam2Cys were synthesized.  In order to see whether specific CD4+ or CD8+ T cell responses were 
induced, freshly isolated PBMC were depleted of CD4+ or CD8+ T cells or not depleted then 
incubated with peptide or Pam2Cys-peptide conjugates (10 µM) in an IFN- ELISPOT. After 40 
hrs, the ELISPOT was developed and spots were counted. Some depleted PBMC were labelled 
with antibodies to CD3, CD4 and CD8 and analysed by flow cytometry to ensure depletion was 
achieved. CD4+ or CD8+ T cells were found to be less than 0.3% and 1.4% respectively in 
depleted PBMCs. 
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Figure 4.1 Schematic diagram of Pam2Cys-peptide conjugates 
 
The IFN- response, measured by the number of spot forming units (SFU), to the 
lipopeptide Pam2Cys-p30-5 was significantly greater (p≤0.05) than the peptide alone or the 
adjuvant control Pam2Cys in PBMC as well as CD4+ and CD8+ depleted PBMC from Donors 7 and 
4 (see Figure 4.2A-B). As the response to Pam2Cys-p30-5 was greater than Pam2Cys in all 
depleted and non-depleted PBMCs, it indicated both CD4+ and CD8 + T cells were responding to 
the lipopeptide Pam2Cys-p30-5. The CD8+ depleted PBMC response to Pam2Cys-p30-5 was 
significantly reduced (p<0.01) compared to the CD4+ depleted and non-depleted PBMC 
indicating CD8+ T cells were producing most of the IFN- response to Pam2Cys-p30-5, although 
there was still some contribution from CD4+ T cells as the response was not as low as the control 
Pam2Cys.  
The lipopeptides that were double conjugated (p9-Pam2Cys-p30-5 and p17-Pam2Cys-
p30-5) had a deleterious effect on the IFN- response when compared to the IFN- response to 
Pam2Cys-p30-5. The IFN- responses to p9-Pam2Cys-p30-5 and p17-Pam2Cys-p30-5 was 
reduced to such an extent that they were not significantly greater than the Pam2Cys control in 
the CD8+ or CD4+ depleted PBMCs from Donor 4. The IFN- responses to p9-Pam2Cys-p30-5 and 
p17-Pam2Cys-p30-5 were not significantly greater than the Pam2Cys control in the CD8+ 
depleted and non-depleted PBMCs from Donor 7. The IFN- responses to p9-Pam2Cys-p30-5 and 
p17-Pam2Cys-p30-5 only remained significantly greater than the Pam2Cys control in the non-
depleted PBMCs from Donor 4 (p≤0.022) and the CD4 depleted PBMCs from Donor 7 (p≤0.026). 
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4.2.2. MDDCs presenting Pam2Cys-p30-5 to isolated CD4+ and CD8+ T cells induced 
strong IFN-  producing T cell responses in HSV seropositive donors. 
As Kim et al has already shown NK cells can respond to Pam2Cys-p30-5 and produce IFN-
. In order to properly delineate the contribution CD8+ and CD4+ T cells make towards IFN- 
responses to Pam2Cys peptides we used autologous iMDDC to present peptides or lipopeptides 
to CD8+ or CD4+ T cells isolated directly ex vivo (without additional in vitro re-stimulation) with 
responses measured by IFN- ELISPOT assay. This was done to simplify the assay so only iMDDCs, 
CD8+ and CD4+ T cells could contribute to Pam2Cys-peptide responses, removing confounding 
responses from other PBMC such as NK cells. 
Purity of isolated CD4+ or CD8+ T cells was assessed by flow cytometry by gating on 
CD3+CD4+ cells or CD3+CD8+ respectively Figure 4.3. Isolated CD4+ T cells were found to have 
purities at 95.7-99.4% and isolated CD8+T cells were found to have purities 91.3-97.8% therefore 
there should have been minimal contribution from other cell types. 
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Figure 4.2 Responses to Pam2Cys-peptide conjugates in PBMC with CD8 or CD4 depletion. 
PBMCs were depleted of CD4+ or CD8+ cells and cultured with peptide/ pam2cys-conjugates (10  
µM)  in triplicate or duplicate for 40 hrs in an IFN- ELISPOT. (A) Donor 7, (B) Donor 4 
 
 
 
Figure 4.3 Purity of isolated T cells 
To check purity cells were labelled with CD3-FITC, CD4-PE Cy7 and CD8-APC (all BD 
Biosciences), incubated at 4°C for 20 minutes, washed with FACSwash and analysed by a BD 
CantoII. 
 
Using autologous iMDDC to present Pam2Cys-peptide conjugates to  CD8+ T cells, there 
was a large IFN- response in Donor 7 to Pam2Cys-p30-5, CD8+ T cells responded with 263 IFN- 
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SFU (per 105 CD8+ T cells) (Figure 4.4). Not only were the number of spots increased but also the 
size of the spot was increased, as shown in the ELISPOT pictures, indicating CD8+ T cells were 
secreting more IFN- per cell. The response to Pam2Cys-p9 was much smaller with 31 IFN- SFU 
per 105 CD8+ T cells above mock. The CD8+ T cell response to the adjuvant (Pam2Cys) alone was 
similar to mock. Interestingly, the response to the double conjugate p9-Pam2Cys-p30-5 was also 
low and similar to mock. It was also evident that conjugation of Pam2Cys-p30-5 was necessary to 
induce the large CD8+ T cell response as adding Pam2Cys and peptide 30-5 separately (non-
conjugated) stimulated responses similar to mock. Adding both Pam2Cys-p9 and Pam2Cys-p30-5 
to the same well did not result in a larger CD8+ T cell response. 
 
Figure 4.4 CD8+ T cells from donor 7 respond to Pam2Cys-peptide conjugates as measured by IFN- 
ELISPOT  
Day 5 autologous iMDDCs (104) were co-cultured with  isolated CD8+ (105) and  peptide/ 
Pam2cys-conjugates (10  µM)  in duplicate for 40 hrs in an IFN- ELISPOT. After 
development, spots were counted using an AID ELISPOT reader. Error bars indicate 
standard deviation across duplicates. Corresponding IFN- ELISPOT well images are shown 
below the graph. Results from Donor 7 are representative of 3 donors. 
A. The CD8+ T cell response to Pam2Cys-peptide conjugates  
IFN- ELISPOT assays have identified ten HSV seropositive donors producing strong 
responses to Pam2Cys-p30-5 (Figure 4.5). The background response (mock which consists of just 
autologous iMDDC and isolated CD8+ T cells) ranged from 3.7 to 62 (median =34.25) IFN- SFU 
per 105 CD8+ T cells. These ten IFN- ELISPOT assays showed the adjuvant alone (Pam2Cys) did 
stimulate a higher background of IFN- secretion by CD8+ T cells stimulating 0 – 77 (median = 
57.5) IFN- SFU per 105 T cells above mock. The CD8+ T cell responses to peptide 30-5 were 
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greatly enhanced by Pam2Cys conjugation with the ten HSV seropositive individuals showing 
29.7 - 263 IFN- SFU per 105 (median = 124.75) CD8+ T cells responding to PamCys-p30-5 above 
mock. Pam2Cys-p30-5 also enhanced the CD8+ T cell response above peptide 30-5 alone (21.3 – 
274.3 IFN- SFU per 105 CD8+T cells) or the adjuvant Pam2Cys alone (21.7 – 266.3 SFU per 105 
CD8+T cells). These show Pam2Cys-p30-5 is able to induce a strong and consistent CD8+ T cell 
response across multiple donors. 
The CD8+T cell response to Pam2Cys-p9 was examined and it was found peptide 9 was 
not consistently enhanced following Pam2Cys conjugation. Pam2Cys-p9 induced a stronger CD8+ 
T cell response than peptide 9 alone in only 6/8 HLA A2+ donors. However, it only induced a 
greater response than Pam2Cys alone in 3/8 HLA A2+ donors (when responses to Pam2Cys were 
subtracted from Pam2Cys-p9, responses ranged from -20.5 to 34.3 (median=  - 8.5) IFN- SFU per 
105 CD8+ T cells). Pam2Cys-p9 induced a response greater than peptide 9 but less than Pam2Cys 
alone in the only HLA A3+ donor tested (Donor 11). These results showed Pam2Cys conjugation 
did not consistently increase the CD8+ T cell response to peptide 9, producing inconsistent 
responses often less than the adjuvant alone. 
The CD8+T cell response to the double peptide conjugate p9-Pam-2Cys-p30-5 was also 
examined. The double conjugate was not tested in Donor 20. It was found the CD8+ T cell 
response to p9-Pam2Cys-p30-5 was only greater than Pam2Cys-p30-5 in one donor (Donors 8 
and 21) tested. The CD8+ T cell response to p9-Pam2Cys-p30-5 was less than Pam2Cys-p30-5 but 
greater than Pam2Cys alone in 4/9 donors (Donors 1, 16, 19, and 21) and as low as the adjuvant 
Pam2Cys alone in 4/9 donors (Donors 4, 7, 11, and 18). These results showed a double peptide 
conjugate may not result in an enhanced CD8+ T cell response and often produced a smaller 
response than Pam2Cys-p30-5 alone. 
The ten IFN- ELISPOTs show a varied pattern of responses to Pam2Cys-peptide 
conjugates overall. However, there were consistently high CD8+ T cell responses to Pam2Cys-
p30-5. Pam2Cys-p9 induced inconsistent CD8+ T cell responses: despite 9 donors being of the 
correct HLA type to produce responses to peptide 9, responses to Pam2Cys-p9 were often less 
than Pam2Cys alone. The double conjugate also induced inconsistent CD8+ T cell responses, 
despite p9-Pam2Cys-p30-5 possessing the same epitope as Pam2Cys-p30-5, p9-Pam2Cys-p30-5 
often induced much smaller CD8+ T cell responses than Pam2Cys-p30-5, sometimes as small as 
the adjuvant alone. 
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B. The CD4+ T cell response to Pam2Cys-peptide conjugates  
The CD4+ T cell response to Pam2Cys-p30-5 has already been examined by Kim et al 
(2012), however, it was important to establish the CD4+ T cell response to Pam2Cys-p30-5 in the 
donors used in this study and to examine the response to the other Pam2Cys-peptide conjugates 
that were novel to this study. The IFN- ELISPOT assays from the ten HSV seropositive donors 
producing strong CD8+ T cell responses to Pam2Cys-p30-5 also showed responses from CD4+ T 
cells (Figure 4.5). The responses by CD4+ T cells to Pam2Cys-peptide conjugates showed a lower 
background in both mock and responses to Pam2Cys alone in comparison to CD8+T cell 
responses: CD4+ T cell mock responses ranging from 2.5 to 14 (median = 3.8) IFN- SFU per 105 
CD4+ T cells and Pam2Cys alone stimulating 0 – 47 (median = 5.5) IFN- SFU per 105 CD4+ T cells 
above mock.  
Pam2Cys-p30-5 did stimulate a CD4+ T cells when presented by iMDDC in an IFN- 
ELISPOT. All donors had a greater CD4+ T cell response to Pam2Cys-p30-5 than mock (3.5-169.5, 
median=18.2 IFN- SFU per 105 CD4+ T cells above mock). Pam2Cys-p30-5 induced a greater 
CD4+ T cell response than Pam2Cys alone in 8/ 10 donors (Donors 18 and 21 had a smaller 
response to Pam2Cys-p30-5 than Pam2Cys alone) with responses ranging from 0 to 122.5 
(median = 13) IFN- SFU per 105 CD4+ T cells above Pam2Cys. The results showed Pam2Cys-p30-
5 did indeed induce a specific CD4+ T cell response that is generally much lower (as the number 
IFN- SFU per 105 T cells) than the CD8+ T cell response. Only Donor 16 showed a higher CD4+ T 
cell response compared to the CD8+ T cell response. 
The lipopeptide Pam2Cys-p9 is not thought to include a CD4+ T cell epitope. The results 
confirmed this as the responses to Pam2Cys-p9 were similar to Pam2Cys alone, CD4+ T cell 
responses ranged from -8 to 5.5 (median = 0.7) IFN- SFU per 105 CD4+ T cells when responses to 
Pam2Cys alone were subtracted. Therefore the results show Pam2Cys-p9 does not stimulate a 
specific CD4+ T cell response.  
The CD4+ T cell response to p9-Pam2Cys-p30-5 was not expected to be higher than 
Pam2Cys-30-5 as peptide 9 is not a CD4+ T cell epitope. The CD8+ T cell response to p9-
Pam2Cys-p30-5 was often found to be less than Pam2Cys-p30-5 alone. The CD4+ T cell response 
to p9-Pam2Cys-p30-5 was less than the response to Pam2Cys-p30-5 in all donors. The CD4+ T 
cell response to p9-Pam2Cys-p30-5 was only greater than the response to Pam2Cys alone in one 
donor (Donor 1). These results showed that similar to the CD8+ T cell responses, having a 
Pam2Cys-double peptide conjugate consisting of both peptide 9 and peptide 30-5, rather than 
just Pam2Cys-p30-5 alone has a deleterious effect on the CD4+ T cell response to the epitope. 
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The ten IFN- ELISPOTs showed that Pam2Cys conjugation enhanced the CD4+ T cell 
response to peptide 30-5, confirming the findings of Kim et al (2012). A lower percentage of 
CD4+ T cells responded to Pam2Cys-p30-5 when compared to the CD8+ T cell response. There 
was no response to peptide 9 or Pam2Cys-p9. The double conjugate (p9-Pam2Cys-p30-5) had a 
similar response to Pam2Cys alone. This showed that Pam2Cys-p30-5 induced a strong CD4+ T 
cell response and a strong CD8+ T cell response. 
4.2.3. The CD8+ T cell response to Pam2Cys-p30-5 is HLA A2 and HLA B44 restricted. 
All donors that gave strong CD8+ T cell responses to Pam2Cys-p30-5 were either HLA 
A2+ or B44+ (Figure 4.5). Donors that were HLA A2- or B44- were screened, but none had a 
significant CD8+ T cell response to Pam2Cys-p30-5 above Pam2Cys alone (for example, Figure 
4.5, donor 22).  
To examine whether the large CD8+ T cell responses to Pam2Cys-p30-5 were stimulated 
through MHC I, specifically through HLA A2 or HLA B44, HLA mismatch was utilised. Day 5 iMDDC 
from donors that were matched through HLA A2, HLA B44, or complete mismatches were used 
to present Pam2Cys-p30-5 to CD8+ T cells from an HLA A2+ or a HLA B44+ donor. CD8+ T cell 
responses (from Donor 1 who is both HLA A2+ and B44+) to iMDDCs presenting Pam2Cys-p30-5 
that were either HLA A2+ or HLA B44+ were maintained, whereas iMDDC that were completely 
HLA mismatched induced a significantly reduced CD8+ T cell responses (Figure 4.6). There was 
an increased CD8+ T cell response to Pam2Cys-p30-5 when presented by Donors 24, 8 and 25, a 
similar increase was also seen in response to the HLA A2 restricted CMV peptide NLV (Donors 1 
and 7 induce a smaller CD8+ T cell response to Pam2Cys-p30-5 and NLV than Donors 24 and 8), 
the reason for this is unknown but could be due to small differences in MDDC maturation and 
phenotype. The phenotype of the day 5 iMDDC from each donor was measured by flow 
cytometry but there was no difference in the maturation markers measured (CD80, CD83, HLA 
DR, data not shown) that could explain this difference in the CD8+ T cell response. The 
phenotype of the iMDDC were not measured after they were pulsed with Pam2Cys-peptides or 
after co-culture with CD8+ T cells which could have resulted in a more mature phenotype. There 
was not a reduced response when comparing the A2+B44+ donors with the A2+B44- or A2-B44+ 
donors, however as there was variation amongst the A2+B44+ donors, it is difficult to draw 
conclusions beyond positive and negative responses. There was still a small CD8+ T cell response 
to Pam2Cys-p30-5 above Pam2Cys when presented by iMDDC that were HLA A2- or B44-, 
however it was below the cut-off for a positive response of 2 SD above mock. 
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Figure 4.6 The CD8+ T cell response to Pam2Cys-p30-5 is HLA-A2 and HLA-B44 restricted. 
Day 5 autologous iMDDCs (6 x 10
3
 per well) from donors that were either HLA A2+, B44+ or A2- or 
B44- were pulsed for 2 hrs with peptide/ Pam2Cys-conjugates (10 µM), washed and co-cultured 
with isolated CD8+ T cells (6 x 10
4
 per well) from Donor 1 (HLA-A*02:01+, B*44:03+) in duplicate 
for 24 hrs in an IFN- ELISPOT. After development, spots were counted using an AID ELISPOT 
reader. The error bars represent the standard deviation (SD) of the duplicate wells. The dashed 
lines represents the cut-off for a positive response, 2 SD above autologous mock. 
 
A similar response was also seen from Donor 8 (who is HLA A2+) with CD8+ T cells 
responding to Pam2Cys-p30-5 when presented by A2+ iMDDC but a reduced response to an A2-
ve donor, and Donor 11 (who is HLA B44+) responded to Pam2Cys-p30-5 when presented by 
B44+ donors but not B44-ve donors (data not shown).  
Epitope prediction was used to predict possible epitopes within peptide 30-5 that could 
bind to HLA-A*02:01 or B*44:02. Peptide 30-5 (PEDPEDSALLED) was analysed by the epitope 
prediction programs SYFPEITHI, RankPep, BIMAS, and NetMHC 3.4 for predicted binding to HLA 
A*02:01 and B*44:02 (only B*44:03 was available in BIMAS). Peptides known to bind to HLA 
A*02:01 and B*44:05 (NLVPMVATV and LEIPGARSF respectively) were included to provide 
comparative scores. No peptides gave a sufficient peptide binding score to suggest binding to 
HLA-A*02:01 (see Appendix Table Appendix Ci). Two peptides (PEDPEDSALL and PEDPEDSAL) 
were predicted to bind to B*44:02 by SYFPEITHI (see Appendix Table Appendix Cii). As no 
peptides were predicted for HLA-A*02:01, the two serines that are used to link Pam2Cys to the 
N-terminus of peptide 30-5 was also included in the analysis, so the full length of the peptide 
analysed was SSPEDPEDSALLED. No peptides were predicted to bind with the two serines 
included at the N-terminus. 
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Epitope prediction is not infallible, as there was good evidence from the large CD8+ T 
cell response to Pam2Cys-p30-5 from HLA A2+ and B44+ donors and through the HLA mismatch 
experiments that the Pam2Cys-p30-5 responses were HLA restricted to HLA A2 and B44, further 
in vitro analysis of peptide binding was carried out. T2 cells were utilised to test binding of 
peptides within peptide 30-5 to HLA-A*02:01. C1R cells expressing ICP47 and B*44:05 were 
utilised in the same way as T2 cells to test peptide binding to HLA B*44:05. As naturally 
presented peptides up to 15 amino acids have been reported to bind to HLA class I molecules 
(Samino et al., 2006), all peptides covering the full length of SSPEDPEDSALLED including all 14 
mers, 13 mers, 12 mers, 11 mers, 10 mers, 9 mers and 8 mers were tested for in vitro binding. 
The peptides NLVPMVATV and LEIPGARSF (peptide 15 from Chapter 3) were used as positive 
controls for A*02:01 and B*44:05 respectively. Peptide 17 from Chapter 3 was used as a 
negative control. No peptides within SSPEDPEDSALLED were found to bind to HLA A*02:01 or 
B*44:05 (as an example Figure 4.7, Appendix D for A*02:01, and Appendix E for B*44:05 binding 
assays). The peptides PEDPEDSALL and PEDPEDSAL predicted to bind by SYFPEITHI were not 
found to bind when tested in vitro. 
These results together indicate the large CD8+ T cell response to Pam2Cys-p30-5 are HLA 
restricted to A2 and B44 but at present the precise epitopes are unknown. 
 
 
Figure 4.7 Peptide 30-5 does not bind to HLA-B*44:05 as tested by HLA I-peptide binding assay. 
C1R.ICP47 cells (2 x 10
5
) expressing HLA-B*44:05 were incubated in AIM-V serum free media with 
indicated concentrations of peptides at 26°C for 14 hrs, then moved to 37°C for 2 hrs before 
staining for surface HLA B*44:05 expression. Expression, indicated by mean fluorescence 
intensity, was analysed by flow cytometry. Peptides were tested in duplicate with error bars 
indicating standard deviation. Negative controls were done with one replicate for each 
concentration. 
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4.2.4. Pam2Cys-peptide conjugates mature MDDC, Pam2Cys-p9 induced a smaller degree 
of MDDC maturation than other Pam2Cys-peptide conjugates at 1 µM 
As T cell responses to Pam2Cys-peptide conjugates were so varied, we wanted to test 
whether the large variation in T cell responses to Pam2Cys-peptide conjugates was due to 
differences in the ability of Pam2Cys-peptides to induce MDDC maturation. Of note, the 
phenotype of iMDDCs differs when cultured in RH10 compared to RF10 as shown by other 
studies (Mallon, Buck, Reece, Crowe, & Cameron, 1999). Specifically iMDDCs generated in RH10 
do not express CD1a and constitutively express a higher level of CD86 compared to iMDDCs 
generated in RF10.  Representative phenotypes of iMDDCs grown in RH10 and RF10 are shown 
in Figure 4.8.  All iMDDCs used for maturation studies and T cell responses were grown in RH10 
and therefore have a higher constitutive level of CD86.  
To examine this, day 5 iMDDC were pulsed with peptides or Pam2Cys-peptide 
conjugates for 2 hrs (concentrations of 10 µM and 1 µM were tested), after 2 hrs media was 
added so final concentrations of Pam2Cys-peptides were 2 µM and 0.2 µM. Maturation mix was 
used as a positive control. After a total incubation of 48 hrs, the MDDC were labelled for surface 
expression of the maturation markers CD80, CD83, CD86, HLA DR, and HLA Class I with 
expression measured by flow cytometry. Expression of markers was measured by mean 
fluorescence intensity (MFI). To compare multiple donors, MFI was converted to fold change 
(normalised to mock) and log transformed prior to analysis in order to stabilise the variance. 
 All Pam2Cys-peptide conjugates matured MDDC with surface expression of CD80 and 
CD83 significantly increasing (by 1.24-2.18 and 1.4-3.4 fold-change, respectively) in all Pam2Cys 
stimulated MDDCs compared to mock or peptide (see Figure 4.9 for representative histograms 
and Figure 4.10 for combined data). Peptides alone did not mature the iMDDC, histograms of 
peptides precisely overlay mock, whereas Pam2Cys-peptides showed strong increases in MFI. 
Increases in CD80 and CD83 surface expression in response to Pam2Cys-peptide conjugates were 
all highly significant compared to peptides with p≤0.003 for CD80 and p≤0.005 for CD83 in 
repeated pairwise comparisons. There was a significant difference between Pam2Cys-p9 and all 
the other Pam2Cys-peptide conjugates at 1 µM, with Pam2Cys-p9 (1 µM) inducing significantly 
lower expression of CD80. Pam2Cys-p9 (1 µM) showed a trend for inducing lower levels CD83 
than other Pam2Cys-peptides, this reached statistical significance when compared to Pam2Cys-
p9 (10 µM) and p9-Pam2Cys-p30-5 (1 µM and 10 µM) and close to statistical significance 
(p=0.066-0.082) for all other Pam2Cys-peptides with the exception of Pam2Cys (1 µM). There 
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was a comparable level of CD80 and CD83 expression induced by all Pam2Cys-peptide 
conjugates at 10 µM. There was a small increase in CD86 surface expression in response to 
Pam2Cys-peptides in some donors as can be seen in the representative plots in Figure 4.5, these 
responses were not consistent across all donors and were not significant when the donors were 
analysed together. There was no increase between mock, peptides and Pam2Cys-peptides when 
examining HLA Class I or DR, there was an increase in both these markers in response to 
maturation mix. 
These results show iMDDC were matured in response to Pam2Cys-peptides, 
upregulating the markers CD80 and CD83. There was a small but significant difference in 
maturation between Pam2Cys-p9 (1 µM) and the other Pam2Cys-peptides.  
 
Figure 4.8 Phenotype of immature MDDCs 
Immature MDDCs grown in (A) RH10 or (B) RF10. Day 5 iMDDCs were washed in PBS and 
incubated with conjugated antibodies to the above markers for 30 mins at 4°C. Cells were washed 
and analysed by flow cytometry on a BDCantoII. The black line represents the isotype control and 
the orange line represents the expression of each marker on iMDDCs after gating on live cells on 
FSC vs SSC. Results are representative of at least four experiments.  
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Figure 4.9 Pam2Cys-peptides mature MDDCs.  
Day 5 iMDDCs were incubated with peptides or Pam2Cys-peptide conjugates (1 µM or 10 µM) for 
48 hrs. MDDC were then washed and labelled for surface expression of the maturation markers 
CD80, CD83, CD86, HLA DR and HLA Class I and analysed on the BD CantoII, histograms 
representative of 4-7 experiments are shown. 
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Figure 4.10 Pam2Cys-peptides mature MDDCs.  
Day 5 iMDDCs were incubated with peptides or Pam2Cys-peptide conjugates (1 µM or 10 µM) for 
48 hrs. MDDC were then washed and labelled for surface expression of the maturation markers 
CD80, CD83, CD86, HLA DR, and HLA Class I and analysed on a BD CantoII and mean fluorescence 
intensity (MFI) was compared. To compare multiple donors, MFI was converted to fold change 
(normalised to mock) and log transformed prior to analysis in order to stabilise the variance. The 
box and whisker plots show the upper and lower quartile, the central bar represents the median, 
while the whiskers show the minimum and maximum for each marker, dots represent outliers. 
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The total IFN- producing T cell response is synergistically enhanced when combining CD4+ 
and CD8+ T cells together with Pam2Cys-p30-5 
As Pam2Cys-p30-5 was found to contain both a CD4+ and a CD8+ T cell epitope, we next 
wanted to investigate whether a Pam2Cys-conjugated peptide containing both a CD4+ and a 
CD8+ T cell epitope against HSV can enhance the total T cell response. To study this IFN- 
ELISPOT was used to see if combining a CD4+ and a CD8+ T cell response to Pam2Cys-p30-5 
resulted in a synergistically enhanced total T cell response. Isolated CD4+, or CD8+, or CD4+ & 
CD8+ T cells co-cultured together (105 of each T cell population per well) were incubated with 
autologous iMDDCs (iMDDC to T cell ratio was kept at 1:10) and with peptide/ Pam2Cys-
conjugate for 40 hours in an IFN- ELISPOT, after development spot number and total spot area 
were counted.  
Combining CD4+ and CD8+ T cells together with iMDDCs presenting Pam2Cys-p30-5 
synergistically increased the total IFN- T cell response (Figure 4.11A). As can be seen in the 
representative plots from Donor 4, combining CD4+ and CD8+ T cells increased the number of 
IFN-SFU as well as the amount of IFN- produced per cell as indicated by the area of the spots 
(as illustrated by the bar graph and the ELISPOT well images).  
A total of ten donors were assessed by ELISPOT and were investigated for synergistic T 
cell responses (individual responses can be seen in Appendix F). Additive responses were 
calculated by adding CD4+ T cells alone + CD8+ T cells alone, the additive response was then 
compared with the observed co-cultured response. Only an additive response was observed in 
the CD4+ and CD8+ T cell co-cultured wells incubated with mock and peptide 30-5 (Figure 4.11B). 
Some synergistic background responses were seen in response to Pam2Cys alone, when the 
additive response to Pam2Cys was subtracted from the observed co-cultured response to 
Pam2Cys alone [additive response – observed co-cultured response] the number of IFN- SFU 
was -3.7 to 85.5 (median = 26) above the additive response. A synergistic response was observed 
in Pam2Cys-p30-5 wells with all responses in Pam2Cys-p30-5 stimulated CD4+ and CD8+ T cell 
co-cultured wells above the additive response by 29 – 247 (median = 58) IFN- SFU, this was 
highly significant with p=0.001 when measured with a paired, two-tailed, t-test. The CD4+ and 
CD8+ T cell co-cultured responses to Pam2Cys-p30-5 were all greater than Pam2Cys alone by 
36.5 – 321 (median = 128) IFN- SFU this was highly significant with p=0.004 when measured 
with a paired, two-tailed, t-test. Likewise the spot area was significantly increased, the spot area 
of Pam2Cys-p30-5 stimulated CD4+ and CD8+ T cell co-cultured wells was significantly above the 
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additive response (p=0.019). The CD4+ and CD8+ T cell co-cultured spot area in response to 
Pam2Cys-p30-5 was greater than Pam2Cys alone (p=0.013). 
These results showed that having a CD4+ and a CD8+ T cell HSV epitope in the same 
Pam2Cys-conjugated lipopeptide resulted in an enhanced total T cell response. 
 
 
Figure 4.11 Co-culturing CD4+ and CD8+ T cells with MDDCs presenting Pam2Cys-p30-5 
synergistically enhanced the total T cell response. 
Day 5 autologous iMDDCs
 
were co-cultured with  isolated CD8+ or CD4+ T cells (10
5 
each per well; 
a ratio of 1 MDDC: 10 T cells was used) and  peptide/ Pam2cys-conjugates (10  µM)  in triplicate 
or duplicate for 40 hrs in an IFN- ELISPOT. After development, spots were counted using an AID 
ELISPOT reader. (A) Representative graphs from Donor 4, the top left graph represents the 
number of spot-forming units (SFU) counted, the middle panel represents the total spot area and 
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the right panel shows representative ELISPOT wells. (B) Combined IFN- response of ten donors 
to Pam2Cys-p30-5, the top panel shows the number of IFN- SFU, the bottom panel represents 
the total IFN- spot area. The box and whisker plots represent the upper and lower quartile, the 
central bar represents the median, while the whiskers show the minimum and maximum for each 
sample. 
 
4.2.5. Pam2Cys-p30-5 induces a multi-functional CD8+ T cell response only after time was 
allowed for cross-presentation. 
To investigate the multi-functional CD8+ T cell response to the Pam2Cys-peptides, a 
similar approach was taken to that used for peptide 9 responses in Chapter 3. Peptides or 
Pam2Cys-peptide conjugates were incubated with PBMC, brefeldin A and monensin were added 
and cells were incubated for 6 hrs before staining for CD8+ T cells and the functional markers 
IFN-, TNF-α, IL-2 and CD107a/b. Unlike the large responses to Pam2Cys-p30-5 found in the IFN- 
ELISPOTs, no responses to Pam2Cys-p30-5 were observed in this experimental setting. Multi-
functional CD8+ T cell responses to Pam2Cys-p9 (which performed poorly in the IFN- ELISPOT) 
were observed in this experimental setting. As it is known that brefeldin A blocks intracellular 
trafficking, including trafficking of MHC I to the cell surface, and monensin abrogates 
intracellular trafficking as well as blocking acidification of the endosome (Tartakoff, 1983; 
Yewdell & Bennink, 1989),  we wanted to test if these were inhibiting the ability of Pam2Cys-
p30-5 to be presented to CD8+ T cells.  
To test this, Pam2Cys-peptides were added to freshly isolated PBMC, then PBMC were 
either incubated with brefeldin A and monensin or were incubated at 37°C or 6 hrs prior to 
addition of brefeldin A and monensin and incubated at 37°C or 6 hrs (Figure 4.12A). With this 
additional incubation allowing time for antigen uptake, processing, and presentation before the 
inhibitors brefeldin A and monensin were added, a CD8+ T cell response similar to that seen in 
the IFN- ELISPOTs was detected. The IFN-, TNF-α, IL-2 and CD107a/b response for donor 8 with 
and without the additional inhibitor-free 6 hr incubation is shown in Figure 4.13. Responses to 
Pam2Cys-p9 with all three cytokines being produced can be seen in the presence of the 
inhibitors. A strong IFN-, TNF-α, and IL-2 response to Pam2Cys-p30-5 can be seen only after an 
initial incubation without the inhibitors for 6 hrs. 
With time allowed for uptake, processing, and presentation, three donors had multi-
functional CD8+ T cell responses to Pam2Cys-p30-5 (Figure 4.14A). To examine the poly-
functionality of responding CD8+ T cells, the mock/background response was subtracted from 
the response to each peptide/Pam2Cys-peptide. The response from Donor 8 was highly specific 
with only peptide 9 and Pam2Cys-p30-5 inducing CD8+ T cells greater than mock. CD8+ T cell 
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responses by Donor 8 showed a high degree of polyfunctionality with peptide 9 and Pam2Cys-
p30-5 inducing none and only 9% mono-functional CD8+ T cells respectively. The response by 
Donor 8 was predominantly TNF-α and IL-2 producing CD8+ T cells, IFN- producing cells all also 
expressed either TNF-α or IL-2 or all three cytokines with CD107a/b and IFN- together only in 
those cells that express all four functional markers. The CD8+ T cell response from Donor 4 to 
Pam2Cys-p30-5 was predominantly mono-functional, with TNF-α and IL-2 co-producing cells 
making up only 30% of responding cells. IFN- was the predominant cytokine in Donor 1’s 
response and CD107a/b the least abundant functional marker. 
These results suggest Pam2Cys-p30-5 could be presented to CD8+ T cells only after there 
was time allowed for cross-presentation in the absence of the inhibitors brefeldin A and 
monensin. After time had been allowed for cross-presentation, Pam2Cys-p30-5 induced a multi-
functional CD8+ T cell response, varying between donors, TNF-α and IL-2 were the most 
abundant functional markers across all three donors and CD107a/b was the least abundant 
functional marker.  
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Figure 4.12 Pam2Cys-p30-5 induces a multi-functional CD8+ T cell response only after time 
was allowed for cross-presentation as shown in donor 4 
(A)Freshly isolated PBMC’s were incubated with peptide/ Pam2Cys-conjugates and Brefeldin A, 
Monensin and CD107a/b antibodies were added either immediately (C) or after a 6 hr incubation 
at 37°C (D). Cells were then incubated for 6 hrs at 37°C. Cells were stained with antibodies to 
CD3, CD8, IFN-, TNF-α and IL-2 and analysed by flow cytometry. The gating strategy is shown in 
B. Results are representative of three donors. 
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Figure 4.13 Pam2Cys-p30-5 induces a multi-functional CD8+ T cell response only after time 
was allowed for cross-presentation as shown in donor 8 
Freshly isolated PBMC’s were incubated with peptide/ Pam2Cys-conjugates and brefeldin A, 
monensin and CD107a/b antibodies were added either immediately (B) or after a 6 hr incubation 
at 37°C (C). Cells were then incubated for 6 hrs at 37°C. Cells were stained with antibodies to CD3, 
CD8, IFN-, TNF-α and IL-2 and analysed by flow cytometery. 
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Figure 4.14 Pam2Cys-p30-5 induces a multi-functional CD8+ T cells in Donors 8, 4 and 1. 
Freshly isolated PBMC’s were incubated with peptide/ Pam2Cys-conjugates for 6 hrs at 37°C , 
brefeldin A, monensin and CD107a/b antibodies were added to cells, then incubated for 6 hrs at 
37°C. Cells were stained with antibodies to CD3, CD8, IFN-, TNF-α and IL-2 and analysed by flow 
cytometery. (A) The total response for each cytokine for three donors. (B) The composition of the 
CD8+ T cell response after the mock response was subtracted (if the response was less than 
mock, <mock is indicated. 
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4.3. Discussion 
In this chapter we evaluated the effect of Pam2Cys-conjugation of HSV epitopes on the 
activation of T cells. As well as testing whether Pam2Cys-conjugation increased the CD8+ T cell 
response to HSV epitopes, we also wanted to investigate whether combining a CD4+ and a CD8+ 
T cell epitope in the same lipopeptide synergistically increased the total T cell response.  
The protective effect of combining a CD4+ T helper cell and a CD8+ cytotoxic T cell 
epitope in the same self-adjuvanted lipopeptide vaccine (with murine-restricted HSV epitopes) 
has already been explored as a proof-of-principle vaccine candidate to prevent genital herpes 
disease in mice. Zhang et al (X. Zhang et al., 2009) demonstrated that a TLR2/ TLR1 agonist, 
Pam3CysK4, conjugated to PADRE and the mouse immunodominant CD8+ T cell epitope gB498-505  
generated a protective HSV2 specific CD8+ T cell response that protected the mice from lethal 
HSV-2 genital infection. Importantly, the corresponding Th-CTL peptide analogue without the 
lipid or, the CTL lipopeptide alone, or the Th lipopeptide alone failed to induce protective 
immunity. This was a good demonstration that including a CD4+ helper T cell epitope with the 
CD8+ T cell epitope in the same lipopeptide construct was essential for inducing protective 
immunity. This vaccine, however, only induced protective CD8+ T cell immunity with the 
inclusion of PADRE showing the effect of CD4+ T cell help, it did not induce HSV2 specific CD4+ T 
cells. Ideally, as suggested in our study, an HSV2 vaccine should induce a protective CD4+ and 
CD8+ T cell response.  
There are many differences between human systems and mouse systems when it comes 
to evaluating HSV infection and vaccination (reviewed in (Dasgupta & BenMohamed, 2011)). As 
such, it is important to evaluate responses to HSV lipopeptides containing human T cell epitopes 
in a human system. Although our study only investigated HSV lipopeptides in an in vitro setting, 
large differences could be seen in the ability of different lipopeptide constructs to induce T cell 
responses.  
Peptide 9 was thought to be an ideal epitope for adjuvanting with Pam2Cys due to its 
ability to bind to not only HLA A2, but also HLA A3 (as shown in Chapter 3). In the context of a 
vaccine, an epitope that can bind to multiple HLA supertypes would be a large advantage. 
Unfortunately, as shown in Figure 4.4 and Figure 4.5, Pam2Cys-p9 induced lower CD8+ T cell 
responses than Pam2Cys alone in most donors. The reason for such a poor response to 
Pam2Cys-p9 is unknown. Other studies investigating in vitro presentation of adjuvanted 
synthetic peptides have found that the adjuvanted peptides induced DC maturation to the same 
extent as the free adjuvant (Zom et al., 2012). However, Pam2Cys-p9 induced a significantly 
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reduced amount of MDDC maturation (Figure 4.10) at the concentration 1 µM as measured by 
CD80 compared to all other Pam2Cys conjugates, this could partly explain why Pam2Cys-p9 
induced a smaller CD8+ T cell response than Pam2Cys in the majority of donors. These results 
imply that perhaps not all peptides will behave similarly when conjugated to Pam2Cys. At 
present little is known to understand why some adjuvant-conjugated peptides perform better 
than others.  
It has, however, been demonstrated that peptide sequences can have a detectable 
effect on the immunological activity of lipopeptides. The amino acid sequences of S. aureus 
Pam2Cys-conjugated peptides critically affected the agnostic function for TLR2 and NK cell 
activation (Azuma et al., 2010). In the study by Azuma et al all conjugated peptides possessed a 
Cysteine as the first N-terminal amino acid, the second and/or third residue had a large effect on 
NK cell activation with a Serine/ Threonine or a Glycine/ Alanine activating TLR2 and Proline/ 
Leucine-Isoleucine associated with a lack of activity. When the poor performing Pam2Cys-
peptides containing a Proline or Leucine-Isoleucine at the second or third residue was replaced 
with Serine/ Asparagine, NK activation was restored. It was also found that a length of more 
than three amino acids was indispensable for BMDC-mediated NK activation. The crystal 
structures of Pam2CSK4 binding to TLR2/ TLR6 heterodimer has been solved by Kang et al (Kang 
et al., 2009). It has been revealed that the second serine residue fits into the narrow neck area of 
the ligand-binding pocket formed by the LRR11 loops of TLR2 and TLR6. In our study all 
lipopeptides were linked through two Serine moieties so this should not have been problematic. 
Kang et al suggested that although amino acid residues beyond the second serine of Pam2CSK4 
have only opportunistic interactions with TLRs in the crystal structure, they can still interact 
substantially with TLRs if the amino acid sequences in the lipoproteins allow it. The interactions, 
although weak can have a role in modulating the immune response. Changing only the C-
terminus of a lipopeptide has been found to have an effect on TLR2/ TLR6 activation expressed 
on HEK293 cells, measured by TNF-α secretion (Okusawa et al., 2004).  Some MALP-2 
derivatives, including FSL-1 (which has an identical diacylated structure but different peptides 
sequence to MALP-2) and FSL-2 (which has an identical structure to FSL-1 except the C-terminal 
phenylalanine is changed to an arginine) had substantially different responses. It was found that 
FSL-1 generated a four-fold greater response than MALP-2, and the single amino acid change to 
FSL-2 reduced the cellular response by 20%. Currently there is incomplete understanding of 
these complex interactions, but it may be Pam2Cys-p9 interacted poorly with TLR2/TLR6, 
resulting in poor activation. It is, however, much more difficult to alter peptide sequences when 
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trying to see the effect on a CD8+ T cell responses due to the requirements of the MHC-peptide: 
TCR interaction. Studies of peptide design therefore are limited to an innate cell setting. 
Some multi-functional CD8+ T cell responses to Pam2Cys-p9 were detected in some 
donors, with enhanced responses well above peptide 9 responses with negligible responses from 
Pam2Cys alone (Figure 4.12). For the flow cytometry experiments, freshly isolated cells were 
always used, also, as the cells in the flow cytometry experiments were stimulated for a much 
shorter time than the IFN- ELISPOT, antibodies against CD28 and CD49d were utilised to help 
stimulate a stronger and faster CD8+ T cell response for detection by the less sensitive method 
of intracellular cytokine staining. This small amount of co-stimulation may have helped the 
response to Pam2Cys-p9, although Pam2Cys-p9 still inconsistently induced CD8+ T cell responses 
even in the flow cytometry experiments.   
Interestingly the double conjugate, p9-Pam2Cys-p30-5, did not consistently produce 
CD8+ T cell responses as high as Pam2Cys-p30-5. Significantly 4/9 donors had responses to p9-
Pam2Cys-p30-5 as small as to Pam2Cys alone. This showed conjugation of an additional peptide 
may have a deleterious effect on activation and presentation of an effective epitope. This shows 
the need to measure the effect of Pam2Cys conjugation on all human epitopes being considered 
for vaccine purposes as the effect of Pam2Cys-conjugation appears to have high variability, 
particularly when adding a second peptide.  
The large responses to Pam2Cys-p30-5 were unexpected as it was not thought to 
contain a CD8+ T cell epitope. Initially, in this study, HLA A2+ donors were used as the study was 
primarily focused on the effect of Pam2Cys-conjugation to peptide 9 (which, as shown in 
Chapter 3, is HLA A2/ A3 restricted) and the effect of the double peptide conjugate with peptide 
30-5. Upon observing the substantial CD8+ T cell responses to Pam2Cys-p30-5, HLA A2- donors 
were screened, it was found the CD8+ T cell response was restricted to HLA A2 and HLA B44. 
This was confirmed by using HLA mismatched MDDCs to present Pam2Cys-p30-5 to CD8+ T cells 
from HLA A2+ or HLA B44+ donors (Figure 4.6). The epitope being presented to CD8+ T cells from 
Pam2Cys-p30-5 has not yet been identified, epitope prediction and peptide binding assays failed 
to identify an epitope that could bind to HLA A2 or HLA B44. This still needs to be determined, as 
the epitope was not identified, it remains a possibility that unconventional CD8+ T cells could be 
responding to a sub-unit of Pam2Cys-p30-5. Throughout the study, particularly as often 
sequential isolation of T cells was used, positive CD8+ selection was used. This does result in a 
selection of all CD8+ cells, including CD3-CD8med cells (NK cells) and CD3+CD8med cells (which 
could contain NKT cells). In future, CD56+ cells should be removed to ensure responding cells are 
bone fide CD8+ T cells, and not NK or NKT cells. 
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The ability of Pam2Cys-p30-5 to stimulate both CD4+ and CD8+ T cells enabled us to 
investigate whether combining a CD4+ and a CD8+ T cell epitope in the one peptide, conjugated 
to the TLR2 agonist Pam2Cys as a lipopeptide vaccine synergistically enhanced T cell activation. 
This was indeed found to be the case as Pam2Cys-p30-5 synergistically enhanced the total T cell 
response in HLA A2+ or HLA B44+ donors when CD4+ and CD8+ T cells were combined. It is well 
known that CD4+ T cells provide help for CD8+ T cells through DC licensing, activation ligand 
interactions and cytokine secretion (Caux et al., 1994; Cella et al., 1996). Pam2Cys-p30-5 showed 
that a good approach to vaccine design may be to screen peptides containing known HSV CD4+ T 
cell epitopes for CD8+ T cell epitope responses. In just investigating the CD4+ T cell epitopes 
from gD2 identified in our lab (M. Kim et al., 2008) several MHC I-restricted epitopes were 
predicted (Appendix G), many from peptide 2 of gD2, which unfortunately has low sequence 
homology to gD1,  as well as one for peptide 24 and two for peptide 30. Given our findings these 
should be conjugated to Pam2Cys to be tested for CD8+ T cell responses. Dervillez et al has also 
identified one CD4+ epitope which also includes a CD8+ T cell epitope (Dervillez et al., 2013). 
The mechanism of inducing CD8+ T cell protection through Pam2Cys-conjugation has 
begun to be investigated. A recent study has found a Pam2Cys electrostatically associated with 
OVA induced a far superior protective CD8+ T cell response compared to using Alum or CFA in 
mice (Chua et al, 2014). A CD8+ T cell response was produced with a distinctly different 
phenotype that was able to quickly mediate strong recall responses leading to more efficient 
viral clearing responses. This is thought to be mediated by limiting excessive inflammation by 
using controlled amounts of TLR agonist that is more conducive to CD8+ T cell responses rather 
than the antibody-based responses induced by excessive inflammation (Badovinac et al, 2005). 
In our study, which only focussed on in vitro activation, a much greater recall response could be 
observed to Pam2Cys-p30-5, this response was predominantly poly-functional, but similar to 
responses to other HSV epitopes. It was still highly variable between donors. Whether Pam2Cys-
p30-5 can induce a superior phenotype from naive cells can only be explored in an in vivo setting 
and is beyond the scope of our study. 
The other unexpected finding of our study was the difference in timing needed for 
Pam2Cys-p9 and Pam2Cys-p30-5 to be taken up and cross-presented. This will be further 
explored in Chapter 5 of this thesis and discussed then.  
As very few CD8+ T cell adjuvants have been identified, this study is important not only 
for HSV vaccine design but also for inducing specific T cell immunity in general. Pam2Cys 
conjugation does appear to enhance CD8+T cell immunity, although the peptide sequence may 
have a large influence on the response. The previously discovered peptide 30-5, when 
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conjugated to Pam2Cys, was far superior, compared to other Pam2Cys-peptide conjugates used 
in this thesis, at inducing a CD8+ T cell response and combined with a CD4+ T cell response 
synergistically enhanced the total T cell response. Pam2Cys-p30-5 also has the advantage of 
containing a promiscuous CD4+ T cell epitope and a CD8+ T cell epitope that stimulates two 
common HLA types. Although further epitopes are needed to induce immunity more broadly 
across the population, Pam2Cys-p30-5 is an ideal proof-of-principle vaccine candidate. 
 
Chapter 5 - Investigating presentation and infection pathways of HSV and HSV lipopeptides by 
MDDCs 
104 
Chapter 5 -  Investigating presentation and infection 
pathways of HSV and HSV lipopeptides by MDDCs 
5.1. Introduction 
DCs are the most important antigen presenting cells for priming naïve T cell responses. 
They are known to take-up antigen and cross-present it on MHC I to CD8+ T cells. The 
mechanisms through which different antigens are cross-presented by DCs are still poorly 
understood with many different pathways reported.  Two main model pathways have been 
proposed for the mechanisms underlying cross-presentation of exogenous antigens – the 
cytosolic pathway where antigen is transferred to the cytoplasm, then largely follows the 
classical MHC I presentation pathway, and the vacuolar pathway where antigens are degraded in 
acidified endosomes and loaded onto recycled MHC I molecules and returned to the cell surface 
(both reviewed in (Joffre et al., 2012)). The two pathways are not mutually exclusive and a 
combination of the pathways can also occur. These studies have been largely established based 
on model antigens and mouse studies. The composition of the human DC compartment and 
susceptibility to viruses differ greatly between mice and humans (van Montfoort et al., 2014) 
and warrants further exploration. 
It has become increasingly evident that different stimulatory factors and the type of 
antigen influence how antigens are cross-presented to CD8+ T cells (Nierkens et al., 2013). TLR 
agonists have been shown to influence many aspects of cross-presentation, including enhancing 
co-stimulatory molecules, enhancing MHC I processing machinery, particularly up-regulation of 
the proteasome activator PA28β (Ossendorp et al., 2005) and upregulation of Rab7 (K. Y. Shen et 
al., 2014), where overexpression of Rab7 has been shown to increase antigen presentation 
(Bertram, Hawley, & Watts, 2002), recruitment of MHC I Rab11a+ vesicles to endosomes (Nair-
Gupta et al., 2014), as well as slowing MHC I-peptide decay rates (Rudd, Brien, Davenport, & 
Nikolich-Zugich, 2008) leading to increased TCR triggering. These signals must be delivered 
directly with the antigen, as antigens not conjugated to TLR ligands are not cross-presented as 
well as TLR ligand-conjugated antigens, even in vitro (Khan et al., 2007). 
At present only five studies have investigated in detail the presentation pathways 
utilized to cross-present lipopeptides to CD8+ T cells (Andrieu et al., 2003; Hoeffel et al., 2007; 
Renaudet et al., 2010; K. Y. Shen et al., 2014; Song et al., 2011). These studies demonstrate 
different lipopeptides are cross-presented via different pathways. Andrieu et al found two 
different HIV lipopeptides, consisting of Pol461-484 or Nef66-97 conjugated to N-E-palmytoyl-lysine, 
were cross-presented by two different pathways with Nef66-97 lipopeptide requiring endosomal 
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acidification to be presented and was independent of proteasomal degradation, whereas the 
Pol461-484 lipopeptide required proteasomal degradation, and was unaffected by inhibitors of 
endosomal acidification when presented by human MDDCs. The same Pol461-484 lipopeptide used 
in the study by Andrieu et al was shown to follow the same presentation pathway when 
presented by mDC and pDC (Hoeffel et al., 2007). A study by Renaudet et al (Renaudet et al., 
2010) found that two glyco-lipopeptide molecules, with identical tumour-associated CD8+ T cell 
epitopes (HER-2) and PADRE as a CD4+ T cell epitope, but differed only in the way the epitopes 
were structurally arranged, one with a linear structure and the other with a branched structure 
for the epitopes, followed distinct cross-presentation pathways to be presented to CD8+ T cells. 
Presentation by mouse BMDCs of the lipopeptide with a linear structure was dependent on 
proteasomal processing, whereas the branched lipopeptide was dependent on endosomal 
acidification. More recently, a lipopeptide derived from the HPV16 E7 protein was found to 
enter cells via an endocytosis-independent route, with the lipopeptide also gaining entry to non-
phagocytic cells as well as BMDC (Song et al., 2011). It was found the lipopeptide was dependent 
on proteasomal processing only. Lastly, a dipalmitoylated lipopeptide containing a H2Db 
restricted CD8 T cell epitope from HPV16 E7 was presented via a TAP-independent, endosomal 
acidification dependent pathway in BMDCs (K. Y. Shen et al., 2014). This small number of studies, 
with only two studies utilizing human cells, show lipopeptide cross-presentation is still poorly 
understood and further information is needed to enable rational design of lipopeptide based 
vaccines.  
Other important approaches to HSV vaccine design have included live-attenuated and 
inactivated viruses with many replication defective vaccines currently tested in animals or in 
development as recent reviews have described (Johnston et al., 2014). With the discovery that 
some HSV strains activate TLR2 (Sato et al., 2006), a rational whole virus vaccine approach may 
be to utilize the natural ability of an HSV strain to stimulate TLR2 which may facilitate cross-
presentation of HSV epitopes to CD8+ T cells. Understanding cross-presentation of HSV is of 
particular importance as it has been found in mice that cross-presentation counteracts HSV1 
immune evasion in mice (Nopora et al., 2012), CD11c-Rac mice, which are incapable of cross-
presenting,  are unable to mount CD8+ T cell responses against a wild-type virus. The CD11c-Rac 
mice were, however, able to control a HSV1 mutant deficient in the immune evasion genes 
UL41, ICP4, ICP22, and ICP27. Given some of HSVs immune evasion genes (such as ICP47s ability 
to downregulate TAP) are specific to human systems (Tomazin et al., 1998), the reliance on 
cross-presentation may be requisite to mount a protective CD8+ T cell response in humans. 
However, HSV entry into DCs is incompletely understood, much less the highly complex process 
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of cross-presentation. Therefore investigations into HSV infection of DCs, as well as beginning 
investigation into cross-presentation of HSV by DCs are greatly needed. 
It has been shown that HSV1 utilises at least three different entry pathways to infect 
different cell types, Vero and neuronal cells are infected via pH-independent fusion at the 
plasma membrane (Nicola et al., 2005), mouse melanoma cells are infected in a pH-independent 
endocytic manner (Milne et al., 2005), and epithelial cells such as keratinocytes and HeLa cells 
are infected by HSV1 in a pH-dependent endocytic manner (Nicola et al., 2005; Nicola et al., 
2003).  The pH-dependent endocytic pathway requires both acidification of endosomes and a 
cascade of host tyrosine kinases that mediate endocytosis. MDDCs are known to be able to be 
infected by HSV (Bosnjak et al., 2005) and express the HSV entry receptors HVE-A, CD111 
(Nectin-1), and CD112 (Nectin-2) (Donaghy et al., 2009). Strong interactions with the C-type 
lectin receptor DC-SIGN also greatly enhance HSV1 infection of MDDCs (de Jong, de Witte, 
Bolmstedt, van Kooyk, & Geijtenbeek, 2008). The pathway that by which HSV infects DCs has not 
yet been investigated.  
Another virus, IAV, requires the low pH of endosomes to initiate membrane fusion to 
infect cells (de Vries et al., 2011). It has been found, at least in pDCs, that an inhibitor of 
acidification abolished cross-presentation of IAV to CD8+ T cells, whereas inhibition of 
proteasomal processing had no effect (Di Pucchio et al., 2008). Therefore, the requirements of 
HSV to enter DCs may also have an effect on HSV cross-presentation. 
In this chapter, we sought to investigate the pathways of cross-presentation of 
Pam2Cys-conjuagted HSV lipopeptides and of the whole virus itself. As infection of DCs by HSV is 
incompletely understood, the infection of MDDCs was also investigated.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
5.2. Results 
5.2.1. Kinetics of Pam2Cys-conjugated peptide presentation to CD8+ T cells. 
In Chapter 4 (Figure 4.13) it was observed that the presence of the inhibitors brefeldin A 
and monensin prevented Pam2Cys-p30-5 from being presented to CD8+ T cells and that a 6 hr 
incubation prior to the addition of brefeldin A allowed CD8+ T cell responses to Pam2Cys-p30-5. 
To investigate this more precisely, iMDDCs were pulsed with Pam2Cys-peptide conjugates on ice 
for 2 hrs to synchronize binding, iMDDCs were then washed and incubated at 37°C to allow time 
for cross-presentation for 6, 5, 4, 3,2, 1, or 0 hours. Brefeldin A was added for 30 min to MDDCs 
to prevent further cross-presentation. PBMCs were added to each sample at the same time so 
CD8+ T cells were all exposed to MDDCs presenting peptides for 12 hours in the presence of 
brefeldin A, CD8+ T cell responses were then measured by flow cytometry for IFN- and TNF-α 
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secretion (see Figure 5.1 B). In donors that were CMV positive, the CMV immunodominant 
protein pp65 was used as a positive control, as it is a whole protein, it is necessary for it to be 
taken up and processed to be presented to CD8+ T cells. CD8+ T cell responses (as measured by 
IFN- and TNF-α secretion) to pp65 were detected after 5 and 6 hours (see Figure 5.1 C for flow 
cytometry plots and Figure 5.2 for graphs). It was found in three donors that Pam2Cys-p30-5 
consistently took 5 hours to be cross-presented to CD8+ T cells. Pam2Cys-p9 was found to be 
presented very quickly, with donors 16 and 4 responding to Pam2Cys-p9 in 0-2 hours, the 
response to Pam2Cys-p9 was too low to be detected in other donors. These results show 
Pam2Cys-p30-5 required a longer period of time, 5 hrs, to be processed and presented to CD8+ T 
cells compared to Pam2Cys-p9.  
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Figure 5.1 Pam2Cys -peptides differ in the time needed for cross-presenting to CD8+ T cells  
Pam2Cys-peptides were incubated with iMDDC for 2 hrs on ice to allow binding, MDDC were 
washed with ice-cold media and incubated at 37°C  for 6, 5, 4, 3, 2, 1, or 0 hours. Brefeldin A was 
added and cells were incubated for 30 min to block intracellular trafficking. MDDC were washed 
and co-cultured with PBMC in the presence of brefeldin A overnight. PBMC were labelled for CD3, 
CD8, Live/Dead, IFN-, and TNF-α and analysed by flow cytometry. (A) Schematic of the 
experimental set-up. (B) After gating on live, single, CD3+CD8+ cells, dot plots of responses to 
Pam2Cys-peptides presented over 0-6 hrs are measured by IFN- and TNF-α secretion. Results 
shown are from Donor 16 and a representative of three experiments. 
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Figure 5.2 Pam2Cys -peptides differ in the time needed for cross-presenting to CD8+ T cells. 
Pam2Cys-peptides were incubated with iMDDC for 2 hrs on ice to allow binding, MDDC were 
washed with ice-cold media and incubated at 37°C  for 6, 5, 4, 3, 2, 1, or 0 hours. Brefeldin A was 
added and cells were incubated for 30 min to block intracellular trafficking. MDDC were washed 
and co-cultured with PBMC in the presence of brefeldin A overnight. PBMC were labelled for CD3, 
CD8, Live/Dead, IFN-, and TNF-α and analysed by flow cytometry. The dashed line represents the 
mock CD8+ T cell response. 
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5.2.2. Cross-presentation of Pam2Cys-p30-5 occurs via the proteasome. 
Due to low CD8+ T cell responses to the Pam2Cys-p9 or p9-Pam2Cys-p30-5 constructs 
shown in chapter 4, only the cross-presentation pathways of Pam2Cys-p30-5 was able to be 
investigated. To further delineate the presentation pathways used to present Pam2Cys-p30-5 to 
CD8+ T cells, lactacystin, a proteasomal inhibitor, and bafilomycin A, an inhibitor of endosomal 
acidification were used to block presentation to CD8+ T cells. The inhibitor was added to 
autologous iMDDCs for 30 min at 37° to ensure blocking before addition of Pam2Cys-conjugated 
peptides. After peptide pulsing for 2 hrs, MDDC were washed to remove unbound peptide and 
added to wells in the continued presence of the inhibitors in duplicate and incubated with 
isolated CD8+ T cells. Cells were then co-cultured for 20 hrs as incubation with inhibitors for 
longer than 24 hrs resulted in increased cell death. After 20 hrs, the IFN- ELISPOT was 
developed and spots were counted. As shown by responses from Donor 16 (Figure 5.3A), 
responses to Pam2Cys-p30-5 were inhibited by lactacystin and not affected by bafilomycin A. As 
a control, the whole CMV protein pp65 and the CMV HLA-A2 restricted peptide NLV were used 
with donors that were also CMV positive. 3/ 5 donors used in this set of experiments were CMV 
positive, therefore responses to pp65 and NLV are representative of three donors only in Figure 
5.3B. NLV can bind directly, exogenously, to HLA A2 and therefore responses to NLV were 
unaffected by lactacystin or bafilomycin A. CD8+ T cell responses to pp65 and to Pam2Cys-p30-5 
were significantly inhibited by lactacystin (p=0.04 and p=0.009 respectively) but were unaffected 
by bafilomycin A. The CD8+ T cell response to Pam2Cys-p30-5 was reduced by lactacystin to such 
an extent that there was no significant difference when compared to the response to Pam2Cys 
alone. To verify bafilomycin A was effective at inhibiting endosomal acidification, the CD4+ T cell 
response to Pam2Cys-p30-5 and pp65 presented by bafilomycin A treated MDDCs was measured 
(Figure 5.3C) as endosomal acidification is known to be required for MHC II presentation.  It was 
found the CD4+ T cell response to Pam2Cys-p30-5 and the whole protein pp65 were both 
inhibited by bafilomycin A treatment, in contrast, the CD4+ T cell response to PHA was 
unaffected (not shown), indicating bafilomycin A was effectively preventing endosomal 
acidification. These results indicated proteasomal processing was necessary for Pam2Cys-p30-5 
presentation to CD8+ T cells and endosomal acidification does not appear to be involved. 
Pam2Cys-p30-5 presentation to CD4+ T cells does require endosomal acidification.  
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Figure 5.3 Pam2Cys-p30-5 presentation to CD8+ T cells is blocked by the 
proteasomal inhibitor lactacystin. 
MDDCs were incubated with no inhibitor, 200 nM Bafilomycin A or 10 µM Lactacystin for 
30 min in an IFN- ELISPOT, Pam2Cys-peptides were added in duplicate or triplicate wells 
and incubated with MDDC for 1 hr before addition of isolated CD8+ T cells, cells were 
cultured in the continued presence of the inhibitors at 37°C for 20 hrs followed by spot 
development and counting with an AID ELISPOT reader. (A) CD8+ T cell response from 
Donor 16, error bars represent standard deviation of duplicate wells. (B) Combined CD8+ 
T cell response from 5 donors, to compare multiple donors, IFN- SFU were converted to 
fold-change (normalised to mock) and log-transformed prior to analysis in order to 
stabilize the variance. The box and whisker plots show the upper and lower quartile, the 
central bar represents the median, while the whiskers show the minimum and maximum 
for each marker, dots represent outliers. Responses to pp65 and NLV are representative 
of 3/ 5 donors. (C) CD4+ T cell response from Donor 16 error bars represent standard 
deviation of duplicate wells, and are representative of three experiments. 
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5.2.3. The effect of lysosomotropic agents on HSV infection of MDDCs. 
As the pathway utilized by HSV to infect DCs has not yet been clearly defined, we 
wanted to investigate whether iMDDCs are infected via the same pH dependent endocytic 
pathway as keratinocytes using two inhibitors of endosomal acidification, bafilomycin A and 
monensin, as well as a tyrosine kinase inhibitor, genistein. As it has already been established that 
Vero cells are infected via a pH-neutral fusion pathway and HeLa cells are infected via a pH-
dependent endocytic pathway (Nicola et al., 2003), Vero and HeLa cells were used as negative 
and positive controls for the assay. A cell dissociation buffer was used for 30 min to lift HeLa and 
Vero cells prior to staining for flow cytometry because cell scraping and trypsin treatment 
affected cell integrity and staining respectively (Appendix H). A post-infection (p.i.) time point of 
16 hrs was chosen to observe HSV infection as the greatest difference between bafilomycin A 
treated and HSV1 infected HeLa cells was seen at 16 hrs p.i. by flow cytometry staining for HSV1 
gC. A large amount of cell death was detected at 24 hrs p.i. (Figure 5.4).  
iMDDCs, HeLa, and Vero cells were treated for 30 min with lysosomotropic agents for 30 
min at the concentrations indicated in Figure 5.5, which were not toxic to any of the cell types 
(Appendix I). HSV1 (MOI 3) was added and allowed to bind to cells at 4°C for 2 hrs, cells were 
washed to remove unbound virus with ice-cold serum-free RPMI-1640 or DMEM and cultured in 
the continued presence of the agents for 16 hrs. MDDCs, HeLa, and Vero cells were stained with 
Live-Dead Aqua and HSV1 gC-FITC and measured by flow cytometry, or lysates were collected for 
QPCR.  
As can be seen in the histograms in Figure 5.5 and the combined graphs in Figure 5.6, 
over increasing concentrations of bafilomycin A, monensin, and genistein, infection of MDDCs 
and HeLa cells was significantly reduced (p≤0.021 for the highest concentration of inhibitors). 
Infection of Vero cells were not significantly affected by any of the lysosomotropic agents. 
Inhibition of HSV1 entry to iMDDCs by the inhibitors bafilomycin A, monensin, and genistein was 
confirmed using QPCR (Figure 5.7). Transcription of both the IE protein ICP4 and the late protein 
glycoprotein B were significantly reduced in the presence of all the lysosomotropic agents 
compared to HSV1 infected controls. HSV2 was also confirmed to utilize a pH-dependent entry 
pathway to infect iMDDCs, with bafilomycin A also significantly inhibiting HSV2 infection (Figure 
5.8). 
As HSV infection of MDDCs was inhibited by two inhibitors of endosomal acidification, 
and by the tyrosine kinase inhibitor genistein, it indicates MDDCs were infected by HSV via a pH-
Chapter 5 - Investigating presentation and infection pathways of HSV and HSV lipopeptides by 
MDDCs 
 
113 
 
dependent, endocytic pathway, in the same way as epithelial cells such as keratinocytes and 
HeLa cells are infected. 
 
 
Figure 5.4 Measuring HSV1 infection of HeLa cells by flow cytometry.  
HeLa cells  (5 x 10
5
 ) were washed with PBS and HSV1 (strain F) was added (MOI of 3) and allowed 
to bind for 2 h at 4°C. Cells were washed  with DMEM, and media was added and cells were 
incubated at 37°C for indicated time points. Cells were washed with PBS and treated with cell-
dissociation buffer for 30 mins, prior to being collected  in PBS and moved to FACS tubes. Cells 
were stained with a HSV1 gC-FITC antibody then analysed by flow cytometry.  Results are 
representative of two experiments. 
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Figure 5.5 The effect of lysosomotropic agents on HSV1 infection of MDDCs  
3 x 10
5
 Day 6 MDDC’s or 5 x 10
5
 HeLa and Vero cells were washed with RPMI  or DMEM and 
treated for 30 min at 37°C with bafilomycin A, monensin or genistein at the concentrations 
shown. HSV-1 (strain F) was added (MOI of 3) in the continued presence of the agents and 
allowed to bind for 2 h at 4°C. Cells were washed  with cold RPMI or DMEM then media 
containing  the inhibitors was added and cells were incubated at 37°C for 16 hr. Cells were 
washed with PBS and stained with a fixeable Live/ Dead stain and an HSV-1 gC-FITC antibody then 
analysed by flow cytometry. Results are representative of four experiments. 
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Figure 5.6 The effect of lysomotropic agents on HSV1 infection of MDDCs. 
3 x 10
5
 Day 6 MDDC’s or 5 x 10
5
 HeLa and Vero cells were washed with RPMI  or DMEM 
and treated for 30 min at 37°C with bafilomycin A, monensin or genistein at the 
concentrations shown. HSV-1 (strain F) was added (MOI of 3) in the continued presence 
of the agents and allowed to bind for 2 h at 4°C. Cells were washed  with cold RPMI or 
DMEM then media containing  the inhibitors was added and cells were incubated at 
37°C for 16 hr. Cells were washed with PBS and stained with a fixeable Live/ Dead stain 
and an HSV-1 gC-FITC antibody then analysed by flow cytometry. The percentage of HSV-
1 infected cells were measured as HSV-1 gC positive cells and no treatment-HSV-1 
infected cells were set as 100% infection. 
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Figure 5.7 . The effect of lysomotropic agents on HSV1 infection of MDDCs 
3 x 10
5
 Day 6 MDDC’s were washed with RPMI and treated for 30 min at 37°C with bafilomycin A, 
monensin or genistein at the concentrations shown above. HSV-1 (strain F) was added (MOI of 3) 
in the continued presence of the inhibitors and allowed to bind for 2 h at 4°C. Cells were washed  
with cold RPMI then media containing  the inhibitors was added and cells were incubated at 37°C 
for 16 hr. Cells were washed with PBS, lysates were collected and QPCR was performed to detect 
HSV1 mRNA for the immediate early protein ICP4 or the late protein glycoprotein B. Fold-change 
compared to mock was calculated and no treatment-HSV-1 infected cells were set as 100% 
infection. 
 
 
Chapter 5 - Investigating presentation and infection pathways of HSV and HSV lipopeptides by 
MDDCs 
 
117 
 
 
Figure 5.8 The effect of bafilomycin A on HSV2 infection of MDDCs.  
3 x 10
5
 Day 6 MDDC’s were washed with RPMI and treated for 30 min at 37°C with bafilomycin A 
(100 nM). HSV-2 (strain 186) was added (MOI of 3 or 1) in the continued presence of bafilomycin 
A and allowed to bind for 2 h at 4°C. Cells were washed  with cold RPMI then media containing  
the inhibitors was added and cells were incubated at 37°C for 16 hrs. Cells were washed with PBS 
and stained with a HSV-2 gD-FITC antibody then analysed by flow cytometry. The percentage of 
HSV-2 infected cells were measured as HSV-2 gD positive cells. Error bars represent the standard 
deviation of three donors. 
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5.2.4. Cross-presentation of whole UV- inactivated HSV1 antigen is not perturbed by 
bafilomycin A  
Given the results above showing that HSV infects MDDC via acidified endosomes, it was 
of interest whether UV-inactivated HSV1 (UV-HSV1) can still enter the cross-presentation 
pathway and be presented to CD8+ T cells in the absence of acidified endosomes. 
Crude preparations of UV-HSV1 include cellular debris and excess antigen not packaged 
in virions that would likely be cross-presented and elicit a CD8+ T cell response. Hence, two 
types of UV-HSV-1 were used for this study, crude UV-HSV1 preparations and a purified UV-HSV1 
preparation purified by ficoll-gradient purification. A MOIequivalent
1 of 10 was found to elicit a 
detectable IFN- CD8+ T cell response, whereas a MOIequivalent of 5 was found to be inconsistent 
at inducing detectable IFN- CD8+ T cell responses (representative graph shown in Figure 5.9). A 
greater MOIequivalent of 10 was difficult to achieve with purified UV-HSV1 preparations as purifying 
HSV1 usually results in low viral titres.  
Similar to the experiment with Pam2Cys-peptides, MDDC were pre-incubated with 
inhibitors prior to addition of UV-HSV1, MDDC were incubated for 2hrs, washed, then co-
cultured with isolated CD8+ T cells in the continued presence of the inhibitors in duplicate IFN- 
ELISPOT wells. The response to the ficoll-gradient-purified UV-HSV1 stock was inconsistent, 3/ 5 
donors gave a response that was significantly greater than mock, of those, two gave augmented 
CD8+ T cell responses in the presence of bafilomycin A, one donor, donor 4,  gave a CD8+ T cell 
response that was inhibited by bafilomycin A. As the purified UV-HSV1 was inconsistent and the 
responses were small, it was left out of the analysis. 
The crudely prepared UV-HSV1 stock induced a consistently augmented response when 
iMDDCs were treated with bafilomycin A (p=0.02) and an inhibited response when iMDDCs were 
treated with lactacystin (p=0.02) (Figure 5.10). This implied that although HSV1 is prevented 
from infecting iMDDC by the presence of bafilomycin A, antigen entering the cross-presentation 
pathway from UV-HSV1 preparations is not inhibited. To ensure bafilomycin A was preventing 
the endosomal acidification in MDDCs, the same bafilomycin A treated, UV-HSV1 pulsed iMDDCs 
were incubated with CD4 T cells. Presentation of UV-HSV1 antigen to CD4+ T cells was prevented 
in the presence of bafilomycin A (Figure 5.8D), PHA stimulation of CD4+ T cells was not affected 
by the presence of bafilomycin A (not shown). 
 
                                                          
1
 MOIequivalent is the amount of virus stock used where the number of pfu/ mL prior to UV-inactivation are used to 
calculate the equivalent MOI 
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Figure 5.9 CD8+ T cell responses to purified UV-HSV1 
iMDDCs were incubated with purified stocks of UV-HSV1 (MOIequivalent of 1, 3, 5 or 10) 2 hrs before 
being washed and added to wells in quadruplicate before addition of isolated CD8+ T cells, cells 
were co-cultured at 37°C for 20 hrs followed by spot development and counting with an AID 
ELISPOT reader. Error bars represent standard deviation of four replicate wells from Donor 4.  
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Figure 5.10 Cross-presentation of UV-HSV1 by MDDCs is enhanced by bafilomycin A 
MDDCs were incubated with no inhibitor, 200 nM bafilomycin A or 10 µM lactacystin for 30 min 
in an IFN- ELISPOT, UV-HSV1 (strain F), either from a purified or a crude stock of UV-HSV1 
(MOIequivalent of 10) were added, MDDC were incubated with UV-inactivated virus for 2 hrs before 
being washed and added to wells in duplicate or before addition of isolated CD8+ T cells, cells 
were cultured in the continued presence of the inhibitors at 37°C for 20 hrs followed by spot 
development and counting with an AID ELISPOT reader. (A) CD8+ T cell response from Donor 16, 
error bars represent standard deviation of duplicate wells. (B) Combined CD8+ T cell response 
from 4 donors, to compare multiple donors, IFN- SFU were converted to fold-change 
(normalised to mock,  no inhibitor) and log-transformed prior to analysis in order to stabilize the 
variance. The box plots show the minimum and maximum and the central bar represents the 
median.(C) CD4+ T cell response from Donor 16. 
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5.3. Discussion 
 
Two main pathways have been suggested for cross-presentation – the cytosolic pathway 
and the vacuolar pathway. In this chapter we have shown that Pam2Cys-p30-5 is cross-
presented through the cytosolic pathway and that cross-presentation is delayed compared to 
Pam2Cys-p9. As well as investigating the pathway by which HSV infects iMDDCs and we also 
explored the cross-presentation of whole UV-HSV1. 
The DC processing routes for endocytosed lipopeptides are unclear. Understanding the 
presentation pathways lipopeptides follow may lead to improved rational vaccine design. 
Pam2Cys-p30-5 was of unique interest as it stimulates both CD4+ T cells as well as CD8+ T cells. 
There are distinctive differences between MHC I and CII antigen presentation. MHC I 
presentation is less durable with presentation of the MHC I-peptide complex on the surface DCs 
endocytosed much faster than MHC II  (van Montfoort et al., 2009). Antigen depots have been 
proposed that can prolong antigen survival to enhance presentation to CD8+ T cells. The speed 
that MHC I molecules are endocytosed is also dependent on the stability of the peptide-MHC I 
interaction. Rudd et al showed that the TLR9 agonist CpG increased TCR triggering on CD8+ T 
cells by slowing peptide MHC I decay rates (Rudd et al., 2008).   
To investigate the kinetics of presentation of Pam2Cys-peptide conjugates, Pam2Cys-
peptide was bound to iMDDCs on ice to synchronize peptide uptake, than washed off so binding, 
uptake, and cross-presentation would occur over a finite period of time. The results from three 
donors suggest Pam2Cys-p30-5 takes 5 hours to be cross-presented, which was similar to the 
time taken for the whole protein pp65 to be cross-presented, although responses to pp65 
continued to increase after 5 hrs. The steep decline in CD8+ T cell responses at 6 hrs suggests 
that it is unlikely there is an antigen depot function for Pam2Cys-p30-5, with most epitopes 
being presented at only 5 hrs. Few studies have investigated the decay rates of presented 
epitopes in great detail. Very stable interactions with model antigens and epitopes such as OVA 
and SIINFEKL appear to take a day before destabilizing (van Montfoort et al., 2009). In the 
setting of infection, Croft et al sampled 3 hr time points post-vaccinia virus infection and 
identified presented epitopes (Croft et al., 2013). Many epitopes, even in the setting of infection, 
peaked at 3.5 hrs post-infection and the number of epitopes per cell decreased by more than a 
log by 6.5 hrs post infection, showing how quickly epitopes can be lost from the cell surface, 
even in the setting of infection where de novo proteins are still being synthesized.   Without 
knowing the epitope, and from the observation in chapter 4 that peptide 30-5 by itself rarely 
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stimulates a CD8+ T cell response, it may be speculated that Pam2Cys-p30-5 may contain a weak 
binding epitope, the presentation of which is greatly facilitated by conjugation to Pam2Cys, 
possibly increasing the amount of epitope that is loaded and slowing the decay rate of MHC I-
peptide molecules. Without knowing the epitope and further study this is highly speculative and 
in need of further investigation. 
 
Figure 5.11 The effect of inhibitors on MHC I presentation pathways 
 
From the results shown in chapter 4, the presentation of Pam2Cys-p30-5 to CD8+ T cells 
was abrogated by presence of the inhibitors brefeldin A and monensin that are used in 
intracellular cytokine staining assays (Figure 4.13). Brefeldin A has been an important research 
tool and is known to induce the formation of numerous long tubules from the golgi complex that 
then fuse to the ER, causing a rapid and reversible block in secretion (Fujiwara, Oda, Yokota, 
Takatsuki, & Ikehara, 1988). Early studies into cross-presentation showed that TAP-dependent 
cross-presentation is sensitive to brefeldin A. This fueled the initial proposal that peptide loading 
occurs in the ER (Compeer, Flinsenberg, van der Grein, & Boes, 2012; Fonteneau et al., 2003; 
Kovacsovics-Bankowski & Rock, 1995). Monensin inhibits trafficking from the golgi network as 
well as acidification of endosomes (Mollenhauer, Morre, & Rowe, 1990). Therefore the use of 
brefeldin A and monensin was inhibiting the golgi-ER complex and prevented new MHC I 
molecules from being transported to the cell surface as well as preventing endosomal 
acidification (Figure 5.11). To further delineate the pathways of cross-presentation, either 
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through the cytosolic pathway, or the vacuolar pathway, inhibitors of the proteasome (such as 
lactacystin) and inhibitors of endosomal acidification (such as bafilomycin A) were used. 
 Cross-presentation pathways of several TLR2-ligand conjugated lipopeptides have been 
investigated by only a few studies (Andrieu et al., 2003; Hoeffel et al., 2007; Hosmalin et al., 
2001; Renaudet et al., 2010; K. Y. Shen et al., 2014; Song et al., 2011). Of these studies 
investigating cross-presentation pathways of lipopeptides, only Andrieu et al and Hoeffel et al 
used human dendritic cells, investigating the cross-presentation pathways of HIV lipopeptides by 
MDDC, mDC, and pDC,   all other studies utilized mouse BMDCs. Therefore lipopeptide cross-
presentation is understudied in human systems. Presentation of some TLR2-ligand conjugated 
lipopeptides to CD8+ T cells have been shown to be blocked by inhibitors of endosomal 
acidification (Andrieu et al., 2003; Hoeffel et al., 2007; Renaudet et al., 2010; K. Y. Shen et al., 
2014). However, Pam2Cys-p30-5 was unaffected by bafilomycin A, indicating endosomal 
acidification is not required. As found in our study, other studies have shown cross-presentation 
of pp65 is not sensitive to proteasomal inhibitors (Weck et al., 2008). Pam2Cys-p30-5 
presentation to CD4+ T cells was affected by bafilomycin A, showing MHC II presentation 
requires endosomal acidification, as is classically the case. Thus Pam2Cys-p30-5 is presented 
through two separate pathways when bound to MHC I and CII. Pam2Cys-p30-5 presentation to 
CD8+ T cells was blocked by the proteasomal inhibitor lactacystin, indicating Pam2Cys-p30-5 
likely follows the cytosolic pathway. Four other lipopeptides have also been found to follow this 
pathway, (Andrieu et al., 2003; Renaudet et al., 2010; Song et al., 2011, Khan, 2007 #424). 
Andrieu et al, Renaudet et al, and Song et al all used single palmitic acid moieties, conjugated to 
Pol461-484, HER-2, or a HPV E7 peptide,  Khan et al used the model epitope SIINFEKL, conjugated to 
Pam3Cys.  
Interestingly, Renaudet et al found that the linear HER-2 lipopeptide construct, that 
required proteasomal degradation (implying that it was cross-presented via the cytosolic 
pathway) to induce a greater protective CD8+ T cell response and increased survival rate against 
tumour challenges compared to the branched HER-2 lipopeptide construct (which was cross-
presented via the vacuolar pathway) (Renaudet et al., 2010). The linear HER-2 lipopeptide 
however also induced greater DC maturation, making it difficult to draw conclusions as to why 
the linear HER-2 lipopeptide construct performed better and whether the cytosolic cross-
presentation pathway is more likely to result in protective CD8+ T cell responses. Whether this is 
the reason Pam2Cys-p30-5 induces such large CD8+ T cell responses is still not known as too 
many factors may influence cross-presentation to CD8+ T cells and there are still too few 
examples to draw rational conclusions. 
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Cross-presentation via the endocytic route has also been shown to involve the vacuolar 
protease cathepsin S (L. Shen, Sigal, Boes, & Rock, 2004). Results from Shen et al suggested that 
capthepsin S may make appropriate cleavages of peptides to generate 8-9mers. Of note, 
cathepsin S is relatively unique among vacuolar cysteine proteases as it is strongly active at 
neutral pH, and cleaves the model antigen OVA to present the epitope SIINFEKL over a wide 
range of pH.  DCs from cathepsin S-deficient mice have a defect in vacuolar but not cytosolic 
cross-presentation. Recently cathepsin S has been implicated in not just the vacuolar, but also 
the cytosolic cross-presentation pathway. A long HPV E7 non-lipidated peptide has recently been 
reported to require cleavage by cathepsin S and proteasomal degradation, presentation was 
unaffected by inhibition of endosomal acidification, showing the peptide was cross-presented 
using both the vacuolar and cytosolic pathways (Song et al., 2011). Interestingly, once the 
peptide was lipidated, it was able to enter cells in an endocytosis independent manner, requiring 
proteasomal processing. Our study did not include cathepsin S when investigating cross-
presentation of Pam2Cys-p30-5. Since cathepsin S had previously been implicated in the 
vacuolar route, and Pam2Cys-p30-5 required proteasomal cleavage it was assumed that 
Pam2Cys-p30-5 was cross-presented via the cytosolic route only. However, in light of Song et als 
findings, future studies should still investigate whether Pam2Cys-p30-5 also requires cleavage by 
cathepsin S. 
Three different pathways have been identified through which HSV infects cells, a pH-
dependent endocytic pathway, a pH independent endocytic pathway and a pH-independent 
fusion pathway at the plasma membrane. From the results in this chapter it has been confirmed 
that MDDCs are infected by HSV1 through the same pH-dependent endocytic manner already 
shown in keratinocytes, HeLa, and CHO-nectin-1 cells (Nicola et al., 2005; Nicola et al., 2003). 
Both acidification of the endosomes which causes a conformational change in gB and tyrosine 
kinases are needed for endocytic entry of HSV. The well characterized tyrosine kinase inhibitor, 
genistein, and inhibition of acidification, disrupted entry into keratinocytes, HeLa, and CHO-
nectin-1 just as it did in MDDCs in our study. As transcription of the IE protein ICP4 was also 
inhibited, by the three lysosomotropic agents, it indicates HSV1 infection is disrupted early in the 
infection cycle, supporting the finding that entry is prevented. HSV2 has been previously shown 
to infect HeLa and CHO-nectin-1 cells in the same manner as HSV1 (Nicola et al., 2003). From our 
study, HSV2 also requires endosomal acidification to infect MDDCs. Therefore both HSV1 and 
HSV2 infect MDDCs via a pH-dependent endocytic pathway. 
Another virus, IAV, has been shown to gain access to the cytoplasm of DCs to be cross-
presented via the same pathway through which they infect DCs (Di Pucchio et al., 2008). From 
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the results in this chapter, however, this is unlikely to be the case for HSV1 as the presence of 
bafilomycin A blocked HSV entry (and subsequent infection) into MDDCs but enhanced cross-
presentation of UV-HSV1. The results from the purified UV-HSV1, which was used to try and 
answer the question of whether virions enter MDDCs and are cross-presented via the same 
route as infection, were unfortunately inconclusive with one donor’s CD8+ T cell response being 
blocked by bafilomycin A and two donors showing enhanced responses when bafilomycin A was 
present. In reality, the crude stock which contains cellular debris and excess antigen in the 
preparation may be more physiologically relevant, as DCs may obtain HSV antigen to cross-
present largely through uptake of debris of apoptotic HSV infected cells. In our study, unlike 
infection, entry of UV-HSV1 antigen to cross-presentation pathways is facilitated rather than 
perturbed by inhibiting endosomal acidification. This is likely due to the observation from many 
other studies that inhibiting endosomal acidification allows the antigen to persist for longer in 
the endosome before degradation, thus allowing more opportunity for the antigen to escape 
into the cytosol and be presented via MHC I (Accapezzato et al., 2005; Belizaire & Unanue, 2009; 
Savina et al., 2006).  
However, it is still possible the virus does gain entry to DCs via its infection pathway to 
be cross-presented, but that persistence of antigen in the endosome has a much greater 
influence on cross-presentation than the loss of viral entry. As is classically the case, inhibiting 
endosomal acidification does inhibit presentation of MHC II and prevents the activation of CD4+ 
T cells. Interestingly, despite the presence of a high concentration of whole viral antigen, 
Pam2Cys-p30-5 still induced a CD8+ T cell response of a similar magnitude (Figure 5.10A), 
showing lipopeptides still have great potential when comparing to whole virion preparations. 
The mechanisms by which whole viral antigen is likely to be cross-presented will be 
difficult to elucidate. Most virus preparations contain debris from apoptotic and necrotic cells 
that will act as signaling ligands for receptors such as DEC-205 and CLEC9A, DC-SIGN has already 
been implicated in HSV infection and could contribute to cross-presentation (de Jong et al., 
2008), TLR2 and TLR9 activated by the virions themselves likely will also make a contribution 
(Sato et al., 2006). To rationally choose virus preparations and strains that are optimally cross-
presented will be a large and complex undertaking, as too little is presently known about the 
complex process of cross-presentation. 
It is thought that better understanding of cross-presentation mechanisms and pathways 
is essential for rational design of PRR-ligand based conjugated synthetic vaccines (Zom et al., 
2012). We have in this chapter tried to delineate the pathway by which Pam2Cys-p30-5 is cross-
presented as well as further understanding of whole virus infection and presentation. There is 
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still a lot to unravel about the complex process of cross-presentation and will need to be 
subjected to future studies.  
Chapter 6 – Conclusions and future directions 
127 
Chapter 6 -  Conclusions and future directions 
HSV types 1 and 2 are ubiquitous human pathogens that represent a significant global 
health burden. HSV1 and 2 can cause significant morbidities including HSV encephalitis, vision 
loss, neonatal herpes and increased HIV acquisition. HSV2 treatment and prevention strategies 
have proven ineffective, disclosure of HSV serostatus (Wald et al., 2006), condom use (Martin et 
al., 2009), male circumcision (Tobian et al., 2012), and the use of antiviral therapy (Corey et al., 
2004) reduce risk of transmission by 50% at best. A prophylactic vaccine would greatly ease the 
health burden caused by HSV and mathematical models suggest that even a moderately 
effective HSV2 vaccine would lead to a marked decrease in HIV incidence if given at a high 
coverage (Freeman et al., 2009). However despite decades of research, human clinical trials have 
failed to produce an efficacious HSV vaccine (Johnston, Koelle, & Wald, 2011; Johnston et al., 
2014). The most efficacious vaccine to reach clinical trials was the HSV2 gD subunit vaccine 
combined with AS04 with dMPLA, a TLR4 agonist, this vaccine elicited strong antibody and CD4+ 
T cell responses, but failed to elicit strong CD8+ T cell responses (Belshe et al., 2012; Bernstein et 
al., 2005; Stanberry et al., 2002). CD8+ T cells have been found to play a major role in clearing 
HSV infection and controlling reactivation. Novel vaccine strategies are needed to elicit 
protective CD8+ T cell immunity in addition to neutralizing antibody and CD4+ T cell mediated 
immunity. The salient findings of this thesis will contribute to human HSV vaccine design 
endeavouring to induce protective CD8+ T cell responses. 
HSV vaccine design aimed at inducing protective CD8+ T cell responses has been 
hampered by a lack of identified MHC I-restricted HSV epitopes. Particularly in need are epitopes 
from the major HLA supertypes. A peptide vaccine across the most common HLA supertypes is 
potentially an effective vaccine approach as the six most frequent HLA supertypes (A2, A3, B7, 
A24, B44, and A1) afford an average population coverage of 99.3% (Sette & Sidney, 1999). Just 
the three HLA supertypes A2, A3, and B7 have an average population coverage of 86.2% (83-
88.4%) among five major ethnic groups (Caucasian, North-American Black, Japanese, Chinese, 
and Hispanic). In recent years, since the commencement of this study, several HSV epitopes have 
been identified (Chentoufi, Binder, et al., 2008; C. Chiu et al., 2014; Dervillez et al., 2013; Jing et 
al., 2012; Laing et al., 2010). However, there remains difficulties in replicating immunodominant 
epitope results found in different study designs and populations (Jing et al., 2012), thus much 
more work is required in this area as there is little consensus on identified epitopes, with many 
being identified after in vitro re-stimulation and are likely present at very low numbers in vivo. 
The findings from chapter 3 in this thesis contribute to this body of work on HSV 
immunodominant epitopes. The main outcomes were: 
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1) Identification of peptide 9 (ALHVVNNIK), an immunodominant CD8+ T cell epitope 
from HSV ICP8. Ex vivo CD8+ T cell responses to peptide 9 were detected in 9/ 50 HSV 
seropositive donors.  
2) Peptide 9 is able to bind to two HLA supertypes. In vitro binding assays showed 
peptide 9, as a 10 mer, binds to HLA-A*03:01, and as a 9 mer (ALHVVNNI), binds to HLA-
A*02:01. In silico peptide prediction further suggests peptide 9 binds to other members 
of the HLA A2 and A3 supertypes. 
3) Peptide 9 induces proliferation and a multi-functional cytokine response in CD8+ T 
cells from HSV seropositive donors.  
The CD8+ T cell responses to peptide 9 were similar to those found for other HSV 
immunodominant epitopes. The frequency of single HSV-specific CD8+ T cells found in the 
circulation is very low compared to other herpes viruses, such as CMV and EBV, and most studies 
have utilised some level of re-stimulation. For studies that have looked directly ex vivo, 
cumulative precursor frequencies for screening across most HSV ORFs has been 0.5-6% of 
circulating CD8+ T cells (Hosken et al., 2006). Another study investigated using tetramers, and 
showed that tetramer positive T cells for single epitopes comprised <10-100/ 100,000 CD8+ T 
cells (<0.01-0.1%) (Dervillez et al., 2013). Peptide 9 responses were of a similar magnitude, with 
responses of a similar range (0.011-0.1%), highlighting the difficulties faced when investigating 
human HSV immunodominant CD8+ T cell responses. By showing that peptide 9 was able to 
induce proliferation and elicit multi-functional CD8+ T cell responses, peptide 9 was established 
as an immunodominant epitope. The cytokine profile induced in CD8+ T cells in response to 
peptide 9 was of a TH1 phenotype (IFN-, TNF-α, and IL-2), Dervillez et al identified that 
immunodominant CD8+ T cell epitopes inducing such a cytokine profile induced asymptomatic 
protection compared to epitopes  inducing a IL-6, IL-8, and IL-17 cytokine profile. These 
cytokines were not included in our study, but the presence of a TH1 cytokine profile is suggestive 
of a protective phenotype.  Identifying true numbers of circulating CD8+ T cells for specific 
epitopes can only be undertaken using tetramers. Therefore follow-up studies would be 
worthwhile performing on peptide 9 to determine true numbers of peptide 9-specific CD8+ T 
cells. Our study was restricted to detecting a cytokine response. Measuring additional cytokines 
would also confirm peptide 9 induces a protective phenotype. Studies from CMV positive donors 
have found some tetramer positive CD8+ T cells can be rendered unresponsive leading to 
decreased protection, therefore it is important to not only determine the cytokine response, but 
also the number of specific CD8+ T cells in circulation. Follow-up studies would be of interest for 
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peptide 9 as it represents a novel epitope, capable of binding to two HLA supertypes thus 
making it an attractive vaccine target for use in a peptide-based vaccine platform. 
Peptide-based vaccines require adjuvants to elicit strong immune responses. 
Lipopeptides, consisting of a TLR2 agonist conjugated to immunodominant T cell epitopes or 
antibody epitopes are increasingly being examined as candidate vaccines. Pam2Cys, a TLR2/ 
TLR6 agonist, is an attractive adjuvant that has been found to be well tolerated in clinical trials 
with few or no side effects (Richmond et al., 2012; Schmidt et al., 2007; Seth et al., 2000) and 
lacking detectable, pyrogenic (Hood et al., 2010), or toxic effects (Wu et al., 2010), in contrast to 
other agonists such as the TLR8 agonists  which are pro-inflammatory and therefore may exert 
systemic toxicity (Hood et al., 2010). Pam2Cys has already been shown to be effective in priming 
immunity in the contexts of viral infections (Alphs et al., 2008; Day et al., 2007; Deliyannis et al., 
2006; Jackson et al., 2004). Our study sought to investigate the effects of Pam2Cys-conjugation 
on the presentation of HSV peptides to T cells. The lipopeptides Pam2Cys-p9, Pam2Cys-p30-5, 
and p9-Pam2Cys-p30-5 were examined. Of particular interest was whether combining a CD4+ 
and a CD8+ T cell epitope in the same vaccine construct would enhance the total T cell response. 
The main findings from evaluating responses to Pam2Cys-peptides were: 
1) The CD8+ T cell response to Pam2Cys-p9 was inconsistent, only eliciting a response 
higher than Pam2Cys alone in 3/ 9 donors. 
2) There was a large variation in the T cell responses to Pam2Cys-peptides, with 
Pam2Cys-p30-5 surprisingly inducing a strong and consistent CD8+ T cell response in 
HLA A2+ and HLA B44+ donors.  
3) The CD8+ T cell response to Pam2Cys-p30-5 was MHC I restricted, only HLA A2 or 
HLA B44 matched MDDC could induce CD8+ T cell responses to Pam2Cys-p30-5. 
4) Pam2Cys-conjugation was required for eliciting CD8+ T cell responses, when peptide 
30-5 and Pam2Cys are added to wells unconjugated, there was no large CD8+ T cell 
response. 
5) The variability in CD8+ T cell responses to Pam2Cys-peptides did not appear to be 
due to differences in maturation of MDDC. 
6) Combining CD4+ T cells and CD8+ T cells responding to the same Pam2Cys-
conjugated epitope resulted in a synergistic enhancement of the total T cell 
response. 
7) The CD8+ T cell response to Pam2Cys-p30-5 was inhibited by brefeldin A and the 
proteasomal inhibitor lactacystin, showing that proteasomal processing is required 
for cross-presentation. 
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The most unexpected finding from chapter 4 of this thesis was the potent CD8+ T cell 
response to Pam2Cys-p30-5 which was previously found to be immunodomminant for CD4+ T 
cells, the poor performance of Pam2Cys-p9 and the variability in response to p9-Pam2Cys-p30-5. 
It appears the differences in responses to the Pam2Cys-peptide conjugates are unlikely to be 
due to differences in maturation induced by TLR2, but rather differences in cross-presentation of 
the different Pam2Cys-conjugated epitopes. Only six studies have explored the cross-
presentation pathways of TLR2-agonist-conjugated peptides in depth (Andrieu et al., 2003; 
Hoeffel et al., 2007; Hosmalin et al., 2001; Renaudet et al., 2010; K. Y. Shen et al., 2014; Song et 
al., 2011). Already these few studies have shown differences between the pathways through 
which the lipopeptides are cross-presented, with some requiring endosomal acidification 
(Andrieu et al., 2003; Renaudet et al., 2010; K. Y. Shen et al., 2014), and others requiring 
proteasomal processing (Andrieu et al., 2003; Renaudet et al., 2010; Song et al., 2011). Currently 
not enough is known about what influences the cross-presentation of lipopeptides. Small 
changes in conformation (for example branched or linear) and the amino acid sequences of the 
conjugated peptides may influence TLR2 signalling (Azuma et al., 2010) and subsequently affect 
cross-presentation pathways. The model systems, such as the OVA/ SIINFEKL model, have 
allowed extensive study and greatly helped our understanding of cross-presentation. However if 
the amino acid sequences influence cross-presentation of epitopes, drawing conclusions from 
such model systems becomes difficult when trying to apply the findings to vaccines against 
human pathogens. Studying of human pathogens, however, is greatly impeded by a lack of tools 
including a lack of identified epitopes, the lack of available tetramers, limited human T cell 
numbers (this is quite evident with HSV where CD8+ T cells responding to single identified 
immunodominant epitopes make up 0.01 to < 1% of the total circulating CD8+ T cell population). 
The lack of tools to delineate between cross-priming (where co-stimulatory and cytokine signals 
may contribute) and cross-presentation (referring to the MHC I-peptide complex on the cell 
surface) such as antibodies to detect MHC I-peptide complexes on the APC surface, even when 
they are available, they are generally not very sensitive. 
In the case of Pam2Cys-p30-5, as the CD8+ T cell epitope has not yet been identified, the 
only experiments that were highly suggestive that Pam2Cys-p30-5 was efficiently cross-
presented rather than simply eliciting superior cross-priming was the blocking of proteasomal 
processing by lactacystin. This was unlikely to result from differences in co-stimulation and 
cytokine secretion, but rather prevented the MHC I-peptide complex from being formed. The 
fact that the CD4+ T cell response required endosomal acidification also illustrated the 
delineation between MHC I cross-presentation and MHC II presentation. The investigation of the 
kinetics (Figures 5.1 and 5.2) showed presentation of Pam2Cys-p30-5 peaked at 5 hrs and 
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decreased at hrs, this initially contrasts with the result from Figure 4.12 which showed that 
PamCys-p30-5 was cross-presented at 6hrs. However, in the experiment in Figure 4.12, 
Pam2Cys-p30-5 was added and left in the culture with the PBMCs and allowed to cross-present, 
so there would be continuous uptake and subsequent cross-presentation of the peptide; in the 
experiment in figure 5.1, the lipopeptide was allowed to bind at 4°C for 2 hours, then washed off 
synchronising uptake to a finite time period, rather than constant uptake. The investigation of 
the kinetics of cross-presentation where CD8+ T cell responses to Pam2Cys-p30-5 peaked at 5 
hrs and significantly decreased by 6 hrs, was also suggestive that Pam2Cys-p30-5 responses were 
due to cross-presentation of a weak binding, unstable, MHC I-peptide that may dissociate 
quickly, rather than just cross-priming through enhanced co-stimulation, or there would not 
have been a significant decrease at 6 hrs..   This is, however, highly speculative and would 
require further study. Recent findings that MHC I-enriched Rab11a+ vesicles are recruited to 
phagosomes containing TLR2-agonistic antigen (Nair-Gupta et al., 2014) has shown that 
targeting antigen to TLR2 influences cross-presentation beyond co-stimulatory signals. Likewise, 
activation of TCRs has also been shown to be influenced by TLR ligands slowing MHC I-peptide 
decay rates (Rudd et al., 2008). Precisely the aspects of Pam2Cys-p30-5 that promote strong 
CD8+ T cell responses is not known and remains to be elucidated. Crucially, the identity of the 
MHC I-restricted epitope being presented to CD8+ T cells in unknown. We attempted to identify 
the epitope through T2 and C1R.ICP47 cell binding assays and through LC-MRM, however both 
these methods have failed to identify the epitope. Both these methods require identification of 
known peptides and have limits on their sensitivity. There are at least two possibilities, 1) the 
CD8+ T cell epitope in Pam2Cys-p30-5 binds weakly to MHC I, the presentation of which is 
greatly facilitated by conjugation to Pam2Cys, possibly increasing the amount of epitope that is 
loaded and slowing the decay rate of MHC I-peptide molecules, but is below the detection limit 
of binding assays. 2)  The epitope is unusually processed, such as peptide modification or splicing 
as has been found in a few studies (Borissenko & Groll, 2007).  
It is also still possible that the responding CD8+ T cells are not bone fide HSV specific 
CD8+ T cells, but unconventional CD8+ T cells responding to a cleaved sub-unit of the Pam2Cys-
p30-5 construct. These are synthetic constructs that have only been studied in a limited number 
of cases. How they are processed is unknown. The lipid moiety, or some of the di-sulfide bond 
may remain, resulting in unconventional presentation of a synthetic sub-unit. There were donors 
screened that were not A2+ or B44+ that gave no response to Pam2Cys-p30-5 , so it does appear 
HLA-restricted, however we will not know if it is conventional until the epitope is identified. One 
limitation of this study is that no HLA A2+ HSV seronegative donors were tested.It will be 
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necessary to produce enriched Pam2Cys-p30-5 specific CD8+ T cells lines through re-stimulation 
to address this. Once the CD8+ T cell lines are created, they can be investigated for their ability 
to kill HLA A2+ or HLA B44+ HSV infected cells. Also, screening HLA A2+ cells presenting 
truncated peptides will help identify the exact epitope being presented. Utilising constructs of 
Pam2Cys-p30-5 with some of the truncated peptides used in this thesis may be useful in the 
future to assist in the identification of the CD8+ T cell epitope in Pam2Cys-p30-5. As use of 
lipopeptides as vaccines has already reached human clinical trials, it is of great importance to 
understand whether bone fide epitopes only are inducing CD8+ T cell responses, and that other 
non-specific T cells to sub-units of the lipopeptide constructs are not being induced. 
Unfortunately, as Pam2Cys-p9 was so poor at eliciting CD8+ T cell responses, as shown in 
chapter 4 it was often less than Pam2Cys alone. Therefore it was not possible to determine if it 
utilised a pathway dependent on endosomal acidification or proteasomal degradation. Results 
from ICS experiments suggested Pam2Cys-p9 presentation was not abruptly inhibited by 
brefeldin A and was presented much faster than Pam2Cys-p30-5, perhaps implicating a recycling 
pathway. It is also possible that that this rapid presentation is due to free peptide contaminating 
Pam2Cys-p9, although mass spectrometry performed by Weiguang Zeng did show this was a 
pure stock. However, as it was inconsistent at inducing responses, with responses often absent 
in HLA A2+ donors, it is difficult to draw conclusions. p9-Pam2Cys-p30-5 also elicited inconsistent 
CD8+ T cell responses: the majority of responses were less than Pam2Cys-p30-5 or as low as 
Pam2Cys alone. This showed that the addition of peptide 9 to the Pam2Cys-p30-5 construct 
somehow interfered with signalling though TLR2, or cross-presentation of the epitope.  
Despite being unable to identify the CD8+ T cell epitope in Pam2Cys-p30-5, the presence 
of a CD8+ T cell epitope and a CD4+ T cell epitope in the same Pam2Cys-conjugate offered an 
opportunity to investigate whether combining CD8+ and CD4+ T cells with MDDCs would result 
in an enhanced T cell responses, which was indeed the case. IFN- ELISPOT did not allow 
investigation into whether the increased IFN- responses were originating from CD8+ T cells, 
CD4+ T cells, or both. IFN- ELISPOT was used as it is more sensitive than ICS. In experiments 
using whole PBMC, the CD4+ T cell responses were unable to be detected, whereas it was 
possible to detect CD8+ T cell responses using ICS, it is therefore likely the enhanced responses 
were from CD8+ T cell responses although this has not been confirmed. The best way to confirm 
this would be through the use of tetramers to identify with certainty the responding T cells. 
However until the CD8+ T cell epitope is identified, making tetramers is not be possible. 
Nonetheless, Pam2Cys-p30-5 appears to be a uniquely useful vaccine candidate due to its ability 
to induce potent CD8+ T cell responses in HLA A2+ and HLA B44+ donors as well as potent CD4+ 
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T cell responses. The latter can be promiscuously elicited from donors with a range of HLA II 
types (M. Kim et al., 2008). 
 Other potential strategies for HSV vaccine development currently under consideration 
are live-attenuated and inactivated whole virus vaccines. HSV is known to utilise three different 
infection pathways, depending on the host cell type: with neuronal cells are infected via neutral 
fusion at the plasma membrane (Nicola et al., 2005), a mouse melanoma cell-line is infected via 
a pH-independent endocytic pathway (Milne et al., 2005), and epithelial cells are infected via a 
pH-dependent endocytic pathway (Nicola et al., 2005). What dictates the choice between 
endocytosis and fusion at the plasma membrane is not fully understood (Eisenberg, Heldwein, 
Cohen, & Krummenacher, 2011). Before our study it was not known which infection pathway 
HSV utilises to infect MDDCs, the major immune cell type responsible for priming adaptive 
immune responses. It was also of interest whether the pathway through which HSV infects 
MDDCs is also the main pathway through which HSV is cross-presented. Another virus, IAV, 
infects DCs via a pH-dependent endocytic pathway and this is also the main pathway through 
which IAV is cross-presented (Di Pucchio et al., 2008). From our studies of whole HSV infection 
and cross-presentation, the main findings were: 
1) HSV 1 and 2 infect iMDDCs via the same pH-dependent pathway  utilised by HeLa and 
keratinocytes, with inhibitors of endosomal acidification and tyrosine kinases blocking 
HSV infection 
2) Preventing endosomal acidification enhances rather than perturbs cross-presentation. 
The HSV receptor gB has been shown to undergo a conformational change at mildly 
acidic conditions such as those found in endosomes (Dollery et al., 2010). Endocytosis is also a 
tightly regulated process involving host kinase activites. The inhibitors of endosomal 
acidification, bafilomycin A and monensin, and also genistein, a well-characterised inhibitor of 
tyrosine kinases, inhibited HSV infection. This shows HSV infection of MDDCs occurs via the 
same pH-dependent endosomal pathway through which epidermal cells are infected.  
The main pathway through which whole inactivated HSV is cross-presented is not 
dependent on the mechanism through which it infects MDDCs, in contrast to what was found for 
IAV. The mechanisms by which whole virus is likely to be cross-presented will be very difficult to 
elucidate. HSV is known to signal via TLR2, TLR3, and TLR9 as well as binding to other scavenger 
receptors such as DEC-205, CLEC9A, and DC-SIGN (de Jong et al., 2008) which also determine 
route of uptake by specific signaling motifs. Our study used a HSV strain that has been shown to 
activate TLR2 (M. Kim et al., 2012). To rationally choose virus preparations and strains that are 
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optimally cross-presented would be a useful for future vaccine design, therefore greater 
understanding of these processes of whole virus preparations is imperative.  
The results from this thesis contribute to the understanding of HSV vaccines by 
identifying CD8+ T cell HSV epitopes, showing a TLR2-agonist conjugated HSV peptide that can 
present antigen to both CD4+ and CD8+ T cells, showing this can synergistically enhance the 
total T cell response, identifying how HSV infects DCs, and beginning investigations into whole-
inactivated viral antigen cross-presentation. 
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Appendix A. IFN-γ ELISPOTs of positive responses to peptides screening 
 
 
 
 
Appendices 
 
160 
 
 
 
Day 5 or 6 autologous iMDDCs (6 x 10
3
 – 1 x 10
4
)
 
were co-cultured with  isolated CD8+ T cells (6 x 
10
4
 – 1 x 10
5
) and  peptides (10  µM)  in triplicate or duplicate for 40 hrs in an IFN- ELISPOT. After 
development, spots were counted using an AID ELISPOT reader. A positive response was taken as 2 
times the standard deviation above mock as indicated by the dotted line. 
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Appendix B. Donor HLA typing 
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Appendix C. Epitope prediction of peptide 30-5 binding to HLA-A*02:01 and B*44:02 
 
         Table Appendix C.i. Prediction of peptide 30-5 binding to HLA-A*02:01 
A*02:01 SYFPEITHI 
score 
Rankpep 
score 
BIMAS score NetMHC 
 10 mers         
SSPEDPEDSA 10 -13.937 0.065 - 
SPEDPEDSAL 13 -10.921 0.037 - 
PEDPEDSALL 11 -6.751 0.004 - 
EDPEDSALLE 6 -15.268 0.000 - 
DPEDSALLED 0 -24.179 0.000 - 
 9 mers         
NLVPMVATV 30 102 159.970 29-SB 
SSPEDPEDS 4 -30 0.001 - 
SPEDPEDSA 9 -11 0.004 - 
PEDPEDSAL 10 -12 0.004 - 
EDPEDSALL 11 9 0.009 - 
DPEDSALLE 0 -17 0.00 - 
PEDSALLED 4 -22 0.00 - 
 
 
                      Table Appendix C.ii. Prediction of peptide 30-5 binding to HLA-B*44:02 
B*44:02 SYFPEITHI 
score 
Rankpep 
score 
BIMAS score NetMHC 
 10 mers         
SSPEDPEDSA 2 -37.571 0.200 - 
SPEDPEDSAL 14 -14.136 0.200 - 
PEDPEDSALL 25 -8.235 0.800 - 
EDPEDSALLE 6 -23.45 0.075 - 
DPEDSALLED 3 -21.661 0.068 - 
 9 mers         
LEIPGARSF 28 13.884 600.00 155-WB 
SSPEDPEDS 3 -21.318 0.200 - 
SPEDPEDSA 2 -10.257 0.200 - 
PEDPEDSAL 26 3.794 0.800 - 
EDPEDSALL 14 -13.561 0.500 - 
DPEDSALLE 4 -12.188 0.045 - 
PEDSALLED 13 0.559 0.090 - 
 
SYFPEITHI scores using Position Specific Scoring Matrices (PSSMs), higher scores indicate a greater 
prediction of binding 
Rankpep scores using PSSMs, higher scores indicate a greater prediction of binding 
BIMAS employs amino acid/position coefficient tables to estimate the half time of disassociation, 
higher scores indicate a greater prediction of binding 
NetMHC gives a readout of SB (Strong Binder) or WB (Weak Binder) – score indicates the predicted 
affinity presented in nM, therefore lower scores indicate a greater prediction of binding. 
- indicates peptides were not predicted to bind by the epitope prediction program. 
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Appendix D. T2 binding assays of peptides within Pam2Cys-p30-5 to HLA-A*02:01 
 
 
 
 
 
Appendix D.i. No peptides within peptide 30-5 bind to HLA-A*02:01 as tested by T2 binding 
assay. T2 cells (2 x 10
5
) expressing HLA A*0201 were incubated in AIM-V serum free media with 
indicated concentrations of peptides at 26°C for 14 hrs, then moved to 37°C for 2 hrs before 
staining for surface HLA A*02:01 expression. Expression, indicated by mean fluorescence 
intensity,  was analysed by flow cytometry. Peptides were done in duplicate with error bars 
indicating standard deviation. If no error bars are shown they are smaller than the marker. 
Negative controls were done with one replicate for each concentration. 
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Appendix D.ii. No peptides within peptide 30-5 bind to HLA-A*02:01 as tested by T2 binding 
assay. T2 cells (2 x 10
5
) expressing HLA A*02:01 were incubated in AIM-V serum free media with 
indicated concentrations of peptides at 26°C for 14 hrs, then moved to 37°C for 2 hrs before 
staining for surface HLA A*02:01 expression. Expression, indicated by mean fluorescence 
intensity,  was analysed by flow cytometry. Peptides were done in duplicate with error bars 
indicating standard deviation. If no error bars are shown they are smaller than the marker. 
Negative controls were done with one replicate for each concentration. 
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Appendix E. C1R ICP47 binding assays of peptides within Pam2Cys-p30-5 to HLA-B*44:05 
 
 
 
 
Appendix E.i. No peptides within peptide 30-5 bind to HLA-B*44:05 as tested by C1R 
ICP47 binding assay. C1R ICP47 cells (2 x 105) expressing HLA B*44:05 were incubated in 
AIM-V serum free media with indicated concentrations of peptides at 26°C for 14 hrs, 
then moved to 37°C for 2 hrs before staining for surface HLA B*44:05 expression. 
Expression, indicated by mean fluorescence intensity,  was analysed by flow cytometry. 
Peptides were done in duplicate with error bars indicating standard deviation. If no error 
bars are shown they are smaller than the marker. Negative controls were done with one 
replicate for each concentration. 
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Appendix E.ii. No peptides within peptide 30-5 bind to HLA-B*44:05 as tested by C1R 
ICP47 binding assay. C1R ICP47 cells (2 x 105) expressing HLA B*44:05 were incubated in 
AIM-V serum free media with indicated concentrations of peptides at 26°C for 14 hrs, 
then moved to 37°C for 2 hrs before staining for surface HLA B*44:05 expression. 
Expression, indicated by mean fluorescence intensity,  was analysed by flow cytometry. 
Peptides were done in duplicate with error bars indicating standard deviation. If no error 
bars are shown they are smaller than the marker. Negative controls were done with one 
replicate for each concentration. 
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Appendix F. Synergistic CD4+ and CD8+ T cell responses to Pam2Cys-p30-5 
 
 
Appendix F.i. Individual donor synergistic CD4+ and CD8+ T cell responses to Pam2Cys-p30-5 
Day 5 autologous iMDDCs
 
were co-cultured with  isolated CD8+ or CD4+ T cells (10
5 
each per well; 
a ratio of 1 MDDC: 10 T cells was used) and  peptide/ Pam2cys-conjugates (10  µM)  in triplicate 
or duplicate for 40 hrs in an IFN- ELISPOT. After development, spots were counted using an AID 
ELISPOT reader. Graphs from each donors, the top graph represents the number of spot-forming 
units (SFU) counted, the middle panel represents the total spot area and the bottom panel shows 
representative ELISPOT wells. Error bars represent standard deviation of replicate wells. 
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Appendix F.ii. Individual donor synergistic CD4+ and CD8+ T cell responses to Pam2Cys-p30-5 
Day 5 autologous iMDDCs
 
were co-cultured with  isolated CD8+ or CD4+ T cells (10
5 
each per well; 
a ratio of 1 MDDC: 10 T cells was used) and  peptide/ Pam2cys-conjugates (10  µM)  in triplicate 
or duplicate for 40 hrs in an IFN- ELISPOT. After development, spots were counted using an AID 
ELISPOT reader. Graphs from each donors, the top graph represents the number of spot-forming 
units (SFU) counted, the middle panel represents the total spot area and the bottom panel shows 
representative ELISPOT wells. Error bars represent standard deviation of replicate wells. 
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Appendix G. Prediction of known CD4+ epitopes binding to HLA class I 
 
Peptide HLA type SYFPEITHI 
score 
Rankpep 
score 
BIMAS 
score 
NetMHC 
(2) AALLVVAVGLRVVCAKYALA          
ALLVVAVGL A*02 - 12.497 79.041 131-WB 
AALLVVAVGL A*02 27 - - - 
VVAVGLRVV A*02 23 - - - 
LLVVAVGLRV A*02 23 - 118.238 247-WB 
AALLVVAVGL A*03 23 - - - 
GLRVVCAKY A*03 23 15.106 18.000 - 
AVGLRVVCAK A*03 25 22.141 - 163-WB 
AVGLRVVCAK A*1101 24 25.319 - 74-WB 
AALLVVAVGLR A*1101 22 - - - 
AALLVVAVGL B*08 18 - - - 
RVVCAKYAL B*0702 - - - 161-WB 
(24) KAYQQGVTVDSIGMLPRFTP      
TVDSIGMLPR A*1101 23 - - 87-WB 
(34) HAPAAPANPGLIIGALAGST      
APAAPANPGL B*0702 25 20.166 240.000 15-SB 
NPGLIIGAL B*0702 - - - 33-SB 
 
SYFPEITHI scores using Position Specific Scoring Matrices (PSSMs), higher scores indicate a greater prediction of 
binding 
Rankpep scores using PSSMs, higher scores indicate a greater prediction of binding 
BIMAS employs amino acid/position coefficient tables to estimate the half time of disassociation, higher scores 
indicate a greater prediction of binding 
NetMHC gives a readout of SB (Strong Binder) or WB (Weak Binder) – score indicates the predicted affinity 
presented in nM, therefore lower scores indicate a greater prediction of binding. 
- indicates peptides were not predicted to bind by the epitope prediction program. 
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Appendix H. Cell dissociation buffer kept cells intact and did not effect staining for HSV1 gC-FITC.  
 
 
 
 
Appendix H. Measuring HSV1 infection of adherant cells by flow cytometry. Vero cells 
(5 x 105 ) were washed with PBS and HSV1 (strain F) was added (MOI of 3) and allowed 
to bind for 2 h at 4°C. Cells were washed with DMEM, and media was added and cells 
were incubated at 37°C for 12 hrs. Cells were washed with PBS and cells were either 
treated with cell-dissociation buffer for 30 mins, treated with trypsin for 5 mins, or 
scraped with a cell scraper prior to being collected in PBS and moved to FACS tubes. 
Cells were stained with a HSV1 gC-FITC antibody then analysed by flow cytometry.  
 
 
  
Cell-dissociation buffer Trypsin Cell Scraper
HSV1 gC-FITC
FSC
SS
C
Mock
HSV 1
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Appendix I. Percentage cell survival in the presentation of inhibitors at 16 hrs 
 
 
 
 
Appendix I. Percentage cell survival in the presentation of inhibitors at 16 hrs. 3 x 10
5
 Day 6 
MDDC’s or 5 x 10
5
 HeLa and Vero cells were washed with RPMI  or DMEM and treated for 30 min 
at 37°C with bafilomycin A, monensin or genistein at the concentrations shown. HSV-1 (strain F) 
was added (MOI of 3) in the continued presence of the agents and allowed to bind for 2 h at 4°C. 
Cells were washed  with cold RPMI or DMEM then media containing  the inhibitors was added 
and cells were incubated at 37°C for 16 hr. Cells were washed with PBS and stained with a 
fixeable Live/ Dead stain and an HSV-1 gC-FITC antibody then analysed by flow cytometry. The 
percentage of live cells was calculated by the percentage of intact cells in the FSC-SSC gate 
multiplied by the percentage of cells negative for live/dead aqua stain. 
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